<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003756.pub3" GROUP_ID="INFECTN" ID="879800013113154860" MERGED_FROM="" MODIFIED="2012-01-18 09:32:18 +0000" MODIFIED_BY="Anne-Marie Stephani" REVIEW_NO="" REVMAN_SUB_VERSION="5.1.6" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.2">
<COVER_SHEET MODIFIED="2012-01-18 09:31:46 +0000" MODIFIED_BY="Anne-Marie Stephani">
<TITLE MODIFIED="2012-01-13 11:33:38 +0000" MODIFIED_BY="[Empty name]">Intermittent preventive treatment for malaria in children living in areas with seasonal transmission</TITLE>
<CONTACT>
<PERSON ID="9001" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Martin</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Meremikwu</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Paediatrics and Child Health</POSITION>
<EMAIL_1>mmeremiku@yahoo.co.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Paediatrics</DEPARTMENT>
<ORGANISATION>University of Calabar Teaching Hospital</ORGANISATION>
<ADDRESS_1>PMB 1115</ADDRESS_1>
<ADDRESS_2/>
<CITY>Calabar</CITY>
<ZIP/>
<REGION>Cross River State</REGION>
<COUNTRY CODE="NG">Nigeria</COUNTRY>
<PHONE_1>+234 8036742377</PHONE_1>
<PHONE_2>+234 872237210</PHONE_2>
<FAX_1>+234 487236208</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2012-01-18 09:31:46 +0000" MODIFIED_BY="Anne-Marie Stephani">
<PERSON ID="9001" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Martin</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Meremikwu</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Paediatrics and Child Health</POSITION>
<EMAIL_1>mmeremiku@yahoo.co.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Paediatrics</DEPARTMENT>
<ORGANISATION>University of Calabar Teaching Hospital</ORGANISATION>
<ADDRESS_1>PMB 1115</ADDRESS_1>
<ADDRESS_2/>
<CITY>Calabar</CITY>
<ZIP/>
<REGION>Cross River State</REGION>
<COUNTRY CODE="NG">Nigeria</COUNTRY>
<PHONE_1>+234 8036742377</PHONE_1>
<PHONE_2>+234 872237210</PHONE_2>
<FAX_1>+234 487236208</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5E63C9C182E26AA200991D56B22E8EB4" ROLE="AUTHOR">
<PREFIX>Miss</PREFIX>
<FIRST_NAME>Sarah</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Donegan</LAST_NAME>
<SUFFIX/>
<POSITION>Research Assistant in Medical Statistics &amp; Meta-analysis</POSITION>
<EMAIL_1>Sarah.Donegan@liverpool.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>International Health Group</DEPARTMENT>
<ORGANISATION>Liverpool School of Tropical Medicine</ORGANISATION>
<ADDRESS_1>Pembroke Place</ADDRESS_1>
<ADDRESS_2/>
<CITY>Liverpool</CITY>
<ZIP>L3 5QA</ZIP>
<REGION>Merseyside</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 151 7053392</PHONE_1>
<PHONE_2/>
<FAX_1>+44 151 7053364</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="795C7A7F82E26AA2016E721201F60C88" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>David</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Sinclair</LAST_NAME>
<SUFFIX/>
<POSITION>Research Associate</POSITION>
<EMAIL_1>sinclad@liverpool.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>International Health Group</DEPARTMENT>
<ORGANISATION>Liverpool School of Tropical Medicine</ORGANISATION>
<ADDRESS_1>Pembroke Place</ADDRESS_1>
<ADDRESS_2/>
<CITY>Liverpool</CITY>
<ZIP>L3 5QA</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="9295E61D82E26AA2007D5B6E4806C0E2" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Ekpereonne</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Esu</LAST_NAME>
<SUFFIX/>
<POSITION>Research Assistant</POSITION>
<EMAIL_1>rhonematic@yahoo.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+2347065810085</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Effective Health Care Research Programme - Nigeria</DEPARTMENT>
<ORGANISATION>University of Calabar Teaching Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Calabar</CITY>
<ZIP>540271</ZIP>
<REGION/>
<COUNTRY CODE="NG">Nigeria</COUNTRY>
<PHONE_1>+234 806 030 3647</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="AD33B93E82E26AA20071EDC002816E54" ROLE="AUTHOR">
<PREFIX>Miss</PREFIX>
<FIRST_NAME>Chioma</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Oringanje</LAST_NAME>
<SUFFIX/>
<POSITION>Research Assistant</POSITION>
<EMAIL_1>chyoma12@yahoo.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Tropical Disease Research and Prevention</DEPARTMENT>
<ORGANISATION>University of Calabar Teaching Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Calabar</CITY>
<ZIP>G.P.O 1241</ZIP>
<REGION>Cross River</REGION>
<COUNTRY CODE="NG">Nigeria</COUNTRY>
<PHONE_1>+23 47064540855</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2012-01-17 17:51:10 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="16" MONTH="6" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="5" MONTH="8" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="5" MONTH="8" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2012-01-13 11:36:01 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-01-13 11:36:01 +0000" MODIFIED_BY="Anne-Marie Stephani">
<DATE DAY="13" MONTH="1" YEAR="2012"/>
<DESCRIPTION>
<P>Significant update and changed focus</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-01-13 11:35:22 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="8" YEAR="2011"/>
<DESCRIPTION>
<P>The original review has been split into two separate topics: "Intermittent treatment for malaria in children (IPTc) living in areas with seasonal transmission" and "Intermittent preventive treatment in infants". This update addresses a focused question on the potential benefit and harm of giving IPTc to children aged below five years living is areas with seasonal malaria transmission. Trials on continuous prophylaxis have been excluded.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-12-13 19:21:19 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-11-15 16:35:54 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format with minor editing.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2011-12-13 19:21:19 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>2008, Issue 2: We included four new trials of intermittent treatment (Chandramohan 2005a; <LINK REF="STD-Ciss_x00e9_-2006" TYPE="STUDY">Cissé 2006</LINK>; Macete 2006a; Kobbe 2007a). We removed quasi-randomized controlled trials from the inclusion criteria and excluded two such trials (<LINK REF="STD-Bradley_x002d_Moore-1985" TYPE="STUDY">Bradley-Moore 1985</LINK>; <LINK REF="STD-Oyediran-1993" TYPE="STUDY">Oyediran 1993</LINK>) that were included in the <LINK REF="REF-Meremikwu-2005" TYPE="REFERENCE">Meremikwu 2005</LINK> version of this review. The evidence on benefits regarding reduction of malaria episodes, severe anaemia, and admissions remains strong and consistent with these changes. We also updated the analysis methods to stratify the individual and cluster-randomized trials. S Donegan and E Esu joined the author team, while P Garner and A Omari stepped down.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of Calabar</NAME>
<COUNTRY CODE="NG">Nigeria</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Liverpool School of Tropical Medicine</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Department for International Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-01-18 09:32:18 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-01-17 16:16:39 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2012-01-16 23:48:30 +0000" MODIFIED_BY="[Empty name]">Administering antimalarial drugs to prevent malaria in children during the malaria transmission season</TITLE>
<SUMMARY_BODY MODIFIED="2012-01-17 16:16:39 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;usually compared with, rather than to&lt;/p&gt;" NOTES_MODIFIED="2012-01-17 16:16:39 +0000" NOTES_MODIFIED_BY="[Empty name]">
<P>In areas where malaria is common, younger children have repeated episodes of malarial illness, which can sometimes be severe and life-threatening. In areas where malaria is seasonal, a practical policy option is to give drugs to prevent malaria at regular intervals during the transmission season, regardless of wether the child has malaria symptoms or not. This is known as Intermittent Preventive Treatment (IPTc).</P>
<P>The authors identified seven trials (12,589 participants); all were conducted in West Africa, and six of seven trials were restricted to children aged less than 5 years. The results show IPTc prevents three quarters of all malaria episodes, including severe episodes, and probably prevents some deaths.</P>
<P>Several antimalarial drugs or combinations have been tried, and shown to be effective. The most studied is amodiaquine plus sulphadoxine-pyrimethamine (AQ+SP). This combination probably doesn't have serious side effects but does cause vomiting in some children.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-01-17 16:07:24 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2012-01-17 06:51:41 +0000" MODIFIED_BY="[Empty name]">
<P>In malaria endemic areas, pre-school children are at high risk of severe and repeated malaria illness. One possible public health strategy, known as Intermittent Preventive Treatment in children (IPTc), is to treat all children for malaria at regular intervals during the transmission season, regardless of whether they are infected or not.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-01-17 06:51:54 +0000" MODIFIED_BY="[Empty name]">
<P>To evaluate the effects of IPTc to prevent malaria in preschool children living in endemic areas with seasonal malaria transmission.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-12-14 09:18:33 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Infectious Diseases Group Specialized Register (July 2011), CENTRAL (<I>The Cochrane Library</I> 2011, Issue 6), MEDLINE (1966 to July 2011), EMBASE (1974 to July 2011), LILACS (1982 to July 2011), <I>m</I>RCT (July 2011), and reference lists of identified trials. We also contacted researchers working in the field for unpublished and ongoing trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-01-17 13:55:12 +0000" MODIFIED_BY="[Empty name]">
<P>Individually randomized and cluster-randomized controlled trials of full therapeutic dose of antimalarial or antimalarial drug combinations given at regular intervals compared with placebo or no preventive treatment in children aged six years or less living in an area with seasonal malaria transmission.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-01-17 16:07:24 +0000" MODIFIED_BY="[Empty name]">
<P>Two authors independently assessed eligibility, extracted data and assessed the risk of bias in the trials. Data were meta-analysed and measures of effects (ie rate ratio, risk ratio and mean difference) are presented with 95% confidence intervals (CIs). The quality of evidence was assessed using the GRADE methods.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-01-17 15:13:50 +0000" MODIFIED_BY="[Empty name]">
<P>Seven trials (12,589 participants), including one cluster-randomized trial, met the inclusion criteria. All were conducted in West Africa, and six of seven trials were restricted to children aged less than 5 years.</P>
<P>IPTc prevents approximately three quarters of all clinical malaria episodes (rate ratio 0.26; 95% CI 0.17 to 0.38; 9321 participants, six trials, <I>high quality evidence</I>), and a similar proportion of severe malaria episodes (rate ratio 0.27, 95% CI 0.10 to 0.76; 5964 participants, two trials, <I>high quality evidence</I>). These effects remain present even where insecticide treated net (ITN) usage is high (two trials, 5964 participants, <I>high quality evidence</I>).</P>
<P>IPTc probably produces a small reduction in all-cause mortality consistent with the effect on severe malaria, but the trials were underpowered to reach statistical significance (risk ratio 0.66, 95% CI 0.31 to 1.39, <I>moderate quality </I>evidence).</P>
<P>The effect on anaemia varied between studies, but the risk of moderately severe anaemia is probably lower with IPTc (risk ratio 0.71, 95% CI 0.52 to 0.98; 8805 participants, five trials, <I>moderate quality evidence</I>).</P>
<P>Serious drug-related adverse events, if they occur, are probably rare, with none reported in the six trials (9533 participants, six trials, <I>moderate quality </I>evidence). Amodiaquine plus sulphadoxine-pyrimethamine is the most studied drug combination for seasonal chemoprevention. Although effective, it causes increased vomiting in this age-group (risk ratio 2.78, 95% CI 2.31 to 3.35; two trials, 3544 participants, <I>high quality evidence</I>).</P>
<P>When antimalarial IPTc was stopped, no rebound increase in malaria was observed in the three trials which continued follow-up for one season after IPTc.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-01-17 15:13:50 +0000" MODIFIED_BY="[Empty name]">
<P>In areas with seasonal malaria transmission, giving antimalarial drugs to preschool children (age &lt; 6 years) as IPTc during the malaria transmission season markedly reduces episodes of clinical malaria, including severe malaria. This benefit occurs even in areas where insecticide treated net usage is high.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-01-17 17:39:01 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-01-17 16:31:46 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Malaria</HEADING>
<P>Malaria, a disease common in both the tropics and subtropics, is caused by <I>Plasmodium</I> parasites transmitted to humans through the bite of infected female anopheline mosquitoes. People who live in or visit areas where malaria commonly occurs (endemic areas) are at risk of malaria infection. Infected people may show no sign of illness (asymptomatic malaria) or may develop fever, chills, malaise, and headache (symptomatic malaria). The severity of malaria infection varies from mild (uncomplicated) to life-threatening (severe). Among the five species of malaria parasites that infect humans, <I>Plasmodium falciparum</I> is the main parasite species responsible for causing severe malaria and is most frequently encountered in sub-Saharan Africa. People with severe malaria become very ill, may develop severe anaemia, convulsions, or become unconscious, and, in some cases, die.</P>
<P>Severe malaria is more likely to occur in people who possess low or no immunity to malaria (<LINK REF="REF-Gilles-2000" TYPE="REFERENCE">Gilles 2000</LINK>). Children living in malaria endemic areas acquire natural immunity to malaria by the age of seven to 10 years old (<LINK REF="REF-Branch-1998" TYPE="REFERENCE">Branch 1998</LINK>; <LINK REF="REF-Warrell-2001" TYPE="REFERENCE">Warrell 2001</LINK>). However, preschool children living in malaria endemic areas have inadequate immunity to malaria. This explains why the majority of the one million malaria deaths that occur each year in endemic areas of sub-Saharan Africa occur in this age group (<LINK REF="REF-WHO-2009" TYPE="REFERENCE">WHO 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Malaria control strategy</HEADING>
<P>Malaria control aims to reduce illness and death from malaria infection. The World Health Organization's (WHO's) global malaria control strategy recommends a multi-pronged control approach that combines multiple preventive interventions with prompt diagnosis and treatment of symptomatic persons with efficacious antimalarial drugs (<LINK REF="REF-WHO-2000" TYPE="REFERENCE">WHO 2000</LINK>; <LINK REF="REF-WHO-2005" TYPE="REFERENCE">WHO 2005</LINK>). Artemisinin-based combination therapy (ACT) regimens have replaced chloroquine in most malaria-endemic countries as the first-line treatment for uncomplicated <I>P. falciparum</I> malaria, due to the widespread development of parasite resistance to chloroquine. The effectiveness of ACTs has been proven by several randomized controlled trials, but access to prompt ACT treatment has remained low in most parts of sub-Saharan Africa due to limited resources for health care (<LINK REF="REF-WHO-2005" TYPE="REFERENCE">WHO 2005</LINK>). Recent reports indicate that less than one-third of African children aged under five years who are sick with malaria receive prompt treatment with ACTs (<LINK REF="REF-UNICEF-2007" TYPE="REFERENCE">UNICEF 2007</LINK>).</P>
<P>Vector control is also another important part of the global malaria control strategy. The effectiveness of insecticide treated nets (ITNs) in reducing malaria morbidity and mortality in preschool children (<LINK REF="REF-Lengeler-2004" TYPE="REFERENCE">Lengeler 2004</LINK>) and pregnant women (<LINK REF="REF-Gamble-2006" TYPE="REFERENCE">Gamble 2006</LINK>) has been confirmed, but coverage of this intervention in most sub-Saharan African countries lags far behind global targets. By 2009, less than one-third of the endemic countries in this region had attained 30% coverage for children under five years, far below the Roll Back Malaria (RBM) targets of 60% and 80% for 2005 and 2010 respectively (<LINK REF="REF-WHO-2009" TYPE="REFERENCE">WHO 2009</LINK>). Indoor residual spraying (IRS) is another vector control measure recommended by the WHO for community protection. However, it is expensive and requires high coverage to be effective (<LINK REF="REF-WHO-2006" TYPE="REFERENCE">WHO 2006</LINK>). Such high levels of coverage would be difficult to attain in many endemic areas, especially those with high perennial transmission.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Malaria prevention using drugs</HEADING>
<P>Prophylaxis and IPT are two drug-based methods for preventing malaria. Prophylaxis refers to "the administration of a drug in such a way that its blood concentration is maintained above the level that inhibits parasite growth, at the pre-erythrocytic or erythrocytic stage of the parasite's life-cycle, for the duration of the period at risk" (<LINK REF="REF-Greenwood-2006" TYPE="REFERENCE">Greenwood 2006</LINK>). Drugs used for malaria prophylaxis are usually given in daily or weekly doses.</P>
<P>Intermittent treatment, also known as 'intermittent preventive treatment' or 'intermittent presumptive treatment' (IPT), is an alternative strategy and is defined as "the administration of a full therapeutic course of an antimalarial or antimalarial combination to a selected, target population at specified times without determining whether or not the subject is infected."(<LINK REF="REF-Greenwood-2010" TYPE="REFERENCE">Greenwood 2010</LINK>). While some experts believe that IPT is of benefit through some mechanism that is qualitatively different to prophylaxis, others suggest it is basically the same mechanism (<LINK REF="REF-White-2005" TYPE="REFERENCE">White 2005</LINK>).</P>
<P>Some scientists are concerned that prophylaxis in children may impair the acquisition of natural immunity to malaria and therefore make them more vulnerable to severe malaria when they grow older (<LINK REF="REF-WHO-1993" TYPE="REFERENCE">WHO 1993</LINK>). Previous research has shown that young African children who received malaria prophylaxis over an extended period of time had lower levels of malaria antibodies than their counterparts, although there is less robust evidence that this increased the risk of death from malaria later in life (<LINK REF="REF-Otoo-1988b" TYPE="REFERENCE">Otoo 1988b</LINK>; <LINK REF="REF-Greenwood-2004" TYPE="REFERENCE">Greenwood 2004</LINK>). Also, there are concerns that the widespread use of antimalarial drugs for prophylaxis in young children could increase the resistance of the malaria parasites to these drugs (<LINK REF="REF-WHO-1990" TYPE="REFERENCE">WHO 1990</LINK>; <LINK REF="REF-WHO-1993" TYPE="REFERENCE">WHO 1993</LINK>; <LINK REF="REF-Alexander-2007" TYPE="REFERENCE">Alexander 2007</LINK>). However, the design of a randomized controlled trial will not detect this.</P>
<P>One of the assumed advantages of IPTc over prophylaxis, especially when used during a defined malaria transmission season, is the belief that short and intermittent use of antimalarial drugs for preventive purposes are unlikely to result in as much compromise of natural immunity as continuous prophylaxis (<LINK REF="REF-Greenwood-2010" TYPE="REFERENCE">Greenwood 2010</LINK>). Researchers have defined an area as having marked seasonality in malaria transmission if 75% or more of all malaria episodes occur within six months or less of the year (<LINK REF="REF-Roca_x002d_Feltrer-2009" TYPE="REFERENCE">Roca-Feltrer 2009</LINK>). IPTc is also likely to have fewer adverse events than prophylaxis because it is taken less often, and be easier to deliver through clinics (<LINK REF="REF-Aponte-2009" TYPE="REFERENCE">Aponte 2009</LINK>).</P>
<P>IPT is now a recommended strategy for preventing the complications of malaria in pregnant women and infants living in endemic settings (<LINK REF="REF-WHO-2005" TYPE="REFERENCE">WHO 2005</LINK>; <LINK REF="REF-WHO-2010" TYPE="REFERENCE">WHO 2010</LINK>). IPT in these population groups is not included in this review but has been evaluated elsewhere (<LINK REF="REF-Garner-2006" TYPE="REFERENCE">Garner 2006</LINK>; <LINK REF="REF-Aponte-2009" TYPE="REFERENCE">Aponte 2009</LINK>).</P>
<P>An earlier version of this systematic review addressed the broader question of the effectiveness of chemoprevention (including prophylaxis and IPT) against malaria in preschool children resident in endemic communities. Continuous prophylaxis is no longer included in this review, as attention has turned towards intermittent treatment strategies, but the details of prophylaxis trials are well documented in the previous versions of this review available from the archives of The Cochrane Collaboration (<LINK REF="REF-Meremikwu-2002" TYPE="REFERENCE">Meremikwu 2002</LINK>, <LINK REF="REF-Meremikwu-2005" TYPE="REFERENCE">Meremikwu 2005</LINK>, <LINK REF="REF-Meremikwu-2008" TYPE="REFERENCE">Meremikwu 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Why it is important to do this review</HEADING>
<P>IPTc has the potential to provide significant health benefits for pre-school age children, especially in areas of seasonal transmission. In order to provide reliable evidence to inform public health guidance and policy on this issue the need for a systematic review on this subject has become pertinent.</P>
<P>A further change in terminology has occurred recently, and the WHO now refer to IPTc targeted at areas of seasonal transmission as 'Seasonal Malaria Chemoprevention'.</P>
</SUBSECTION>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-01-17 08:25:08 +0000" MODIFIED_BY="[Empty name]">
<P>To evaluate the effects of Intermittent Preventive Treatment (IPTc) to prevent malaria in preschool children living in endemic areas with seasonal transmission.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-01-17 17:01:24 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-01-17 17:01:24 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2012-01-13 11:48:10 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials. The randomization unit may be the individual participant or a cluster, such as a household.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-01-17 16:27:50 +0000" MODIFIED_BY="[Empty name]">
<P>Children aged below six years living in an area where malaria is endemic with seasonal transmission. Children with unknown infection status (ie unknown whether each child was infected or uninfected) or known infection status, were eligible.</P>
<P>Trials that included only infants (age &lt; 12 months) and trials that included only anaemic participants were excluded from this review.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-01-17 15:13:50 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Intervention</HEADING>
<UL>
<LI>IPTc, defined as a full curative dose of an antimalarial alone or in combination given to children monthly or every two months during the malaria transmission season.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Control</HEADING>
<UL>
<LI>Placebo or no treatment.</LI>
</UL>
<P>Trials that allocated an additional intervention to both the intervention and control group were also included providing the additional intervention was the same for each group.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-01-17 17:01:24 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Primary</HEADING>
<UL>
<LI>Clinical malaria (clinical feature of malaria with asexual peripheral parasitaemia of any density).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary</HEADING>
<UL>
<LI>Severe malaria (as defined by WHO, (<LINK REF="REF-WHO-2000" TYPE="REFERENCE">WHO 2000</LINK>)).</LI>
<LI>Parasitaemia.</LI>
<LI>Death from any cause.</LI>
<LI>Hospital admission for any reason.</LI>
<LI>Severe anaemia (ie haemoglobin &lt; 5 g/dL).</LI>
<LI>Moderately severe anaemia (ie haemoglobin &lt; 8 g/dL or haematocrit &lt; 25%).</LI>
<LI>Any anaemia (ie haemoglobin &lt; 11 g/dL).</LI>
<LI>Haemoglobin (or haematocrit).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<UL>
<LI>Serious adverse events (ie any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage).</LI>
<LI>Non-serious adverse events (ie any adverse change in health or side effect that occurs in a person within the follow-up time of the trial, but is not a serious adverse event).</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-08-11 13:29:58 +0100" MODIFIED_BY="[Empty name]">
<P>We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress).</P>
<SUBSECTION>
<HEADING LEVEL="3">Databases</HEADING>
<P>We searched the following databases using the search terms and strategy described in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>: Cochrane Infectious Diseases Group Specialized Register (July 2011); Cochrane Central Register of Controlled Trials (CENTRAL), published in <I>The Cochrane Library </I>(2011, Issue 6 ); MEDLINE (1966 to July 2011); EMBASE (1974 to July 2011); and LILACS (1982 to July 2011). We also searched the <I>meta</I>Register of Controlled Trials (<I>m</I>RCT) using 'malaria', 'child*', 'intermittent', 'prevent*' and 'IPT' as search terms (July 2011).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Researchers</HEADING>
<P>We contacted researchers working in the field for unpublished and ongoing trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Reference lists</HEADING>
<P>We also checked the reference lists of all studies identified by the above methods.</P>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-01-17 16:35:42 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2012-01-17 16:34:29 +0000" MODIFIED_BY="[Empty name]">
<P>Two authors (EE, CO) independently screened the results of the literature search for potentially relevant trials and obtained the full reports of the potentially relevant trials. Two authors (EE, CO) independently assessed their eligibility using a form based on the inclusion criteria. Each trial report was scrutinized to ensure that multiple publications from the same trial were included only once. The trial's investigators were contacted for clarification if eligibility was unclear. We resolved disagreements through discussion, and when necessary, by consulting a member of The Cochrane Infectious Diseases Group editorial team. We listed the excluded studies and the reasons for their exclusion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-01-17 16:34:50 +0000" MODIFIED_BY="[Empty name]">
<P>Two authors (MM, EE) independently extracted data from the included trials using a data extraction form. We resolved disagreements through discussion by all four reviewers and, when necessary, by consulting a member of the Cochrane Infectious Diseases Group editorial team. We contacted the corresponding publication author in the case of unclear information or missing data.</P>
<P>For each outcome, we extracted the number of patients randomized and the number analysed in each treatment group for each trial.</P>
<P>For dichotomous outcomes from trials that randomized individual patients, we recorded the number of participants experiencing the event and the number analysed in each treatment group. For continuous outcomes, we extracted arithmetic means and standard deviations, along with the number of patients analysed, for each treatment group. For each count outcome, we extracted a rate ratio with its standard error, however, when this information was not given we extracted the number of episodes and the number of person-years for each treatment group.</P>
<P>For trials that randomized clusters, we recorded the number of clusters in the trial, the average size of clusters, and the randomization unit (eg household or institution). The statistical methods used to analyse the trial were documented along with details describing whether these methods adjusted for clustering or other covariates. When reported, estimates of the intra-cluster correlation (ICC) coefficient for each outcome were recorded. When the trials' analyses had adjusted for clustering, we extracted the treatment effect and a corresponding measure of variability. Where the analyses were not adjusted for clustering, we extracted the same data as for the trials that randomized individual patients.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-01-16 15:30:12 +0000" MODIFIED_BY="[Empty name]">
<P>Two authors (MM, CO) independently assessed the risk of bias of each trial using a risk of bias form. We attempted to contact the authors if this information was not specified or if it was unclear. We resolved any disagreements by discussion between review authors.</P>
<P>For trials that randomized individuals, six components were assessed: generation of the randomization sequence, allocation concealment, blinding, incomplete outcome data, selective outcome reporting and other biases (such as the trial stopped early). For trials that randomized clusters, additional components were assessed, that is, recruitment bias, baseline imbalances, loss of clusters, incorrect analysis and comparability with trials that randomized individuals.</P>
<P>Judgements of 'yes', 'no' and 'unclear' were made to indicate a low, high or unclear risk of bias. We presented the results of the assessment in a risk of bias graph, risk of bias tables and a risk of bias summary.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-01-13 13:47:22 +0000" MODIFIED_BY="[Empty name]">
<P>The risk ratio was used to summarise dichotomous outcomes, the mean difference was reported for continuous outcomes, and the rate ratio was used for count outcomes. All measures of effect were presented with 95% CI.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2012-01-13 14:45:24 +0000" MODIFIED_BY="[Empty name]">
<P>If the original trial analyses had not adjusted for clustering, we planned to adjust the results for clustering, by multiplying the standard errors of the treatment effect by the square root of the design effect. The design effect is calculated as 1+(m-1)*ICC where m is the average cluster size and ICC is the intra-cluster correlation coefficient.  We planned to estimate the ICC from other trials included in the review or by contacting trial investigators.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2011-12-14 09:26:59 +0000" MODIFIED_BY="[Empty name]">
<P>We aimed to carry out the analysis according to the intention-to-treat principle. However, when there was loss to follow up, a complete-case analysis was employed, such that, patients for whom no outcome was reported were excluded from the analysis. This analysis assumes that the patients for whom an outcome is available are representative of the original randomized patients.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-01-17 16:35:20 +0000" MODIFIED_BY="[Empty name]">
<P>We inspected the forest plots to detect overlapping CIs, applied the Chi<SUP>2</SUP> test and a P value of 0.10 was used as the cut-off value to determine statistical significance. We also estimated the I<SUP>2</SUP> statistic with values of 30 to 59%, 60 to 89% , and 90 to 100%  used to denote moderate, substantial and considerable levels of heterogeneity respectively.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-05-03 07:04:37 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to explore publication biases by constructing a funnel plot providing sufficient studies contributed to the treatment comparison.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-01-13 15:16:04 +0000" MODIFIED_BY="[Empty name]">
<P>We used <LINK REF="REF-Review-Manager-_x0028_RevMan_x0029_-5" TYPE="REFERENCE">Review Manager (RevMan) 5</LINK> for data analysis.</P>
<P>We stratified the analyses by whether the outcome was measured during intervention or postintervention.</P>
<P>We combined cluster randomized trials that adjusted for clustering with trials that randomized individual patients using generic inverse variance meta-analysis. We tabulated the results from cluster randomized trials that did not adjusted for clustering.</P>
<P>In the first instance, we applied a fixed-effect meta-analysis. However, if we detected a degree of heterogeneity but still considered it appropriate to combine the trials, we used a random-effects approach.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-01-17 16:35:42 +0000" MODIFIED_BY="[Empty name]">
<P>If heterogeneity was detected, we explored possible causes using subgroup analyses. Subgroups used were: type of antimalarial drug and additional interventions (no additional intervention versus ITN versus other).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2012-01-16 15:30:16 +0000" MODIFIED_BY="[Empty name]">
<P>We conducted a sensitivity analysis to investigate the robustness of the results to the risk of bias components by including only trials that concealed the allocation and had low incomplete outcome data (i.e. &lt;10%).</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-01-17 17:37:15 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-01-17 08:32:42 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2012-01-17 07:53:31 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed the search results and included seven trials (see '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'), and excluded 95 studies (see '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>').</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2012-01-17 08:32:42 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Location</HEADING>
<P>All seven trials (12,589 participants) were conducted in West Africa: one in each of Burkina Faso, Gambia and Senegal; two in Ghana and Mali respectively.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Malaria endemicity</HEADING>
<P>The pattern of malaria transmission was seasonal in all trial sites. Five trials reported entomological inoculation rates (infective bites per person per year): 173 bites (<LINK REF="STD-Konate-2011" TYPE="STUDY">Konate 2011</LINK>); from 1 to 177 bites (<LINK REF="STD-Sesay-2011" TYPE="STUDY">Sesay 2011</LINK>), 65 bites (<LINK REF="STD-Kweku-2008" TYPE="STUDY">Kweku 2008</LINK>), from 6 to 37 bites (<LINK REF="STD-Dicko-2011" TYPE="STUDY">Dicko 2011</LINK>) and 10 bites (<LINK REF="STD-Ciss_x00e9_-2006" TYPE="STUDY">Cissé 2006</LINK>). Two trials did not report entomological inoculation rates but described malaria endemicity as hyperendemic in the study areas (<LINK REF="STD-Dicko-2008" TYPE="STUDY">Dicko 2008</LINK>, <LINK REF="STD-Tagbor-2011" TYPE="STUDY">Tagbor 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Trial design</HEADING>
<P>Six of the trials randomized individuals, while one randomized clusters (communities) (<LINK REF="STD-Tagbor-2011" TYPE="STUDY">Tagbor 2011</LINK>). This trial adjusted for clustering in its analysis by analysing the data at the community level. The length of follow-up for the included trials varied from six months to two years; with one year being most common.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interventions</HEADING>
<P>All seven trials comprehensively used IPTc for the primary prevention of anaemia and malaria in healthy preschool children during malaria transmission seasons from three to six months.</P>
<P>The trial regimens consisted of:</P>
<UL>
<LI>Standard treatment doses of sulfadoxine-pyrimethamine given monthly or every two months during the malaria transmission season (<LINK REF="STD-Dicko-2008" TYPE="STUDY">Dicko 2008</LINK>; <LINK REF="STD-Kweku-2008" TYPE="STUDY">Kweku 2008</LINK>),</LI>
<LI>A combination of standard treatment doses of sulphadoxine-pyrimethamine and amodiaquine monthly for three consecutive courses during the peak malaria transmission season (<LINK REF="STD-Dicko-2011" TYPE="STUDY">Dicko 2011</LINK>; <LINK REF="STD-Konate-2011" TYPE="STUDY">Konate 2011</LINK>;<LINK REF="STD-Sesay-2011" TYPE="STUDY">Sesay 2011</LINK>),</LI>
<LI>A combination of artesunate (4 mg/kg) plus amodiaquine (10 mg/kg) monthly or every two months (<LINK REF="STD-Kweku-2008" TYPE="STUDY">Kweku 2008</LINK>; <LINK REF="STD-Tagbor-2011" TYPE="STUDY">Tagbor 2011</LINK>),</LI>
<LI>A combination of the standard dose of sulfadoxine-pyrimethamine plus one dose of artesunate (4 mg/kg body weight) once monthly for three consecutive months (<LINK REF="STD-Ciss_x00e9_-2006" TYPE="STUDY">Cissé 2006</LINK>).</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">Co-interventions</HEADING>
<P>Two trials (<LINK REF="STD-Sesay-2011" TYPE="STUDY">Sesay 2011</LINK>, <LINK REF="STD-Tagbor-2011" TYPE="STUDY">Tagbor 2011</LINK>) studied the effect of IPTc in areas where access to antimalarials was also being improved through home-based management of malaria (HMM).</P>
<P>Two trials (<LINK REF="STD-Dicko-2011" TYPE="STUDY">Dicko 2011</LINK>, <LINK REF="STD-Konate-2011" TYPE="STUDY">Konate 2011</LINK>) administered IPTc alongside ITN distribution and promotion.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes</HEADING>
<P>Clinical malaria: Six trials reported on incidence of clinical malaria, while one reported incidence of fever episodes without parasitological confirmation (<LINK REF="STD-Tagbor-2011" TYPE="STUDY">Tagbor 2011</LINK>). Trialists reported clinical malaria defined by different parasite density cut-off points and defined by any parasitaemia but we extracted data on clinical malaria with any parasitaemia. Two trials provided adequate information on severe malaria for meta-analysis. Clinical malaria and severe malaria were reported as incidence rates.</P>
<P>Anaemia: All included trials provided some data on anaemia but only five provided adequate information for inclusion in meta-analysis. (<LINK REF="STD-Ciss_x00e9_-2006" TYPE="STUDY">Cissé 2006</LINK>; <LINK REF="STD-Dicko-2008" TYPE="STUDY">Dicko 2008</LINK>; <LINK REF="STD-Dicko-2011" TYPE="STUDY">Dicko 2011</LINK>; <LINK REF="STD-Konate-2011" TYPE="STUDY">Konate 2011</LINK>; <LINK REF="STD-Kweku-2008" TYPE="STUDY">Kweku 2008</LINK>). All five trials reported data on moderately severe anaemia (haemoglobin &lt; 8 g/dL or packed cell volume &lt; 25%) but only two (<LINK REF="STD-Dicko-2011" TYPE="STUDY">Dicko 2011</LINK>, <LINK REF="STD-Konate-2011" TYPE="STUDY">Konate 2011</LINK>) provided information on severe anaemia (haemoglobin &lt; 5 g/dL). Three trials (<LINK REF="STD-Dicko-2011" TYPE="STUDY">Dicko 2011</LINK>; <LINK REF="STD-Konate-2011" TYPE="STUDY">Konate 2011</LINK>; <LINK REF="STD-Tagbor-2011" TYPE="STUDY">Tagbor 2011</LINK>) provided data on mild anaemia (haemoglobin &lt; 11 g/dL). <LINK REF="STD-Tagbor-2011" TYPE="STUDY">Tagbor 2011</LINK> was a cluster-randomized trial and provided adequate information for calculation of design effect; anaemia data from this trial was therefore included in meta-analysis following adjustment for cluster design effect.</P>
<P>Other outcomes: Other relevant outcomes reported were death (six trials included in meta-analysis), hospital admission (three trials) and parasitaemia (six trials).</P>
<P>Adverse events: All trials reported on adverse events; information on adverse events are summarized in a table. Data on reported adverse events were included in meta-analysis if they helped to provide additional information to explain any remarkable differences observed between treatment and control groups.</P>
<P>Post-intervention (rebound) events: Data on post-intervention assessment of trial outcomes were included in meta-analysis if they were adequate; only a few trials provided adequate post-intervention data for meta-analysis. Three trials provided adequate information on incidence of clinical malaria post-intervention (<LINK REF="STD-Ciss_x00e9_-2006" TYPE="STUDY">Cissé 2006</LINK>; <LINK REF="STD-Dicko-2008" TYPE="STUDY">Dicko 2008</LINK>; <LINK REF="STD-Kweku-2008" TYPE="STUDY">Kweku 2008</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2012-01-16 23:59:21 +0000" MODIFIED_BY="[Empty name]">
<P>The excluded studies and the reason for their exclusion are shown in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-01-17 00:00:19 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>See </I>
<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>
<I> </I>and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> for a summary of the risk of bias assessments.</P>
<ALLOCATION MODIFIED="2012-01-17 00:00:19 +0000" MODIFIED_BY="[Empty name]">
<P>Six trials used suitable methods to generate the allocation sequence and were classified as low risk of bias. Four used a computer; one trial was randomized in permuted blocks of 10 by a statistician (<LINK REF="STD-Konate-2011" TYPE="STUDY">Konate 2011</LINK>), while another (<LINK REF="STD-Kweku-2008" TYPE="STUDY">Kweku 2008</LINK>) used simple balloting with tokens. One trial did not describe the procedure used (<LINK REF="STD-Tagbor-2011" TYPE="STUDY">Tagbor 2011</LINK>) and was of unclear risk.</P>
<P>Allocation was adequately concealed in six trials that used identical and centrally-coded drugs and placebo or sealed, opaque envelopes. Allocation concealment was unclear in one trial (<LINK REF="STD-Tagbor-2011" TYPE="STUDY">Tagbor 2011</LINK>.</P>
</ALLOCATION>
<BLINDING MODIFIED="2012-01-16 16:34:22 +0000" MODIFIED_BY="[Empty name]">
<P>Five trials blinded participants and care providers/assessors. Blinding was unclear in one trial (<LINK REF="STD-Tagbor-2011" TYPE="STUDY">Tagbor 2011</LINK>), and not used in another described as open-label (<LINK REF="STD-Dicko-2008" TYPE="STUDY">Dicko 2008</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2012-01-16 16:34:35 +0000" MODIFIED_BY="[Empty name]">
<P>Four trials included more than 90% of randomized participants in the analysis and were classified as low risk of bias.</P>
<P>Three trials (<LINK REF="STD-Dicko-2008" TYPE="STUDY">Dicko 2008</LINK>; <LINK REF="STD-Sesay-2011" TYPE="STUDY">Sesay 2011</LINK>; <LINK REF="STD-Tagbor-2011" TYPE="STUDY">Tagbor 2011</LINK>) had greater than 10% attrition and were classified as high risk of bias.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2012-01-16 16:34:52 +0000" MODIFIED_BY="[Empty name]">
<P>All seven trials were judged to be at low risk of selective reporting.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2012-01-16 16:35:07 +0000" MODIFIED_BY="[Empty name]">
<P>The six trials that randomized individuals (<LINK REF="STD-Ciss_x00e9_-2006" TYPE="STUDY">Cissé 2006</LINK>; <LINK REF="STD-Dicko-2008" TYPE="STUDY">Dicko 2008</LINK>; <LINK REF="STD-Dicko-2011" TYPE="STUDY">Dicko 2011</LINK>; <LINK REF="STD-Konate-2011" TYPE="STUDY">Konate 2011</LINK>; <LINK REF="STD-Kweku-2008" TYPE="STUDY">Kweku 2008</LINK>; <LINK REF="STD-Sesay-2011" TYPE="STUDY">Sesay 2011</LINK>) were judged to be free of other sources of bias and thus low risk of bias.</P>
<P>The cluster randomized trial (<LINK REF="STD-Tagbor-2011" TYPE="STUDY">Tagbor 2011</LINK>) adjusted for clustering in the analysis (low risk of bias), had reasonably comparable treatment groups at baseline (low risk of bias); did not appear to be biased in terms of the recruited patients (low risk of bias); and showed no obvious differences with the trials that randomized individuals (low risk of bias).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-01-17 17:37:15 +0000" MODIFIED_BY="[Empty name]">
<P>Three trials compared IPTc versus placebo (<LINK REF="STD-Ciss_x00e9_-2006" TYPE="STUDY">Cissé 2006</LINK>; <LINK REF="STD-Dicko-2008" TYPE="STUDY">Dicko 2008</LINK>; <LINK REF="STD-Kweku-2008" TYPE="STUDY">Kweku 2008</LINK>).Two trials compared IPTc plus distribution and promotion of ITNs versus ITNs alone (<LINK REF="STD-Dicko-2011" TYPE="STUDY">Dicko 2011</LINK>; <LINK REF="STD-Konate-2011" TYPE="STUDY">Konate 2011</LINK>); and two trials compared IPTc plus Home-based Manaegement of malaria (HMM) versus HMM alone (<LINK REF="STD-Tagbor-2011" TYPE="STUDY">Tagbor 2011</LINK>; <LINK REF="STD-Sesay-2011" TYPE="STUDY">Sesay 2011</LINK>). The cluster randomized trial (<LINK REF="STD-Tagbor-2011" TYPE="STUDY">Tagbor 2011</LINK>) adjusted for clustering.</P>
<SUBSECTION>
<HEADING LEVEL="4">Clinical malaria</HEADING>
<P>Overall, IPTc prevented around three-quarters of clinical malaria episodes during the intervention period (rate ratio 0.26, 95% CI 0.17 to 0.38; 9321 participants, six trials; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The size of this effect varied from a 45% reduction in Mali (<LINK REF="STD-Dicko-2008" TYPE="STUDY">Dicko 2008</LINK>) to an 86% reduction in Senegal (<LINK REF="STD-Ciss_x00e9_-2006" TYPE="STUDY">Cissé 2006</LINK>). This variation could be explained by differences in efficacy between the antimalarial regimen used, by variation in local transmission or resistance patterns, or other factors related to the conduct of the trials. However there were insufficient trials to make meaningful conclusions from subgroup analyses exploring the effects of these factors (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
<P>Three studies continued to monitor children for a full transmission season after IPTc was stopped. There was no observed rebound increase in malaria in children who had received the intervention compared to controls (2299 participants, three trials; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Severe malaria</HEADING>
<P>IPTc also prevented around three-quarters of severe malaria episodes (rate ratio 0.27, 95% CI 0.10 to 0.76; 5964 participants, two trials; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). Two other trials [<LINK REF="STD-Ciss_x00e9_-2006" TYPE="STUDY">Cissé 2006</LINK>, <LINK REF="STD-Dicko-2008" TYPE="STUDY">Dicko 2008</LINK>] reported on severe malaria but did not provide suitable information for inclusion in the meta-analysis: <LINK REF="STD-Dicko-2008" TYPE="STUDY">Dicko 2008</LINK> reported that five cases of severe malaria occurred during the first 12 months of the follow-up, all in the control group incidence rate of 0.048 episodes per 1000 persons-days at risk. One child in the control group of <LINK REF="STD-Ciss_x00e9_-2006" TYPE="STUDY">Cissé 2006</LINK> died from severe malaria.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Parasitaemia</HEADING>
<P>The prevalence of parasitaemia was also reduced by IPTc compared to controls (risk ratio 0.35, 95% CI 0.25 to 0.50; 8781 participants, six trials; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). Again, although all trials favoured IPTc, there was substantial heterogeneity regarding the size of the effect but too few trials to explain this heterogeneity using subgroup analyses (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
<P>In the post-intervention transmission season, none there was no statistically significant difference in the prevalence of parasitaemia between IPTc and controls (1627 participants, two trials; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Death from any cause</HEADING>
<P>The number of deaths observed in these trials was very low. Although fewer deaths were seen in the children who received IPTc the difference was not statistically significant (9533 participants, six trials; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>The difference in deaths was also not statistically significant in the transmission season after IPTc was stopped (1,207 participants, one trial; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Hospital admission for any reason</HEADING>
<P>No significant difference in risk of hospitalization was found between IPTc and control groups, during the intervention (7171 participants, three trials; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>); or post-intervention (1207 participants, one trial; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Severe anaemia (haemoglobin &lt; 5 g/dL)</HEADING>
<P>Although the number of cases of severe anaemia reported in these trials was very low, there was a statistically significant reduction in the risk of severe anaemia with IPTc (risk ratio 0.24, 95% CI 0.06 to 0.94; 5964 participants, two trials; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Moderately severe anaemia (haemoglobin &lt; 8 g/dL or haematocrit &lt; 25%)</HEADING>
<P>During the intervention, there was a reduction in the risk of moderately severe anaemia in children given IPTc (risk ratio 0.71, 95% CI 0.52 to 0.98; 8805 participants, five trials; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). There was substantial heterogeneity between trials, with three trials suggesting benefit and two showing almost no difference (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). The cause of this heterogeneity is unclear. The trials showing greatest benefit were <LINK REF="STD-Dicko-2011" TYPE="STUDY">Dicko 2011</LINK> and <LINK REF="STD-Konate-2011" TYPE="STUDY">Konate 2011</LINK> which both administered IPTc as amodiaquine plus sulfadoxine-pyrimethamine (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>; <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>).</P>
<P>One cluster-randomized trial of IPTc plus HMM versus HMM (<LINK REF="STD-Tagbor-2011" TYPE="STUDY">Tagbor 2011</LINK>), which was not included in the meta-analysis, reported that the prevalence of severe anaemia (defined by trial authors as haemoglobin &lt; 7 g/dL) during the intervention was 0.44% in the IPTc arm compared to 1.75% in the control arm.</P>
<P>Post-intervention, no difference between IPTc and control was found (768 participants, one trial; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Any anaemia (haemoglobin &lt; 11 g/dL)</HEADING>
<P>During the intervention, the risk of mild anaemia did not significantly differ between IPTc and control groups (6786 participants, three trials; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).There was heterogeneity regarding the size of the effect but again, all of the trials favoured IPTc or showed almost no difference (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
<P>One cluster-randomized trial of IPTc plus HMM versus HMM (<LINK REF="STD-Tagbor-2011" TYPE="STUDY">Tagbor 2011</LINK>), which was not included in the meta-analysis, reported that the prevalence of mild anaemia (defined by trial authors as haemoglobin &lt; 11 g/dL) during the intervention was 46.4% in the IPTc arm compared to 47.2% in the control arm.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Haemoglobin</HEADING>
<P>During the intervention, three trials found no significant difference in mean haemoglobin concentration between IPTc and control arms (2266 participants, three trials; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). Post-intervention, no difference between IPTc and control was found (1207 participants, one trial; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">IPTc plus co-interventions</HEADING>
<P>Two trials distributed and promoted the use of ITNs to both the intervention and control groups (<LINK REF="STD-Dicko-2011" TYPE="STUDY">Dicko 2011</LINK> and <LINK REF="STD-Konate-2011" TYPE="STUDY">Konate 2011</LINK>). Despite ITN use being reported as &gt;90% in both treatment arms, IPTc had high protective efficacy against both clinical malaria (rate ratio 0.22, 95% CI 0.13 to 0.38; 5964 participants, two trials; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) and severe malaria (rate ratio 0.27, 95% CI 0.10 to 0.76; 5964 participants, two trials; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>Two trials were conducted in the context of a program of home-based management of malaria (HMM) which was provided to both the intervention and control groups (<LINK REF="STD-Sesay-2011" TYPE="STUDY">Sesay 2011</LINK>; <LINK REF="STD-Tagbor-2011" TYPE="STUDY">Tagbor 2011</LINK>). Only <LINK REF="STD-Sesay-2011" TYPE="STUDY">Sesay 2011</LINK> reported data on clinical malaria or anaemia, and failed to show a statistically significant effect (146 participants, one trial <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>, <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). Neither trial demonstrated a statistically significant reduction in parasitaemia follwing IPTc in the presence of HMM (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Serious adverse events during the intervention</HEADING>
<P>All seven trials reported that there were no cases of drug-related serious adverse events.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Non-serious adverse events during the intervention</HEADING>
<P>
<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK> displays adverse events reported by the three trials (<LINK REF="STD-Dicko-2011" TYPE="STUDY">Dicko 2011</LINK>; <LINK REF="STD-Konate-2011" TYPE="STUDY">Konate 2011</LINK>; and <LINK REF="STD-Sesay-2011" TYPE="STUDY">Sesay 2011</LINK>) that compared sulfadoxine-pyrimethamine plus amodiaquine versus a control. Children given IPTc were more likely to vomit than those in the control group (risk ratio 2.78, 95% CI 2.31 to 3.35; 3544 patients, two trials). When comparing the IPTc versus control groups, no difference in risk of diarrhoea (3951 patients, two trials), loss of appetite (3950 patients, two trials), jaundice (1353 patients, one trial), skin rash (5227 patients, three trials), itching (3949 patients, two trials), fever (3951 patients, two trials), drowsiness (2951 patients, two trials), or coughing (3913 patients, two trials), was detected.</P>
<P>
<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK> displays adverse events reported by <LINK REF="STD-Ciss_x00e9_-2006" TYPE="STUDY">Cissé 2006</LINK> that compared sulfadoxine-pyrimethamine plus artesunate versus a control. When comparing the IPTc versus control groups, there was no difference in risk of severe skin or neurological reaction (941 patients, one trial), convulsions (942 patients, one trial), minor skin rash (945 patients, one trial), dizziness (946 patients, one trial), diarrhoea (947 patients, one trial), or vomiting after first dose (948 patients, one trial). A difference between IPTc and control was detected in terms of the risk of nervousness (risk ratio 1.39, 95% CI 1.13 to 1.70; 943 patients, one trial) and pruritus (risk ratio 3.74, 95% CI 1.06 to 13.18, 944 patients, one trial). <LINK REF="STD-Ciss_x00e9_-2006" TYPE="STUDY">Cissé 2006</LINK> also found that children given IPTc were more likely to vomit than those in the control group after the second (risk ratio 7.26, 95% CI 2.58 to 20.39; 949 patients, one trial) and third dose (risk ratio 13.11, 95% CI 1.73 to 99.27; 950 patients, one trial).</P>
<P>Data reported by <LINK REF="STD-Tagbor-2011" TYPE="STUDY">Tagbor 2011</LINK>, that compared sulfadoxine-pyrimethamine plus amodiaquine versus control, is presented in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> but does not adjust for clustering.</P>
<P>
<LINK REF="STD-Dicko-2008" TYPE="STUDY">Dicko 2008</LINK>, that compared sulfadoxine-pyrimethamine versus control, simply reported that 'No subject was withdrawn because of allergy to sulfadoxine-pyrimethamine.'</P>
<P>
<LINK REF="STD-Kweku-2008" TYPE="STUDY">Kweku 2008</LINK>, that compared sulfadoxine-pyrimethamine plus artesunate versus control, reported that 'Adverse events were reported slightly less frequently in each of the three IPTc groups compared to the placebo group throughout the intervention period (5.6 % vs 5.9%). Diarrhoea, vomiting, drowsiness and abdominal pains were the most frequently reported symptoms in both IPTc and placebo groups. The number of children who reported at least one adverse event or any specific adverse event did not differ significantly between the study groups.' <LINK REF="STD-Kweku-2008" TYPE="STUDY">Kweku 2008</LINK> also reported that 'The incidence of mild adverse events such as fever, general weakness, vomiting, diarrhoea, abdominal pain and cough were similar in the placebo and IPTc groups'.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-01-17 17:39:01 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2012-01-17 16:14:30 +0000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
<P>IPTc given to children in areas with seasonal malaria transmission can prevent approximately three quarters of clinical malaria episodes (<I>high quality evidence</I>), and a similar proportion of severe malaria episodes (<I>high quality evidence; </I>
<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>). These effects remain present even where insecticide treated net (ITN) usage is high (<I>high quality evidence; </I>
<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</P>
<P>IPTc probably also produces a small reduction in all-cause mortality, but the trials were underpowered to reach statistical significance (<I>moderate quality </I>evidence).</P>
<P>The effect on anaemia varied between studies but the risk of moderately severe anaemia is probably reduced by IPTc (<I>moderate quality evidence</I>).</P>
<P>Serious drug-related adverse events, if they occur, are probably rare, with none reported in the six trials (<I>moderate quality </I>evidence). Amodiaquine plus sulphadoxine-pyrimethamine is the most studied drug combination for seasonal chemoprevention. Although effective, it does cause increased vomiting in this age-group (<I>high quality evidence; </I>
<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>).</P>
<P>When antimalarial IPTc was stopped, no rebound increase in malaria was observed in the three trials which continued follow-up for one season after IPTc (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-01-17 17:38:17 +0000" MODIFIED_BY="[Empty name]">
<P>All seven trials included in the review were conducted in areas of West Africa where <I>P. falciparum</I> is the predominant cause of malaria and transmission is highly seasonal, and the results can reasonably be applied to other areas with similar conditions. Most studies included healthy children aged between 3 and 59 months.</P>
<P>Several different IPTc regimens have been proposed and evaluated and all appear effective. Amodiaquine plus sulphadoxine-pyrimethamine is the most studied with more than 50% of all trial participants, but has not been directly compared with alternative regimens.</P>
<P>The reduction in clinical malaria episodes was large in all the trials but with some variation in the size of this effect. The reasons for this variation are unclear, but could be due to differences in the drug regimen, or differences in the local malaria transmission or resistance patterns. The trials were too few in number to perform meaningful subgroup analyses.</P>
<P>The results of trials included in this review demonstrated that IPTc given to preschool children over a short period (during malaria transmission season) is unlikely to result in a rebound effect on malaria morbidity or mortality, once IPTc is stopped. While the trials that reported detailed post-intervention data are few, these results are consistent across trials and appear to support the hypothesis that IPTc, allows longer periods in between treatments for children to acquire protective malarial immunity and are therefore less likely to cause rebound morbidity and mortality than continuous prophylaxis.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2012-01-17 17:39:01 +0000" MODIFIED_BY="[Empty name]">
<P>The quality of evidence has been assessed using the GRADE methodology.</P>
<P>The GRADE system considers &#8216;quality&#8217; to be a judgment of the extent to which we can be confident that the estimates of effect are correct. The level of &#8216;quality&#8217; is judged on a 4-point scale. Evidence from randomized controlled studies is initially graded as high and downgraded by one, two or three levels after full consideration of: any limitations in the design of the studies, the directness (or applicability) of the evidence, the consistency and precision of the results, and the possibility of publication bias.</P>
<P>The evidence that IPTc reduces clinical malaria episodes and severe malaria episodes is considered to be of 'High quality', which implies that we are confident in these estimates of effect and further research addressing these aspects is not necessary (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>The full GRADE profiles with reasons for the downgrading of evidence quality are available as <LINK TAG="APPENDICES" TYPE="SECTION">Appendices</LINK> addressing 5 questions:</P>
<UL>
<LI>Does IPTc reduce all-cause mortality and malaria morbidity in children aged &lt; 5 years?</LI>
<LI>Is there a rebound increase in all-cause mortality or malaria morbidity once IPTc is stopped?</LI>
<LI>Is IPTc still effective when ITN usage is high?</LI>
<LI>Is IPTc still effective where home-based management of malaria is practiced?</LI>
<LI>Is amodiaquine plus sulfadoxine-pyrimethamine an effective and safe option for IPTc?</LI>
</UL>
</QUALITY_OF_EVIDENCE>
<AGREEMENT MODIFIED="2012-01-17 15:35:55 +0000" MODIFIED_BY="[Empty name]">
<P>The findings of this review agree broadly with a similar systematic review published in 2011 (<LINK REF="REF-Wilson-2011" TYPE="REFERENCE">Wilson 2011</LINK>), but there are some differences in the conclusions regarding an effect on mortality.</P>
<P>
<LINK REF="REF-Wilson-2011" TYPE="REFERENCE">Wilson 2011</LINK> concludes that IPTc 'appears to have a substantial protective effect against all-cause mortality'. We have excluded data from some uncontrolled observational trials included by <LINK REF="REF-Wilson-2011" TYPE="REFERENCE">Wilson 2011</LINK>, and consequently our estimates do not reach statistical significance. However, we agree that a reduction in mortality with IPTc is likely and would be consistent with the high quality evidence of a reduction in severe malaria. However, the magnitude of this reduction, appears to be around 1 averted death per 1,000 children receiving IPTc.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-01-17 11:19:10 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2012-01-17 08:48:14 +0000" MODIFIED_BY="[Empty name]">
<P>Giving antimalarial drugs to preschool children (age &lt; six years) as IPTc during the malaria transmission season reduces the incidence of clinical malaria, and severe malaria. Several antimalarial drug combination options have been evaluated and show good levels of effectiveness, even in the presence of high levels of ITN use.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-01-17 11:19:10 +0000" MODIFIED_BY="[Empty name]">
<P>The evidence for benefit in areas with seasonal transmission is of high quality and further assessment of these antimalarials in these settings is unnecessary.</P>
<P>The effectiveness of IPT for pre-school age children living in settings with perennial transmission remains unclear, and may be an area for further research. However, concerns about the practicality, adverse effects, or costs of IPT in these settings may limit the usefulness of the intervention. </P>
<P>Concern remains about the potential for IPT to increase the development of antimalarial resistance, and resistance monitoring should be integrated into appropriate pharmaco-epidemiological studies and surveillance programmes.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-01-17 17:39:45 +0000" MODIFIED_BY="[Empty name]">
<P>Paul Garner, the Co-ordinating Editor of the Cochrane Infectious Diseases Group, supervised this update, read and commented on several versions of the draft. Aika Omari and Paul Garner co-authored the first version of this review with Martin Meremikwu (<LINK REF="REF-Meremikwu-2005" TYPE="REFERENCE">Meremikwu 2005</LINK>). The protocol for this review (<LINK REF="REF-Meremikwu-2002" TYPE="REFERENCE">Meremikwu 2002</LINK>) was developed during the Fellowship Programme organized by the Cochrane Infectious Diseases Group in November 2001. The UK Department for International Development (DFID) supports this Programme through the Effective Health Care Alliance Programme at the Liverpool School of Tropical Medicine. </P>
<P>This document is an output from a project funded by DFID for the benefit of developing countries. The views expressed are not necessarily those of DFID. The update was partly funded by a grant from the World Health Organization.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-01-16 15:10:42 +0000" MODIFIED_BY="[Empty name]">
<P>Martin Meremikwu, Ekpereonne Esu and Chioma Oringanje identified and extracted data from eligible trials for this update. Sarah Donegan, David Sinclair and Martin Meremikwu analysed the data, with Sarah Donegan playing the key role in handling the difficult statistical issues. Martin Meremikwu prepared the first draft, and the other authors read through and made input to all sections of the review. David Sinclair and Martin Meremikwu developed the GRADE profiles and summary of findings tables.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-01-18 09:32:18 +0000" MODIFIED_BY="[Empty name]">
<P>This version of the review differs from the first protocol and previous versions (<LINK REF="REF-Meremikwu-2002" TYPE="REFERENCE">Meremikwu 2002</LINK>, <LINK REF="REF-Meremikwu-2005" TYPE="REFERENCE">Meremikwu 2005</LINK>, <LINK REF="REF-Meremikwu-2008" TYPE="REFERENCE">Meremikwu 2008</LINK>), because it includes only trials that administered short duration (monthly or every two months) antimalarial treatments as IPTc to preschool children living in areas with seasonal malaria transmission. Unlike the earlier versions, it excluded trials on prolonged daily or weekly chemoprophylaxis and those that gave IPT to only, or predominantly, infants. </P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-01-17 17:49:01 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-01-17 17:49:01 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-12-14 11:07:56 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ciss_x00e9_-2006" MODIFIED="2011-12-13 19:21:19 +0000" MODIFIED_BY="[Empty name]" NAME="Cissé 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cissé B, Sokhna C, Boulanger D, Milet J, Bâ el H, Richardson K, et al</AU>
<TI>Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>367</VL>
<NO>9511</NO>
<PG>659-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dicko-2008" MODIFIED="2011-12-14 11:07:56 +0000" MODIFIED_BY="[Empty name]" NAME="Dicko 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-12-14 11:07:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dicko A, Sagara I, Sissoko MS, Guindo O, Diallo AI, Kone M, et al</AU>
<TI>Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali</TI>
<SO>Malaria Journal</SO>
<YR>2008</YR>
<VL>7</VL>
<PG>123-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dicko-2011" MODIFIED="2011-12-14 10:39:23 +0000" MODIFIED_BY="[Empty name]" NAME="Dicko 2011" YEAR="2008">
<REFERENCE MODIFIED="2011-12-14 10:39:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dicko A, Diallo AI, Tembine I, Dicko Y, Dara N, Sidibe Y, et al</AU>
<TI>Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Mali: a randomised, double-blind, placebo-controlled trial</TI>
<SO>PLoS Medicine</SO>
<YR>2011</YR>
<VL>8</VL>
<NO>2</NO>
<PG>e1000407</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Konate-2011" MODIFIED="2011-12-14 10:40:59 +0000" MODIFIED_BY="[Empty name]" NAME="Konate 2011" YEAR="2008">
<REFERENCE MODIFIED="2011-12-14 10:40:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Konate AT, Yaro JB, Oue´draogo AZ, Diarra A, Gansane A, Soulama I, et al</AU>
<TI>Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: A randomised, double-blind, placebo-controlled trial</TI>
<SO>PLoS Medicine</SO>
<YR>2011</YR>
<VL>8</VL>
<NO>2</NO>
<PG>e1000408</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kweku-2008" MODIFIED="2011-12-14 10:38:07 +0000" MODIFIED_BY="[Empty name]" NAME="Kweku 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-12-14 10:37:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Conteh L, Patouillard E, Kweku M, Legood R, Greenwood B, Chandramohan D</AU>
<TI>Cost effectiveness of seasonal intermittent preventive treatment using amodiaquine and artesunate or sulphadoxine-pyrimethamine in Ghanaian children</TI>
<SO>PLoS ONE</SO>
<YR>2010</YR>
<VL>5</VL>
<NO>8</NO>
<PG>e12223</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-14 10:38:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kweku M, Liu D, Adjuik M, Binka F, Seidu M, Greenwood B, et al</AU>
<TI>Seasonal intermittent preventive treatment for the prevention of anaemia and malaria in Ghanaian children: a randomized, placebo controlled trial</TI>
<SO>PloS One</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>12</NO>
<PG>e4000</PG>
<IDENTIFIERS MODIFIED="2011-12-14 10:38:02 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sesay-2011" MODIFIED="2011-12-14 10:46:02 +0000" MODIFIED_BY="[Empty name]" NAME="Sesay 2011" YEAR="2008">
<REFERENCE MODIFIED="2011-12-14 10:46:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sesay S, Milligan P, Touray E, Sowe M, Webb EL, Greenwood BM, et al</AU>
<TI>A trial of intermittent preventive treatment and home-based management of malaria in a rural area of The Gambia</TI>
<SO>Malaria Journal</SO>
<YR>2011</YR>
<VL>10</VL>
<PG>2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tagbor-2011" MODIFIED="2011-12-14 10:43:05 +0000" MODIFIED_BY="[Empty name]" NAME="Tagbor 2011" YEAR="2007">
<REFERENCE MODIFIED="2011-12-14 10:43:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tagbor H, Cairns M, Nakwa E, Browne E, Sarkodie B, Counihan H, et al</AU>
<TI>The clinical impact of combining intermittent preventive treatment with home management of malaria in children aged below 5 years: cluster randomised trial</TI>
<SO>Tropical Medicine and International Health</SO>
<YR>2011</YR>
<VL>16</VL>
<NO>3</NO>
<PG>280-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-01-17 17:49:01 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Akenzua-1985" NAME="Akenzua 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akenzua GI, Ihongbe JC, Imasuen IW</AU>
<TI>Haemopoietic response of Nigerian village children to iron, folate supplementation and malaria prophylaxis</TI>
<SO>Journal of Tropical Pediatrics</SO>
<YR>1985</YR>
<VL>31</VL>
<NO>1</NO>
<PG>59-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Allen-1990" NAME="Allen 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allen SJ, Otoo LN, Cooke GA, O'Donnell A, Greenwood BM</AU>
<TI>Sensitivity of Plasmodium falciparum to chlorproguanil in Gambian children after five years of continuous chemoprophylaxis</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1990</YR>
<VL>84</VL>
<NO>2</NO>
<PG>218</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alonso-1993" MODIFIED="2011-04-19 04:27:42 +0100" MODIFIED_BY="[Empty name]" NAME="Alonso 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-04-19 04:27:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alonso PL, Lindsay SW, Armstrong JR, Conteh M, Hill AG, David PH, et al</AU>
<TI>The effect of insecticide-treated bed nets on mortality of Gambian children</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>337</VL>
<NO>8756</NO>
<PG>1499-502</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-04-19 04:27:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alonso PL, Lindsay SW, Armstrong Schellenberg JR, Keita K, Gomez P, Shenton FC, et al</AU>
<TI>A malaria control trial using insecticide-treated bed nets and targeted chemoprophylaxis in a rural area of The Gambia, west Africa. 6. The impact of the interventions on mortality and morbidity from malaria</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1993</YR>
<VL>87 Suppl 2</VL>
<PG>37-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-04-19 04:27:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Picard J, Aikins M, Alonso PL, Armstrong Schellenberg JR, Greenwood BM, Mills A</AU>
<TI>A malaria control trial using insecticide-treated bed nets and targeted chemoprophylaxis in a rural area of The Gambia, west Africa. 8. Cost-effectiveness of bed net impregnation alone or combined with chemoprophylaxis in preventing mortality and morbidity from malaria in Gambian children</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1993</YR>
<VL>87 Suppl 2</VL>
<PG>53-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-04-19 04:27:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Picard J, Mills A, Greenwood B</AU>
<TI>The cost-effectiveness of chemoprophylaxis with Maloprim administered by primary health care workers in preventing death from malaria amongst rural Gambian children aged less than five years old</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1992</YR>
<VL>86</VL>
<NO>6</NO>
<PG>580-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Archibald-1956" NAME="Archibald 1956" YEAR="1956">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Archibald HM, Bruce-Chwatt LJ</AU>
<TI>Suppression of malaria with pyrimethamine in Nigerian schoolchildren</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1956</YR>
<VL>15</VL>
<NO>3-5</NO>
<PG>775-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-A_x002d_Schellenberg-2010" MODIFIED="2011-12-14 10:46:41 +0000" MODIFIED_BY="[Empty name]" NAME="A-Schellenberg 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-12-14 10:46:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Armstrong Schellenberg JR, Shirima K, Maokola W, Manzi F, Mrisho M, Mushi A, et al</AU>
<TI>Community effectiveness of intermittent preventive treatment for infants (IPTi) in rural southern Tanzania</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2009</YR>
<VL>82</VL>
<NO>5</NO>
<PG>772-81</PG>
<IDENTIFIERS MODIFIED="2011-12-14 10:46:32 +0000" MODIFIED_BY="Anne-Marie Stephani"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barger-2009" MODIFIED="2011-12-14 10:47:35 +0000" MODIFIED_BY="[Empty name]" NAME="Barger 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-12-14 10:47:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barger B, Maiga H, Traore OB, Tekete M, Tembine I, Dara A, et al</AU>
<TI>Intermittent preventive treatment using artemisinin-based combination therapy reduces malaria morbidity among school-aged children in Mali</TI>
<SO>Tropical Medicine and International Health</SO>
<YR>2009</YR>
<VL>14</VL>
<NO>7</NO>
<PG>784-91</PG>
<IDENTIFIERS MODIFIED="2011-12-14 10:47:35 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bell-2008" MODIFIED="2011-12-14 10:47:45 +0000" MODIFIED_BY="[Empty name]" NAME="Bell 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-12-14 10:47:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bell DJ, Nyirongo SK, Mukaka M, Zijlstra EE, Plowe CV, Molyneux ME et al</AU>
<TI>Sulfadoxine-pyrimethamine-based combinations for malaria: a randomised blinded trial to compare efficacy, safety and selection of resistance in Malawi</TI>
<SO>PLoS ONE</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>2</NO>
<PG>e1578</PG>
<IDENTIFIERS MODIFIED="2011-12-14 10:47:45 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bjorkman-1985a" NAME="Bjorkman 1985a" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bjorkman A, Brohult J, Willcox M, Pehrson PO, Rombo L, Hedman P, et al</AU>
<TI>Malaria control by chlorproguanil. I. Clinical effects and susceptibility of Plasmodium falciparum in vivo after seven years of monthly chlorproguanil administration to children in a Liberian village</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>1985</YR>
<VL>79</VL>
<NO>6</NO>
<PG>597-601</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bjorkman-1985b" NAME="Bjorkman 1985b" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bjorkman A, Rombo L, Hetland G, Willcox M, Hanson AP</AU>
<TI>Susceptibilty of Plasmodium falciparum to chloroquine in northern Liberia after 20 years of chemosuppression and therapy</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>1985</YR>
<VL>79</VL>
<NO>6</NO>
<PG>603-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bjorkman-1986" NAME="Bjorkman 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bjorkman A, Brohult J, Pehrson PO, Willcox M, Rombo L, Hedman P, et al</AU>
<TI>Monthly antimalarial chemotherapy to children in a holoendemic area of Liberia</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>1986</YR>
<VL>80</VL>
<NO>2</NO>
<PG>155-167</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bojang-2010a" MODIFIED="2011-12-14 10:47:58 +0000" MODIFIED_BY="[Empty name]" NAME="Bojang 2010a" YEAR="2007">
<REFERENCE MODIFIED="2011-12-14 10:47:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bojang K, Akor F, Bittaye O, Conway D, Bottomley C, Milligan P, et al</AU>
<TI>A randomized trial to compare the safety, tolerability and efficacy of three drug combinations for intermittent preventive treatment in children</TI>
<SO>PLoS One</SO>
<YR>2010</YR>
<VL>5</VL>
<NO>6</NO>
<PG>e11225</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-08-06 13:31:39 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bojang-2010b" MODIFIED="2012-01-06 14:18:05 +0000" MODIFIED_BY="[Empty name]" NAME="Bojang 2010b" YEAR="2004">
<REFERENCE MODIFIED="2012-01-06 14:18:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bojang KA, Milligan PJ, Conway DJ, Sisay-Joof F, Jallow M, Nwakanma DC, et al</AU>
<TI>Prevention of the recurrence of anaemia in Gambian children following discharge from hospital.</TI>
<SO>PLoS One</SO>
<YR>2010</YR>
<VL>5(6)</VL>
<NO>6</NO>
<PG>e11227</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bradley_x002d_Moore-1985" NAME="Bradley-Moore 1985" YEAR="1985">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bradley-Moore AM, Greenwood BM, Bradley AK, Akintunde A, Attai ED, Fleming AF, et al</AU>
<TI>A comparison of chloroquine and pyrimethamine as malaria chemoprophylactics in young Nigerian children</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1985</YR>
<VL>79</VL>
<NO>5</NO>
<PG>722-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bradley-Moore AM, Greenwood BM, Bradley AK, Akintunde A, Attai ED, Fleming AF, et al</AU>
<TI>Malaria chemoprophylaxis with chloroquine in young Nigerian children. IV. Its effect on haematological measurements</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>1985</YR>
<VL>79</VL>
<NO>6</NO>
<PG>585-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bradley-Moore AM, Greenwood BM, Bradley AK, Bartlett A, Bidwell DE, Voller A, et al</AU>
<TI>Malaria chemoprophylaxis with chloroquine in young Nigerian children. I. Its effect on mortality, morbidity and the prevalence of malaria</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>1985</YR>
<VL>79</VL>
<NO>6</NO>
<PG>549-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bradley-Moore AM, Greenwood BM, Bradley AK, Bartlett A, Bidwell DE, Voller A, et al</AU>
<TI>Malaria chemoprophylaxis with chloroquine in young Nigerian children. II. Effect on the immune response to vaccination</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>1985</YR>
<VL>79</VL>
<NO>6</NO>
<PG>563-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bradley-Moore AM, Greenwood BM, Bradley AK, Kirkwood BR, Gilles HM</AU>
<TI>Malaria chemoprophylaxis with chloroquine in young Nigerian children. III. Its effect on nutrition</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>1985</YR>
<VL>79</VL>
<NO>6</NO>
<PG>575-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Chandramohan-2005" MODIFIED="2012-01-06 14:11:00 +0000" MODIFIED_BY="[Empty name]" NAME="Chandramohan 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-06 14:11:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chandramohan D, Owusu-Agyei S, Carneiro I, Awine T, Amponsa-Achiano K, Mensah N, et al</AU>
<TI>Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana</TI>
<SO>BMJ</SO>
<YR>2005</YR>
<VL>331</VL>
<NO>7519</NO>
<PG>727-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Charles-1961" NAME="Charles 1961" YEAR="1961">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Charles LJ</AU>
<TI>Field trials with chlorproguanil in the prophylaxis of malaria in Ghana</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1961</YR>
<VL>24</VL>
<PG>457-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cisse-2009" MODIFIED="2011-12-14 10:55:50 +0000" MODIFIED_BY="[Empty name]" NAME="Cisse 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-12-14 10:55:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cisse B, Cairns M, Faye EN, Diaye O, Faye B, Cames C, et al</AU>
<TI>Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children</TI>
<SO>PloS One</SO>
<YR>2009</YR>
<VL>4</VL>
<NO>9</NO>
<PG>e7164</PG>
<IDENTIFIERS MODIFIED="2010-06-03 20:55:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-06-03 20:55:05 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE=" 10.1371/journal.pone.0007164"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clarke-2008" MODIFIED="2011-12-14 10:55:58 +0000" MODIFIED_BY="[Empty name]" NAME="Clarke 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-12-14 10:55:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clarke SE, Jukes MC, Njagi JK, Khasakhala L, Cundill B, Otido J, et al</AU>
<TI>Effect of intermittent preventive treatment of malaria on health and education in schoolchildren: a cluster-randomised, double-blind, placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>372</VL>
<NO>9633</NO>
<PG>127-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colbourne-1955" NAME="Colbourne 1955" YEAR="1955">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colbourne MJ</AU>
<TI>The effect of malaria suppression in a group of Accra school children</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1955</YR>
<VL>49</VL>
<NO>4</NO>
<PG>556-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coosemans-1987" NAME="Coosemans 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coosemans MH, Barutwanayo M, Onori E, Otoul C, Gryseels B, Wery M</AU>
<TI>Double-blind study to assess the efficacy of chlorproguanil given alone or in combination with chloroquine for malaria chemoprophylaxis in an area with Plasmodium falciparum resistance to chloroquine, pyrimethamine and cycloguanil</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1987</YR>
<VL>81</VL>
<NO>1</NO>
<PG>151-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coulibaly-2002" NAME="Coulibaly 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coulibaly D, Diallo DA, Thera MA, Dicko A, Guindo AB, Kone AK, et al</AU>
<TI>Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2002</YR>
<VL>67</VL>
<NO>6</NO>
<PG>604-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-David-1997" MODIFIED="2011-04-19 04:29:00 +0100" MODIFIED_BY="[Empty name]" NAME="David 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-04-19 04:29:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>David KP, Marbiah NT, Lovgren P, Greenwood BM, Petersen E</AU>
<TI>Hyperpigmented dermal macules in children following the administration of Maloprim for malaria chemoprophylaxis</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1997</YR>
<VL>91</VL>
<NO>2</NO>
<PG>204-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-04-19 04:29:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marbiah NT, Petersen E, David K, Magbity E, Lines J, Bradley DJ</AU>
<TI>A controlled trial of lambda-cyhalothrin-impregnated bed nets and/or dapsone/pyrimethamine for malaria control in Sierra Leone</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1998</YR>
<VL>58</VL>
<NO>1</NO>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delmont-1981" MODIFIED="2011-12-14 10:56:17 +0000" MODIFIED_BY="[Empty name]" NAME="Delmont 1981" YEAR="1981">
<REFERENCE MODIFIED="2011-12-14 10:56:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delmont J, Ranque P, Balique H, Tounkara A, Soula G, Quilici M, et al</AU>
<TI>The influence of malaria chemoprophylaxis on health of a rural community in West Africa</TI>
<TO>Influence d'une chimiprophylaxie antipaludique sur l'etat de sante d'une communaute rurale en Afrique de l'ouest. Resultats preliminaires</TO>
<SO>Bulletin de la Societe de Pathologie Exotique et de ses Filiales</SO>
<YR>1981</YR>
<VL>74</VL>
<NO>6</NO>
<PG>600-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Desai-2003" MODIFIED="2011-04-24 21:02:17 +0100" MODIFIED_BY="[Empty name]" NAME="Desai 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-04-24 21:02:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Desai MR, Mei JV, Kariuki SK, Wannemuehler KA, Philips-Howard PA, Nahlen BL, et al</AU>
<TI>Randomized, controlled trial of daily iron supplementation and intermittent sulfadoxine-pyrimethamine for the treatment of mild childhood anemia in western Kenya</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2003</YR>
<VL>187</VL>
<NO>4</NO>
<PG>658-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dicko-2010" MODIFIED="2012-01-13 14:48:02 +0000" MODIFIED_BY="[Empty name]" NAME="Dicko 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-01-13 14:48:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dicko A, Sagara I, Djimde AA, Toure SO, Traore M, Dama S, et al</AU>
<TI>Molecular markers of resistance to sulphadoxine-pyrimethamine one year after implementation of intermittent preventive treatment of malaria in infants in Mali</TI>
<SO>Malaria Journal</SO>
<YR>2010</YR>
<VL>9</VL>
<PG>9</PG>
<IDENTIFIERS MODIFIED="2012-01-13 14:48:02 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-01-13 14:48:02 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="   10.1186/1475-2875-9-9"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-06-03 21:13:47 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Escudie-1961" NAME="Escudie 1961" YEAR="1961">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Escudie A, Hamon J, Ricosse JH, Chartol A</AU>
<TI>Results of 2 years of antimalarial chemoprophylaxis in the rural African area in the pilot zone of Bobo Dioulasso (Haute Volta)</TI>
<TO>Resultats de deux annees de chimioprophylaxie antipaludique en milieur rural africain dans la zone pilote de Bobo Dioulasso (Haute Volta)</TO>
<SO>Medicine Tropicale</SO>
<YR>1961</YR>
<VL>21 Special</VL>
<PG>689-728</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fasan-1970" NAME="Fasan 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fasan PO</AU>
<TI>Field trial of cycloguanil pamoate in the treatment and suppression of malaria in Nigerian schoolchildren: a preliminary report</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1970</YR>
<VL>64</VL>
<NO>6</NO>
<PG>839-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fasan-1971" NAME="Fasan 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fasan PO</AU>
<TI>Trimethoprim plus sulphamethoxazole compared with chloroquine in the treatment and suppression of malaria in African schoolchildren</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>1971</YR>
<VL>65</VL>
<NO>1</NO>
<PG>117-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fernando-2006" NAME="Fernando 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernando D, De Silva D, Carter R, Mendis KN, Wickremasinghe R</AU>
<TI>A randomized, double-blind, placebo-controlled, clinical trial of the impact of malaria prevention on the educational attainment of school children</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2006</YR>
<VL>74</VL>
<NO>3</NO>
<PG>386-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gosling-2009" MODIFIED="2012-01-06 13:55:15 +0000" MODIFIED_BY="[Empty name]" NAME="Gosling 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-01-06 13:55:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gosling RD, Gesase S, Mosha JF, Carneiro I, Hashim R, Lemnge M, et al</AU>
<TI>Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>September 17, 2009</YR>
<VL>374</VL>
<NO>9700</NO>
<PG>1521-32</PG>
<IDENTIFIERS MODIFIED="2011-12-14 10:56:55 +0000" MODIFIED_BY="Anne-Marie Stephani"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenwood-1988" MODIFIED="2011-04-19 04:30:30 +0100" MODIFIED_BY="[Empty name]" NAME="Greenwood 1988" YEAR="1988">
<REFERENCE MODIFIED="2011-04-19 04:30:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenwood BM, Greenwood AM, Bradley AK, Snow RW, Byass P, Hayes RJ, et al</AU>
<TI>Comparison of two strategies for control of malaria within a primary health care programme in the Gambia</TI>
<SO>Lancet</SO>
<YR>1988</YR>
<VL>1</VL>
<NO>8595</NO>
<PG>1121-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenwood-1989" MODIFIED="2011-04-19 04:30:40 +0100" MODIFIED_BY="[Empty name]" NAME="Greenwood 1989" YEAR="1989">
<REFERENCE MODIFIED="2011-04-19 04:30:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fuller NJ, Bates CJ, Hayes RJ, Bradley AK, Greenwood AM, Tulloch S, et al</AU>
<TI>The effects of antimalarials and folate supplements on haematological indices and red cell folate levels in Gambian children</TI>
<SO>Annals of Tropical Paediatrics</SO>
<YR>1988</YR>
<VL>8</VL>
<NO>2</NO>
<PG>61-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-04-19 04:30:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Greenwood BM, Greenwood AM, Smith AW, Menon A, Bradley AK, Snow RW, et al</AU>
<TI>A comparative study of Lapudrine (chlorproguanil) and Maloprim (pyrimethamine and dapsone) as chemoprophylactics against malaria in Gambian children</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1989</YR>
<VL>83</VL>
<NO>2</NO>
<PG>182-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenwood-1995" MODIFIED="2011-04-19 04:30:48 +0100" MODIFIED_BY="[Empty name]" NAME="Greenwood 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-04-19 04:30:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenwood BM, David PH, Otoo-Forbes LN, Allen SJ, Alonso PL, Armstrong Schellenberg JR, et al</AU>
<TI>Mortality and morbidity from malaria after stopping malaria chemoprophylaxis</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1995</YR>
<VL>89</VL>
<NO>6</NO>
<PG>629-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grobusch-2007" MODIFIED="2011-12-14 10:58:28 +0000" MODIFIED_BY="[Empty name]" NAME="Grobusch 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-12-14 10:58:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Grobusch MP, Lell B, Schwarz NG, Gabor J, Dornemann J, Potschke M, et al</AU>
<TI>Intermittent preventive treatment against malaria in infants in Gabon - a randomized, double-blind, placebo-controlled trial</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2007</YR>
<VL>196</VL>
<NO>11</NO>
<PG>1595-602</PG>
<IDENTIFIERS MODIFIED="2011-12-14 10:58:28 +0000" MODIFIED_BY="Anne-Marie Stephani"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harland-1975" MODIFIED="2011-12-14 10:58:08 +0000" MODIFIED_BY="[Empty name]" NAME="Harland 1975" YEAR="1975">
<REFERENCE MODIFIED="2011-12-14 10:58:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harland PS, Frood JD, Parkin JM</AU>
<TI>Some effects of partial malaria suppression in Ugandan children during the first three years of life</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1975</YR>
<VL>69</VL>
<NO>2</NO>
<PG>261-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hogh-1993" MODIFIED="2011-12-14 10:58:19 +0000" MODIFIED_BY="[Empty name]" NAME="Hogh 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-12-14 10:58:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hogh B, Marbiah NT, Petersen E, Dolopaye E, Willcox M, Bjorkman A, et al</AU>
<TI>Classification of clinical falciparum malaria and its use for the evaluation of chemosuppression in children under six years of age in Liberia, West Africa</TI>
<SO>Acta Tropica</SO>
<YR>1993</YR>
<VL>54</VL>
<NO>2</NO>
<PG>105-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hogh-1994" NAME="Hogh 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hogh B, Thompson R, Lobo V, Dgedge M, Dziegiel M, Borre M, et al</AU>
<TI>The influence of Maloprim chemoprophylaxis on cellular and humoral immune responses to Plasmodium falciparum asexual blood stage antigens in schoolchildren living in a malaria endemic area of Mozambique</TI>
<SO>Acta Tropica</SO>
<YR>1994</YR>
<VL>57</VL>
<NO>4</NO>
<PG>265-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karunakaran-1980" NAME="Karunakaran 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karunakaran CS</AU>
<TI>A clinical trial of malaria prophylaxis using a single dose of chloroquine at different intervals in an endemic malarious area</TI>
<SO>Journal of Tropical Medicine and Hygiene</SO>
<YR>1980</YR>
<VL>83</VL>
<NO>5</NO>
<PG>195-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karwacki-1990" NAME="Karwacki 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karwacki JJ, Shanks GD, Limsomwong N, Singharaj P</AU>
<TI>Proguanil-sulphonamide for malaria prophylaxis</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1990</YR>
<VL>84</VL>
<NO>1</NO>
<PG>55-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kobbe-2007" MODIFIED="2011-04-24 20:47:27 +0100" MODIFIED_BY="[Empty name]" NAME="Kobbe 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-04-24 20:47:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kobbe R, Kreuzberg C, Adjei S, Thompson B, Langefeld I, Thompson PA, et al</AU>
<TI>A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2007</YR>
<VL>45</VL>
<NO>1</NO>
<PG>16-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-04-24 20:47:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marks F, von Kalckreuth V, Kobbe R, Adjei S, Adjei O, Horstmann RD, et al</AU>
<TI>Parasitological rebound effect and emergence of pyrimethamine resistance in Plasmodium falciparum after single-dose sulfadoxine-pyrimethamine</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2005</YR>
<VL>192</VL>
<NO>11</NO>
<PG>1962-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kollaritsch-1988" NAME="Kollaritsch 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kollaritsch H, Stemberger H, Mailer H, Kremsner P, Kollaritsch R, Leimer R, et al</AU>
<TI>Tolerability of long-term malaria prophylaxis with the combination mefloquine + sulfadoxine + pyrimethamine (Fansimef): results of a double blind field trial versus chloroquine in Nigeria</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1988</YR>
<VL>82</VL>
<NO>4</NO>
<PG>524-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kweku-2009" MODIFIED="2011-06-25 22:57:09 +0100" MODIFIED_BY="[Empty name]" NAME="Kweku 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-06-25 22:57:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kweku M, Webster J, Adjuik M, Abudey S, Greenwood B, Chandramohan D</AU>
<TI>Options for the delivery of intermittent preventive treatment for malaria to children: a community randomised trial</TI>
<SO>PloS One</SO>
<YR>2009</YR>
<VL>4</VL>
<NO>9</NO>
<PG>e7256</PG>
<IDENTIFIERS MODIFIED="2010-06-03 20:35:45 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-06-03 20:35:45 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1371/journal.pone.0007256"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laing-ABG-1970" NAME="Laing ABG 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laing AB</AU>
<TI>Malaria suppression with fortnightly doses of pyrimethamine with sulfadoxine in the Gambia</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1970</YR>
<VL>43</VL>
<NO>4</NO>
<PG>513-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lell-1998" NAME="Lell 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lell B, Luckner D, Ndjave M, Scott T, Kremsner PG</AU>
<TI>Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>351</VL>
<NO>9104</NO>
<PG>709-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lell-2000" NAME="Lell 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lell B, Faucher JF, Missinou MA, Borrmann S, Dangelmaier O, Horton J, et al</AU>
<TI>Malaria chemoprophylaxis with tafenoquine: a randomised study</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<NO>9220</NO>
<PG>2041-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lemnge-1997" MODIFIED="2011-04-19 04:33:15 +0100" MODIFIED_BY="[Empty name]" NAME="Lemnge 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-04-19 04:33:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lemnge MM, Msangeni HA, Ronn AM, Salum FM, Jakobsen PH, Mhina JI, et al</AU>
<TI>Maloprim malaria prophylaxis in children living in a holoendemic village in north-eastern Tanzania</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1997</YR>
<VL>91</VL>
<NO>1</NO>
<PG>68-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewis-1975" NAME="Lewis 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewiw AN, Ponnampalam JT</AU>
<TI>Suppression of malaria with monthly administration of combined sulphadoxine and pyrimethamine</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>1975</YR>
<VL>69</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Limsomwong-1988" NAME="Limsomwong 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Limsomwong N, Pang LW, Singharaj P</AU>
<TI>Malaria prophylaxis with proguanil in children living in a malaria-endemic area</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1988</YR>
<VL>38</VL>
<NO>2</NO>
<PG>231-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pang LW, Limsomwong N, Singharaj P, Canfield CJ</AU>
<TI>Malaria prophylaxis with proguanil and sulfisoxazole in children living in a malaria endemic area</TI>
<SO>Bulletin of the World Health Organisation</SO>
<YR>1989</YR>
<VL>67</VL>
<NO>1</NO>
<PG>51-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lucas-1969" NAME="Lucas 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lucas AO, Hendrickse RG, Okubadejo OA, Richards WH, Neal RA, Kofie BA</AU>
<TI>The suppression of malarial parasitaemia by pyrimethamine in combination with dapsone or sulphormethoxine</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1969</YR>
<VL>63</VL>
<NO>2</NO>
<PG>216-229</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lwin-1997" NAME="Lwin 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lwin M, Lin H, Linn N, Kyaw MP, Ohn M, Maung NS, et al</AU>
<TI>The use of personal protective measures in control of malaria in a defined community</TI>
<SO>Southeast Asian Journal of Tropical Medicine and Public Health</SO>
<YR>1997</YR>
<VL>28</VL>
<NO>2</NO>
<PG>254-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MacCormack-1983" NAME="MacCormack 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>MacCormack CP, Lwihula G</AU>
<TI>Failure to participate in a malaria chemosuppression programme: North Mara, Tanzania</TI>
<SO>Journal of Tropical Medicine and Hygiene</SO>
<YR>1983</YR>
<VL>86</VL>
<NO>3</NO>
<PG>99-107</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Macete-2006" MODIFIED="2011-04-24 20:47:37 +0100" MODIFIED_BY="[Empty name]" NAME="Macete 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-04-24 20:47:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Macete E, Aide P, Aponte JJ, Sanz S, Mandomando I, Espasa M, et al</AU>
<TI>Intermittent preventive treatment for malaria control administered at the time of routine vaccination in Mozambican infants: a randomised, placebo-controlled trial</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2006</YR>
<VL>194</VL>
<NO>3</NO>
<PG>276-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Massaga-2003" MODIFIED="2011-04-24 20:47:48 +0100" MODIFIED_BY="[Empty name]" NAME="Massaga 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-04-24 20:47:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Massaga JJ, Kitua AY, Lemnge MM, Akida JA, Malle LN, Ronn AM, et al</AU>
<TI>Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>361</VL>
<NO>9372</NO>
<PG>1853-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGregor-1966" NAME="McGregor 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McGregor IA, Williams K, Walker GH, Rahman AK</AU>
<TI>Cycloguanil pamoate in the treatment and suppression of malaria in the Gambia, West Africa</TI>
<SO>British Medical Journal</SO>
<YR>1966</YR>
<VL>5489</VL>
<PG>695-701</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Menendez-1997" MODIFIED="2011-04-19 04:31:33 +0100" MODIFIED_BY="[Empty name]" NAME="Menendez 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-04-19 04:31:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alonzo Gonzalez M, Menendez C, Font F, Kahigwa E, Kimario J, Mshinda H, et al</AU>
<TI>Cost-effectiveness of iron supplementation and malaria chemoprophylaxis in the prevention of anaemia and malaria among Tanzanian infants</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>2000</YR>
<VL>78</VL>
<NO>1</NO>
<PG>97-107</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-04-19 04:31:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beck HP, Felger I, Vounatsou P, Hirt R, Tanner M, Alonso P, et al</AU>
<TI>Effect of iron supplementation and malaria prophylaxis in infants on Plasmodium falciparum genotypes and multiplicity of infection</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1999</YR>
<VL>93 Suppl 1</VL>
<PG>41-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-04-19 04:31:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Menendez C, Kahigwa E, Hirt R, Vounatsou P, Aponte JJ, Font F, et al</AU>
<TI>Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<NO>9081</NO>
<PG>844-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Menon-1990" MODIFIED="2011-04-19 04:31:57 +0100" MODIFIED_BY="[Empty name]" NAME="Menon 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-04-19 04:31:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Menon A, Snow RW, Byass P, Greenwood BM, Hayes RJ, N'Jie AB</AU>
<TI>Sustained protection against mortality and morbidity from malaria in rural Gambian children by chemoprophylaxis given by village health workers</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1990</YR>
<VL>84</VL>
<NO>6</NO>
<PG>768-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1954" NAME="Miller 1954" YEAR="1954">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller MJ</AU>
<TI>A comparison of the antimalarial effects of suppressive doses of chloroquine amodiaquin and pyrimethamine</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1954</YR>
<VL>3</VL>
<NO>3</NO>
<PG>458-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mockenhaupt-2007" MODIFIED="2011-12-14 10:59:28 +0000" MODIFIED_BY="[Empty name]" NAME="Mockenhaupt 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-12-14 10:59:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mockenhaupt FP, Reither K, Zanger P, Roepcke F, Danquah I, Saad E, et al</AU>
<TI>Intermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, placebo-controlled trial in northern Ghana</TI>
<SO>Antimicrobial agents and chemotherapy</SO>
<YR>2007</YR>
<VL>51</VL>
<NO>9</NO>
<PG>3273-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murphy-1993" NAME="Murphy 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murphy GS, Basri H, Purnomo, Andersen EM, Bangs MJ, Mount DL, et al</AU>
<TI>Vivax malaria resistant to treatment and prophylaxis with chloroquine</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>341</VL>
<NO>8837</NO>
<PG>96-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nahum-2007" MODIFIED="2011-12-14 10:59:44 +0000" MODIFIED_BY="[Empty name]" NAME="Nahum 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-12-14 10:59:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nahum A, Erhart A, Gazard D, Agbowai C, Van Overmeir C, van Loen H, et al</AU>
<TI>Adding artesunate to sulphadoxine-pyrimethamine greatly improves the treatment efficacy in children with uncomplicated falciparum malaria on the coast of Benin, West Africa</TI>
<SO>Malaria Journal</SO>
<YR>2007</YR>
<VL>6</VL>
<PG>170</PG>
<IDENTIFIERS MODIFIED="2010-06-03 20:28:42 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-06-03 20:28:42 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1186/1475-2875-6-170"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nakibuuka-2009" MODIFIED="2011-12-14 11:00:02 +0000" MODIFIED_BY="[Empty name]" NAME="Nakibuuka 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-12-14 11:00:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nakibuuka V, Ndeezi G, Nakiboneka D, Ndugwa CM, Tumwine JK</AU>
<TI>Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial</TI>
<SO>Malaria Journal</SO>
<YR>2009</YR>
<VL>8</VL>
<PG>237</PG>
<IDENTIFIERS MODIFIED="2010-06-03 20:31:43 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-06-03 20:31:43 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1186/1475-2875-8-237"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nevill-1988" MODIFIED="2011-12-14 11:00:15 +0000" MODIFIED_BY="[Empty name]" NAME="Nevill 1988" YEAR="1988">
<REFERENCE MODIFIED="2011-12-14 11:00:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nevill CG, Watkins WM, Carter JY, Munafu CG</AU>
<TI>Comparison of mosquito nets, proguanil hydrochloride, and placebo to prevent malaria</TI>
<SO>British Medical Journal</SO>
<YR>1988</YR>
<VL>297</VL>
<NO>6645</NO>
<PG>401-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nevill-1994" NAME="Nevill 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nevill CG, Lury JD, Mosobo MK, Watkins HM, Watkins WM</AU>
<TI>Daily chlorproguanil is an effective alternative to daily proguanil in the prevention of Plasmodium falciparum malaria in Kenya</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1994</YR>
<VL>88</VL>
<NO>3</NO>
<PG>319-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nsimba-2008" MODIFIED="2012-01-17 17:49:01 +0000" MODIFIED_BY="[Empty name]" NAME="Nsimba 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-17 17:49:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nsimba B, Guiyedi V, Mabika-Mamfoumbi M, Mourou-Mbina JR, Ngoungou E, Bouyou-Akotet M, et al</AU>
<TI>Sulphadoxine/pyrimethamine versus amodiaquine for treating uncomplicated childhood malaria in Gabon: a randomized trial to guide national policy</TI>
<SO>Malaria Journal</SO>
<YR>2008</YR>
<PG>31</PG>
<IDENTIFIERS MODIFIED="2012-01-17 17:48:55 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nwokolo-2001" NAME="Nwokolo 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nwokolo C, Wambebe C, Akinyanju O, Raji AA, Audu BS, Emordi IJ, et al</AU>
<TI>Mefloquine versus proguanil in short-term malaria chemoprophylaxis in sickle cell anaemia</TI>
<SO>Clinical Drug Investigation</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>8</NO>
<PG>537-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Odhiambo-2010" MODIFIED="2011-12-14 11:00:42 +0000" MODIFIED_BY="[Empty name]" NAME="Odhiambo 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-12-14 11:00:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Odhiambo FO, Hamel MJ, Williamson J, Lindblade K, ter Kuile FO, Peterson E, et al</AU>
<TI>Intermittent preventive treatment in infants for the prevention of malaria in rural Western Kenya: a randomized, double-blind placebo-controlled trial</TI>
<SO>PLoS ONE</SO>
<YR>2010</YR>
<VL>5</VL>
<NO>4</NO>
<PG>e10016</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Onori-1982" NAME="Onori 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Onori E, Grab B, Ambroise-Thomas P, Thelu J</AU>
<TI>Incipient resistance of Plasmodium falciparum to chloroquine among a semi-immune population of the United Republic of Tanzania. 2. The impact of chloroquine used as a chemosuppressant on the immune status of the population</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1982</YR>
<VL>60</VL>
<NO>6</NO>
<PG>899-906</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Otoo-1988a" MODIFIED="2011-04-19 04:32:20 +0100" MODIFIED_BY="[Empty name]" NAME="Otoo 1988a" YEAR="1988">
<REFERENCE MODIFIED="2011-04-19 04:32:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Otoo LN, Riley EM, Menon A, Byass P, Greenwood BM</AU>
<TI>Cellular immune responses to Plasmodium falciparum antigens in children receiving long term anti-malarial chemoprophylaxis</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1989</YR>
<VL>83</VL>
<NO>6</NO>
<PG>778-782</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-04-19 04:32:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Otoo LN, Snow RW, Menon A, Byass P, Greenwood BM</AU>
<TI>Immunity to malaria in young Gambian children after a two-year period of chemoprophylaxis</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1988</YR>
<VL>82</VL>
<NO>1</NO>
<PG>59-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oyediran-1993" NAME="Oyediran 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oyediran AB, Topley E, Osunkoya BO, Bamgboye A, Williams AI, Ogunba EO, et al</AU>
<TI>Severe morbidity among children in a trial malaria chemoprophylaxis with pyrimethamine or chloroquine in Ibarapa, Nigeria</TI>
<SO>African Journal of Medicine and Medical Sciences</SO>
<YR>1993</YR>
<VL>22</VL>
<NO>1</NO>
<PG>55-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pang-1989" NAME="Pang 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pang LW, Limsomwong N, Singharaj P, Canfield CJ</AU>
<TI>Malaria prophylaxis with proguanil and sulfisoxazole in children living in a malaria endemic area</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1989</YR>
<VL>67</VL>
<NO>1</NO>
<PG>51-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Panton-1985" NAME="Panton 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Panton LJ, Tulloch S, Bradley AK, Greenwood BM</AU>
<TI>Susceptibility of Plasmodium falciparum in the Gambia to pyrimethamine, Maloprim and chloroquine</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1985</YR>
<VL>79</VL>
<NO>4</NO>
<PG>484-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pividal-1992" NAME="Pividal 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pividal J, Viktinski V, Streat E, Schapira A</AU>
<TI>Efficacy of dapsone with pyrimethamine (Maloprim) for malaria prophylaxis in Maputo, Mozambique</TI>
<SO>East African Medical Journal</SO>
<YR>1992</YR>
<VL>69</VL>
<NO>6</NO>
<PG>303-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pribadi-1986" NAME="Pribadi 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pribadi W, Muzaham F, Santoso T, Rasidi R, Rukmono B, Soeharto</AU>
<TI>The implementation of community participation in the control of malaria in rural Tanjung Pinang, Indonesia</TI>
<SO>Southeast Asian Journal of Tropical Medicine and Public Health</SO>
<YR>1986</YR>
<VL>17</VL>
<NO>3</NO>
<PG>371-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pringle-1966" NAME="Pringle 1966" YEAR="1966">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pringle G, Avery-Jones S</AU>
<TI>Observations on the early course of untreated falciparum malaria in semi-immune African children following a short period of protection</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1966</YR>
<VL>34</VL>
<NO>2</NO>
<PG>269-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ringwald-1989" NAME="Ringwald 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ringwald P, Le Bras J, Havermann K, Flachs H</AU>
<TI>A study of the efficacy of the chemoprevention of malaria using chlorproguanil alone or in combination with chloroquine in French expatriates in Dar-es-Salaam, Tanzania</TI>
<TO>Etude de l'efficacite d'une chimioprophylaxie du paludisme par le chlorproguanil associe ou non a la chloroquine chez des expatries francais a Dar-es-Salaam, Tanzanie</TO>
<SO>Bulletin de la Societe de Pathologie Exotique et de ses Filiales</SO>
<YR>1989</YR>
<VL>82</VL>
<NO>1</NO>
<PG>124-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robert-1989" NAME="Robert 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Robert V, Hervy JP, Baudon D, Roux J, Legros F, Carnevale P</AU>
<TI>The effect of 2 chloroquine-based drug strategies (prevention and therapy of febrile cases] on malaria transmission</TI>
<TO>Influence de deux strategies medicamenteuses par chloroquine (prophylaxie et therape des acces febriles) sur la transmission du paludisme</TO>
<SO>Bulletin de la Societe de Pathologie Exotique et de ses Filiales</SO>
<YR>1989</YR>
<VL>82</VL>
<NO>2</NO>
<PG>243-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rohner-2010" MODIFIED="2011-12-14 11:01:29 +0000" MODIFIED_BY="[Empty name]" NAME="Rohner 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-12-14 11:01:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rohner F, Zimmermann MB, Amon RJ, Vounatsou P, Tschannen AB, N'Goran EK, et al</AU>
<TI>In a randomized controlled trial of iron fortification, anthelmintic treatment, and intermittent preventive treatment of malaria for anemia control in Ivorian children, only anthelmintic treatment shows modest benefit</TI>
<SO>Journal of Nutrition</SO>
<YR>2010</YR>
<VL>140</VL>
<NO>3</NO>
<PG>635-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rooth-1991" NAME="Rooth 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rooth I, Sinani HM, Bjorkman A</AU>
<TI>Proguanil daily or chlorproguanil twice weekly are efficacious against falciparum malaria in a holoendemic area of Tanzania</TI>
<SO>Journal of Tropical Medicine and Hygiene</SO>
<YR>1991</YR>
<VL>94</VL>
<NO>1</NO>
<PG>45-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosen-2005" NAME="Rosen 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosen JB, Breman JG, Manclark CR, Meade BD, Collins WE, Lobel HO, et al</AU>
<TI>Malaria chemoprophylaxis and the serologic response to measles and diphtheria-tetanus-whole-cell pertussis vaccines</TI>
<SO>Malaria Journal</SO>
<YR>2005</YR>
<VL>4</VL>
<PG>53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saarinen-1988" NAME="Saarinen 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saarinen M, Thoren E, Iyambo N, Caristedt A, Shinyafa L, Fernanda M, et al</AU>
<TI>Malaria prophylaxis with proguanil to Namibian refugee children in Angola</TI>
<SO>Tropical Medicine and Parasitology</SO>
<YR>1988</YR>
<VL>39</VL>
<NO>1</NO>
<PG>40-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schapira-1988" NAME="Schapira 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schapira A, Da Costa F</AU>
<TI>Studies on malaria prophylaxis with chlorproguanil or chloroquine in Mozambique</TI>
<SO>Central African Medical Journal of Medicine</SO>
<YR>1988</YR>
<VL>34</VL>
<NO>3</NO>
<PG>44-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schellenberg-2001" MODIFIED="2011-04-24 20:48:35 +0100" MODIFIED_BY="[Empty name]" NAME="Schellenberg 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-04-24 20:48:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, Tanner M, et al</AU>
<TI>Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<NO>9267</NO>
<PG>1471-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schellenberg-2004" NAME="Schellenberg 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schellenberg D, Kahigwa E, Sanz S, Aponte JJ, Mshinda H, Alonso P, et al</AU>
<TI>A randomized comparison of two anemia treatment regimens in Tanzanian children</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2004</YR>
<VL>71</VL>
<NO>4</NO>
<PG>428-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schellenberg-2005" MODIFIED="2011-12-14 11:01:43 +0000" MODIFIED_BY="[Empty name]" NAME="Schellenberg 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-04-24 20:48:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Aponte J, Schellenberg D, Menendez C, Kahigwa E, Tanner M, Mshinda H, et al</AU>
<TI>Extended follow-up of intermittent preventive anti-malarial treatment in Tanzanian infants</TI>
<SO>4th MIM Malaria Conference; Yaounde, Cameroon</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-14 11:01:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schellenberg D, Menendez C, Aponte JJ, Kahigwa E, Tanner M, Mshinda H, et al</AU>
<TI>Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>365</VL>
<NO>9469</NO>
<PG>1481-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schneider-1962" NAME="Schneider 1962" YEAR="1962">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneider J, Escudie A, Ouedraogo A, Sales P</AU>
<TI>Chemioprophylaxis of malaria by weekly distributions of chloroquine or a chloroquine-primaquine-pyrimethamine combination</TI>
<TO>Chimioprophylaxie du paludisme par distributions herbomadaires de chloroquine ou d'une association chloroquine-primaquine-pyrimethamine</TO>
<SO>Bulletin de la Societe de Pathologie Exotique et des ses Filiales</SO>
<YR>1962</YR>
<VL>55</VL>
<PG>280-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sokhna-2008" MODIFIED="2011-12-14 11:02:00 +0000" MODIFIED_BY="[Empty name]" NAME="Sokhna 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-12-14 11:02:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sokhna C, Cisse B, Ba el H, Milligan P, Hallett R, Sutherland C, et al</AU>
<TI>A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children</TI>
<SO>PLoS ONE</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>1</NO>
<PG>e1471</PG>
<IDENTIFIERS MODIFIED="2011-12-14 11:01:53 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stace-1981" NAME="Stace 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stace JD, Pariwa S</AU>
<TI>Reduction in malaria parasite rate in young children by distribution of prophylactic amodiaquine through voluntary village workers</TI>
<SO>Papua New Guinea Medical Journal</SO>
<YR>1981</YR>
<VL>24</VL>
<NO>4</NO>
<PG>254-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sukwa-1999" NAME="Sukwa 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sukwa TY, Mulenga M, Chisdaka N, Roskell NS, Scott TR</AU>
<TI>A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1999</YR>
<VL>60</VL>
<NO>4</NO>
<PG>521-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thera--2005" NAME="Thera  2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thera MA, Sehdev PS, Coulibaly D, Traore K, Garba MN, Cissoko Y, et al</AU>
<TI>Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2005</YR>
<VL>192</VL>
<NO>10</NO>
<PG>1823-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verhoef-2002" MODIFIED="2011-04-24 21:02:36 +0100" MODIFIED_BY="[Empty name]" NAME="Verhoef 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-04-24 21:02:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verhoef H, West CE, Nzyuko SM, de Vogel S, van der Valk R, Wanga MA, et al</AU>
<TI>Intermittent administration of iron and sulfadoxine-pyrimethamine to control anaemia in Kenyan children: a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<NO>9337</NO>
<PG>908-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-von-Seidlein-2003" NAME="von Seidlein 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>von Seidlein L, Walraven G, Milligan PJ, Alexander N, Manneh F, Deen JL, et al</AU>
<TI>The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2003</YR>
<VL>97</VL>
<NO>2</NO>
<PG>217-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vrbova-1992" NAME="Vrbova 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vrbova H, Gibney S, Gibson FD, Jolley D, Heywood PF, Stace J, et al</AU>
<TI>Chemoprophylaxis against malaria in Papua New Guinea: trial of amodiaquine and a combination of dapsone and pyrimethamine</TI>
<SO>Papua New Guinea Medical Journal</SO>
<YR>1992</YR>
<VL>35</VL>
<NO>4</NO>
<PG>275-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watkins-1987" NAME="Watkins 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watkins WM, Brandling-Bennet AD, Oloo AJ, Howells RE, Gilles HM, Koech DK</AU>
<TI>Inadequacy of chlorproguanil 20 mg per week as chemoprophylaxis for falciparum malaria in Kenya</TI>
<SO>Lancet</SO>
<YR>1987</YR>
<VL>1</VL>
<NO>8525</NO>
<PG>125-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weiss-1995" NAME="Weiss 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weiss WR, Oloo AJ, Johnson A, Koech D, Hoffman SL</AU>
<TI>Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine doxycycline and chloroquine plus proguanil</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1995</YR>
<VL>171</VL>
<NO>6</NO>
<PG>1569-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Win-1985" NAME="Win 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Win K, Lwin TT, Thwe Y, Win K</AU>
<TI>Combination of mefloquine with sulfadoxine-pyrimethamine compared with two sulfadoxine-pyrimethamine combinations in malaria chemoprophylaxis</TI>
<SO>Lancet</SO>
<YR>1985</YR>
<VL>2</VL>
<NO>8457</NO>
<PG>694-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolde-1994" MODIFIED="2011-04-19 04:32:40 +0100" MODIFIED_BY="[Empty name]" NAME="Wolde 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-04-19 04:32:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolde B, Pickering J, Wotton K</AU>
<TI>Chloroquine chemoprophylaxis in children during peak transmission period in Ethopia</TI>
<SO>Journal of Tropical Medicine and Hygiene</SO>
<YR>1994</YR>
<VL>97</VL>
<NO>4</NO>
<PG>215-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2012-01-17 07:52:59 +0000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-01-17 17:48:27 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-01-17 17:48:27 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alexander-2007" NAME="Alexander 2007" TYPE="JOURNAL_ARTICLE">
<AU>Alexander N, Sutherland C, Roper C, Cisse B, Schellenberg D</AU>
<TI>Modelling the impact of intermittent preventive treatment for malaria on selection pressure for drug resistance</TI>
<SO>Malaria Journal</SO>
<YR>2007</YR>
<VL>6</VL>
<PG>9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Aponte-2009" MODIFIED="2011-12-14 11:02:35 +0000" MODIFIED_BY="[Empty name]" NAME="Aponte 2009" TYPE="JOURNAL_ARTICLE">
<AU>Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro L, Critchley J et al</AU>
<TI>Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials</TI>
<SO>Lancet</SO>
<YR>2009</YR>
<VL>374</VL>
<PG>1533-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Branch-1998" NAME="Branch 1998" TYPE="JOURNAL_ARTICLE">
<AU>Branch OH, Udhayakumar V, Hightower AW, Oloo AJ, Hawley WA, Nahlen BL, et al</AU>
<TI>A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1998</YR>
<VL>58</VL>
<NO>2</NO>
<PG>211-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gamble-2006" MODIFIED="2012-01-17 17:48:01 +0000" MODIFIED_BY="[Empty name]" NAME="Gamble 2006" TYPE="COCHRANE_REVIEW">
<AU>Gamble C, Ekwaru JP, ter Kuile FO</AU>
<TI>Insecticide-treated nets for preventing malaria in pregnancy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-01-17 17:48:01 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-01-17 17:48:01 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003755.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Garner-2006" MODIFIED="2012-01-17 17:48:27 +0000" MODIFIED_BY="[Empty name]" NAME="Garner 2006" TYPE="COCHRANE_REVIEW">
<AU>Garner P, Gülmezoglu AM</AU>
<TI>Drugs for preventing malaria in pregnant women</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-01-17 17:48:27 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-01-17 17:48:27 +0000" MODIFIED_BY="Anne-Marie Stephani" TYPE="DOI" VALUE="10.1002/14651858.CD000169.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gilles-2000" NAME="Gilles 2000" TYPE="BOOK">
<AU>Gilles HM</AU>
<SO>Management of severe malaria: a practical handbook</SO>
<YR>2000</YR>
<EN>2nd</EN>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greenwood-2004" NAME="Greenwood 2004" TYPE="JOURNAL_ARTICLE">
<AU>Greenwood B</AU>
<TI>The use of anti-malarial drugs to prevent malaria in the population of malaria-endemic areas</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2004</YR>
<VL>70</VL>
<NO>1</NO>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greenwood-2006" NAME="Greenwood 2006" TYPE="JOURNAL_ARTICLE">
<AU>Greenwood B</AU>
<TI>Review: Intermittent preventive treatment--a new approach to the prevention of malaria in children in areas with seasonal malaria transmission</TI>
<SO>Tropical Medicine and International Health</SO>
<YR>2006</YR>
<VL>11</VL>
<NO>7</NO>
<PG>983-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greenwood-2010" MODIFIED="2011-04-25 02:45:02 +0100" MODIFIED_BY="[Empty name]" NAME="Greenwood 2010" TYPE="JOURNAL_ARTICLE">
<AU>Greenwood B</AU>
<TI>Anti-malarial drugs and the prevention of malaria in the population of malaria endemic areas</TI>
<SO>Malaria Journal</SO>
<YR>2010</YR>
<VL>9</VL>
<NO>Suppl 3</NO>
<PG>S2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2006" NAME="Higgins 2006" TYPE="OTHER">
<AU>Higgins J, Green S, editors</AU>
<TI>Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Appendix 5b</TI>
<SO>www.cochrane.org/resources/handbook/hbook.htm</SO>
<YR>(accessed 1 May 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lengeler-2004" MODIFIED="2008-08-22 16:35:52 +0100" MODIFIED_BY="[Empty name]" NAME="Lengeler 2004" TYPE="COCHRANE_REVIEW">
<AU>Lengeler C</AU>
<TI>Insecticide-treated bed nets and curtains for preventing malaria</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-08-22 16:35:52 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-22 16:35:52 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000363.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Otoo-1988b" MODIFIED="2008-08-22 16:27:32 +0100" MODIFIED_BY="[Empty name]" NAME="Otoo 1988b" TYPE="JOURNAL_ARTICLE">
<AU>Otoo LN, Snow RW, Menon A, Byass P, Greenwood BM</AU>
<TI>Immunity to malaria in young Gambian children after a two-year period of chemoprophylaxis</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1988</YR>
<VL>82</VL>
<NO>1</NO>
<PG>59-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager-_x0028_RevMan_x0029_-5" MODIFIED="2011-11-21 12:30:02 +0000" MODIFIED_BY="[Empty name]" NAME="Review Manager (RevMan) 5" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roca_x002d_Feltrer-2009" MODIFIED="2011-11-01 21:28:47 +0000" MODIFIED_BY="Martin M Meremikwu" NAME="Roca-Feltrer 2009" TYPE="JOURNAL_ARTICLE">
<AU>Roca-Feltrer A, Armstrong Schellenberg JRM, Smith M, Carneiro I</AU>
<TI>A simple method for defining malaria seasonality</TI>
<SO>Malaria Journal</SO>
<YR>2009</YR>
<VL>8</VL>
<PG>276</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-UNICEF-2007" NAME="UNICEF 2007" TYPE="BOOK">
<AU>UNICEF</AU>
<SO>Malaria &amp; children. Progress in intervention coverage</SO>
<YR>2007</YR>
<PB>United Nations Children's Fund</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Warrell-2001" MODIFIED="2012-01-13 14:48:37 +0000" MODIFIED_BY="[Empty name]" NAME="Warrell 2001" TYPE="JOURNAL_ARTICLE">
<AU>Warrell DA</AU>
<TI>To search and study out the secret of tropical diseases by way of experiment</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>358</VL>
<NO>9297</NO>
<PG>1983-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-White-2005" NAME="White 2005" TYPE="JOURNAL_ARTICLE">
<AU>White NJ</AU>
<TI>Intermittent presumptive treatment for malaria</TI>
<SO>PLoS Medicine</SO>
<YR>2005</YR>
<VL>2</VL>
<NO>1</NO>
<PG>e3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1990" MODIFIED="2008-08-22 16:27:47 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 1990" TYPE="BOOK">
<AU>WHO Scientific Group on the Chemotherapy of Malaria</AU>
<SO>Practical chemotherapy of malaria: report of a WHO scientific group [meeting held in Geneva from 5 to 12 June 1989]. World Health Organization Technical Report Series; no. 805</SO>
<YR>1990</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1993" MODIFIED="2008-08-22 16:27:51 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 1993" TYPE="BOOK">
<AU>WHO Study Group on the Implementation of the Global Plan of Action for Malaria Control</AU>
<SO>Implementation of the global malaria control strategy: report of a WHO Study Group on the Implementation of the Global Plan of Action for Malaria Control 1993-2000 [meeting held in Geneva from 8 to 12 February 1993]. WHO Technical Report Series; no. 839</SO>
<YR>1993</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2000" MODIFIED="2012-01-17 16:29:00 +0000" MODIFIED_BY="[Empty name]" NAME="WHO 2000" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organization</AU>
<TI>Severe falciparum malaria</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>2000</YR>
<VL>94</VL>
<NO>Suppl 1</NO>
<PG>1-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2005" MODIFIED="2011-12-13 19:46:19 +0000" MODIFIED_BY="[Empty name]" NAME="WHO 2005" TYPE="BOOK">
<AU>Global Partnership to Roll Back Malaria</AU>
<SO>World malaria report: 2005</SO>
<YR>2005</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2006" NAME="WHO 2006" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organization</AU>
<TI>Malaria vector control and personal protection: report of a WHO study group</TI>
<SO>WHO Technical Report Series</SO>
<YR>2006</YR>
<VL>936</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2009" MODIFIED="2011-06-28 16:41:28 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2009" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>World Malaria Report 2009, Geneva</TI>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2010" MODIFIED="2011-06-28 16:42:58 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2010" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>WHO policy recommendation on Intermittent preventive treatment during infancy with sulfadoxine-pyrimethamine (SP-IPTi) for <I>Plasmodium falciparum </I>malaria control in Africa</TI>
<YR>March 2010</YR>
<PG>1-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilson-2011" MODIFIED="2011-12-14 11:03:52 +0000" MODIFIED_BY="[Empty name]" NAME="Wilson 2011" TYPE="JOURNAL_ARTICLE">
<AU>Wilson AL, on behalf of the IPTc Taskforce</AU>
<TI>A Systematic Review and Meta-Analysis of the Efficacy and Safety of Intermittent Preventive Treatment of Malaria in Children (IPTc)</TI>
<SO>PLoS ONE</SO>
<YR>2011</YR>
<VL>6</VL>
<NO>2</NO>
<PG>e16976</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-01-17 17:47:33 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Meremikwu-2002" MODIFIED="2011-12-14 11:04:54 +0000" MODIFIED_BY="[Empty name]" NAME="Meremikwu 2002" TYPE="COCHRANE_REVIEW">
<AU>Meremikwu M, Omari AAA</AU>
<TI>Antimalarial drugs given at regular intervals for preventing clinical malaria and severe anaemia in preschool children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-08-22 16:36:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-22 16:36:39 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003756"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Meremikwu-2005" MODIFIED="2011-12-14 11:05:01 +0000" MODIFIED_BY="[Empty name]" NAME="Meremikwu 2005" TYPE="COCHRANE_REVIEW">
<AU>Meremikwu MM, Omari AAA, Garner P</AU>
<TI>Chemoprophylaxis and intermittent treatment for preventing malaria in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-08-22 16:37:13 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-22 16:37:13 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003756"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Meremikwu-2008" MODIFIED="2012-01-17 17:47:33 +0000" MODIFIED_BY="[Empty name]" NAME="Meremikwu 2008" TYPE="COCHRANE_REVIEW">
<AU>Meremikwu MM, Donegan S, Esu E</AU>
<TI>Chemoprophylaxis and intermittent treatment for preventing malaria in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-01-17 17:47:33 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-01-17 17:47:33 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003756.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-01-17 12:08:45 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-01-17 12:08:45 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-01-13 13:48:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ciss_x00e9_-2006">
<CHAR_METHODS MODIFIED="2011-12-14 09:35:21 +0000" MODIFIED_BY="[Empty name]">
<P>Design: Randomized controlled trial</P>
<P>Unit of randomisation: patient</P>
<P>Length of follow up: 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-14 09:35:27 +0000" MODIFIED_BY="[Empty name]">
<P>Number enrolled: 1088 children aged from two to 59 months</P>
<P>Inclusion criteria: aged from two to 59 months; residence in study area</P>
<P>Exclusion criteria: severe illness including severe anaemia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-12-14 09:35:28 +0000" MODIFIED_BY="[Empty name]">
<P>1. Intermittent treatment: IPTi with sulfadoxine-pyrimethamine plus artesunate given once monthly</P>
<P>Sulfadoxine-pyrimethamine (25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine) plus artesunate (4 mg/kg give once monthly for three consecutive months); 542 children<BR/>2. Placebo; 546 children</P>
<P>All participants concurrently received routine immunization with diphtheria-pertussis-tetanus (DPT) and measles vaccines</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-13 13:48:54 +0000" MODIFIED_BY="[Empty name]">
<P>1. Clinical malaria episodes<BR/>2. Anaemia<BR/>3. Hospital admissions<BR/>4. Death</P>
<P>5. Severe malaria<BR/>6. Adverse events<BR/>7. Sulfadoxine- pyrimethamine resistance markers</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-14 09:35:30 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Niakkhar, Senegal</P>
<P>Malaria transmission: high/seasonal</P>
<P>Registration number: NCT00132561</P>
<P>Adverse events measurement: Adverse events were monitored by three physicians. A random sample of 300 participants were visited at home within three days of being given the drug, were physically examined and their parents interviewed.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-17 12:08:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dicko-2008">
<CHAR_METHODS MODIFIED="2012-01-17 12:08:34 +0000" MODIFIED_BY="[Empty name]">
<P>Design: Randomized controlled trial</P>
<P>Unit of randomization: patient</P>
<P>Length of follow up: 24 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-14 09:35:46 +0000" MODIFIED_BY="[Empty name]">
<P>262 children aged from months to 10 years</P>
<P>Inclusion criteria:</P>
<P>1) parental or other legal guardian consent;</P>
<P>2) aged from six months to 10 years;</P>
<P>3) having no chronic illness or symptomatic malaria;</P>
<P>4) agreeing to seek initial medical care for all medical illness in the study<BR/>clinic during the entire study period;</P>
<P>5) having no plan to travel for a long time during the study period.</P>
<P>Specific exclusion criteria:</P>
<P>Children with a history of allergy to sulpha drugs or SP.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-08-26 13:24:17 +0100" MODIFIED_BY="[Empty name]">
<P>1. Standard recommended treatment doses of SP (Fansidar®, F. Hoffman-La Roche Ltd, Basel, Switzerland) was given for IPT:1/4 tablet per 5 kg wt for age &#8804;12 years.</P>
<P>All subjects were observed for at least 60 minutes for vomiting. If vomiting occurred within 30 minutes, the full dose was repeated and if it occurred within 60 minutes, 1/2 of the dose was repeated.</P>
<P>2. No IPT</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-13 13:49:14 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome:</P>
<P>Incidence rate of malaria disease during intervention</P>
<P>Secondary outcomes:</P>
<P>Incidence rate of malaria after cessation of intervention</P>
<P>In vivo therapeutic efficacy of SP.</P>
<P>Severe malaria.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-14 09:35:47 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Kambila, Mali</P>
<P>Transmission: Seasonal and hyperendemic (parasitaemia rates 40&#8211;50% in the dry season (November &#8211; May) and 70&#8211;85% in the rainy season (June &#8211; October).</P>
<P>Adverse events measurement: serious adverse events were monitored during the duration of the study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-17 12:08:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dicko-2011">
<CHAR_METHODS MODIFIED="2012-01-17 12:08:45 +0000" MODIFIED_BY="[Empty name]">
<P>Design: Randomized controlled trial</P>
<P>Unit of randomization: patient</P>
<P>Length of follow up: 6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-14 09:36:08 +0000" MODIFIED_BY="[Empty name]">
<P>Participants: 3017 children aged from 3 to 59 months.</P>
<P>Inclusion criteria:</P>
<P>Aged from 3 to 59 months at the time of enrolment</P>
<P>Permanent residence in study area with no intention of leaving during the study period.</P>
<P>Exclusion criteria:</P>
<P>Presence of a severe, chronic illness, such as severe malnutrition or AIDS, history of significant adverse reaction to SP or AQ.</P>
<P>NB: Cases of an acute illness, such as malaria, were not excluded. Such cases were treated appropriately and the child randomized and retained in the trial.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-12-14 09:36:29 +0000" MODIFIED_BY="[Empty name]">
<P>1. IPT with Sulphadoxine Pyrimethamine (SP) and Amodiaquine (AQ) + long-lasting insecticidal nets (LLIN)</P>
<P>SP tablets:</P>
<P>children 5 to 9 kg: sulphadoxine 175 mg and pyrimethamine 8.75 mg per tablet</P>
<P>children 10 to 18 kg: sulphadoxine 350 mg and pyrimethamine 17.5 mg per tablet</P>
<P>children 19 kg or more: sulphadoxine 550 mg and pyrimethamine 26.25 mg per tablet</P>
<P>AQ dose = 7.8 to 14 mg/kg/d:</P>
<P>children 5 to 9 kg: 70 mg per tablet</P>
<P>children 10 to 18 kg: 140 mg per tablet</P>
<P>children 19 kg or more: 220 mg per tablet</P>
<P>2. Placebo + long-lasting insecticidal nets (LLIN): identical with treatment tablets and given in the same schedule<BR/>
</P>
<P>Sulphadoxine Pyrimethamine (SP) SP + Amodiaquiune AQ or Placebo tablets were given during the peak malaria transmission season, with one month intervals between treatments.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-13 14:46:57 +0000" MODIFIED_BY="[Empty name]">
<P>(i) the incidence of clinical malaria (defined as "the presence of fever or a history of fever in the past 24 hours and the presence of <I>P. falciparum</I> asexual parasitaemia at any density");</P>
<P>(ii) incidence of severe malaria (WHO definition)<BR/>(iii) malaria infection defined as the presence of asexual parasitaemia;</P>
<P>(iv) mild, moderate, or severe anaemia defined as an haemoglobin (Hb) concentration &lt; 11 g/dL, &lt; 8 g/dL, and &lt; 5 g/dL, respectively;</P>
<P>(v) hospital admission defined as a stay of at least 24 hours in hospital for treatment;</P>
<P>(vi) anthropometric indicators including wasting, stunting, and underweight (WHO definition)</P>
<P>(vii) safety and tolerability measured by the occurrence of non-serious and serious adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-26 12:57:07 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Kati District in the Savannah region of Mali</P>
<P>Transmission: highly seasonal (80%&#8211;90% of malaria cases occur August-November)<BR/>Entomological inoculation rate (EIR): 9.4 and 6.6 and 37.3 infective bites per person per season, respectively in Siby and Ouelessebougou (two localities far from any river) and 37.3<BR/>infective bites per person per season in Djoliba (located on the bank of the Niger River).</P>
<P>Adverse events measurement: "Adverse events were monitored immediately after the administration of each course of IPTc and throughout the follow-up period.&#8221;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-13 14:02:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Konate-2011">
<CHAR_METHODS MODIFIED="2012-01-13 14:02:02 +0000" MODIFIED_BY="[Empty name]">
<P>Design: Randomized controlled trial</P>
<P>Unit of randomization: patient</P>
<P>Length of follow up: 6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-14 09:36:43 +0000" MODIFIED_BY="[Empty name]">
<P>Children aged from three to 59 months</P>
<P>Inclusion criteria:</P>
<UL>
<LI>Body weight at least 5 kg</LI>
<LI>Residence in one of the study villages with no plan</LI>
</UL>
<UL>
<LI>Signs or symptoms of severe chronic illness</LI>
<LI>Absence of signs of severe malnutrition</LI>
<LI>Signed inform consent obtained from the caregiver</LI>
</UL>
<P>Exclusion criterion:</P>
<UL>
<LI>History of sensitivity to any antimalarial drug</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-12-14 09:36:56 +0000" MODIFIED_BY="[Empty name]">
<P>1. IPT with Sulphadoxine Pyrimethamine (SP) and Amodiaquine (AQ) + long-lasting insecticidal nets (LLIN)</P>
<P>SP tablets:</P>
<P>children 5 to 9 kg: sulphadoxine 175 mg and pyrimethamine 8.75 mg per tablet</P>
<P>children 10 to 18 kg: sulphadoxine 350 mg and pyrimethamine 17.5 mg per tablet</P>
<P>children 19 kg or more: sulphadoxine 550 mg and pyrimethamine 26.25 mg per tablet</P>
<P>AQ dose = 7.8 to 14 mg/kg/d):</P>
<P>children 5 to 9 kg: 70 mg per tablet</P>
<P>children 10 to 18 kg: 140 mg per tablet</P>
<P>children 19 kg or more: 220 mg per tablet</P>
<P>2. Placebo + long-lasting insecticidal nets (LLIN): identical with treatment tablets and given in the same schedule<BR/>
</P>
<P>Sulphadoxine Pyrimethamine (SP) SP + Amodiaquiune AQ or Placebo tablets were given in August, September, and October during the peak malaria transmission season, with one month intervals between treatments.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-14 09:37:04 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome:</P>
<P>Incidence of clinical malaria with <I>P. falciparum</I> asexual parasites density of at least 5000 asexual parasites of <I>P. falciparum</I> per microlitre.</P>
<P>Secondary outcomes:</P>
<P>(1) incidence of clinical malaria (<I>P. falciparum </I>asexual parasites at any density)<BR/>(2) the incidence of severe malaria defined according to WHO criteria</P>
<P>(3) the prevalence of anaemia at the end of malaria transmission season (anaemia = Hb &lt; 11 g/dL, moderately severe anaemia = Hb &lt; 8 g/dL; severe anaemia = Hb &lt; 5 g/dL)</P>
<P>(4) the prevalence of parasitaemia at the end of the malaria transmission season;</P>
<P>(5) the prevalence of wasting, stunting, and underweight at the end of malaria transmission<BR/>season;</P>
<P>(6) the incidence of all-cause hospitalization</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-14 09:37:07 +0000" MODIFIED_BY="[Empty name]">
<P>Entomological inoculation rate (EIR) was estimated to be 173 infective bites per person per year (in 2002) with a peak in September (Burkina Faso)</P>
<P>Proportions of children that slept under LLINs was similar in the control and in the intervention<BR/>groups (92.7% versus 92.8%).</P>
<P>Adverse events measurement: Adverse events were monitored on the day of administration of each dose and on the day after the last dose of each treatment course by trained members of the research team who were not involved in giving treatment. Questions were asked specifically about the occurrence of listed symptom/events.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-13 14:47:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kweku-2008">
<CHAR_METHODS MODIFIED="2011-12-14 09:37:12 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial</P>
<P>Lenght of follow up: No active follow up after six months duration of the intervention (Surveys and malaria tests done at 12months).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-13 14:47:02 +0000" MODIFIED_BY="[Empty name]">
<P>Number enrolled: 2451</P>
<P>Inclusion criteria: Children aged from two to 59 months in the selected communities; children resident in the study area  and likely to be available for follow-up for six-12 months; consent by parent /guardian of child; absence of severe malnutrition, chronic diarrhoea or history of convulsions; absence of prostration, extreme weakness (inability to stand or sit) at the time of enrolment; no history of AQ, SP or AS intake within the past two weeks; absence of history of hypersensitivity to any of the study drugs.</P>
<P>Exclusion criteria:failure to meet any of the above inclusion criteria</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-12-14 09:37:36 +0000" MODIFIED_BY="[Empty name]">
<P>1. Intermittent treatment: IPTc with artesunate plus amodiaquine (AS+AQ) monthly or every two months, or sulphadoxine-pyrimethamine (SP) every two months and placebo over a period of six months.</P>
<P>Children aged from three to five months received a quarter of a tablet, those aged six&#8211;11 months half a tablet, those aged from 12 to 23 months three quarters of a tablet (3/4) and those aged 24 months and above received one tablet each of SP, co-formulated AS+AQ or placebo.</P>
<P>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-13 14:02:14 +0000" MODIFIED_BY="[Empty name]">
<P>1. Anaemia</P>
<P>2. Severe anaemia</P>
<P>3. Clinical episodes of malaria</P>
<P>4. Hospitalizations</P>
<P>5. Malaria admissions (severe malaria)</P>
<P>6. Deaths</P>
<P>7. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-14 09:37:39 +0000" MODIFIED_BY="[Empty name]">
<P>Location: Hohoe district, Ghana</P>
<P>Malaria transmission:Intense with two seasonal peaks and entomological inoculation rate of 65 infective bites/person/year.</P>
<P>Adverse events measurement: Field workers visited study children to solicit any adverse events seven to 10 days after administration of study drugs. Reported adverse events were investigated and managed by a study clinician.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-16 15:31:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sesay-2011">
<CHAR_METHODS MODIFIED="2011-12-14 09:37:41 +0000" MODIFIED_BY="[Empty name]">
<P>Design: Randomized controlled trial</P>
<P>Unit of randomization: patient</P>
<P>Length of follow up:6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-14 09:37:43 +0000" MODIFIED_BY="[Empty name]">
<P>Children aged from three to 59 months</P>
<P>Number enrolled: 1277 (Intervention 638; Control 639)</P>
<P>Inclusion criteria:</P>
<P>Written informed consent from parents or guardians</P>
<P>No clinically significant acute or chronic disease.</P>
<P>Exclusion criteria<BR/>Known allergy to any antimalarial drug<BR/>Presence of acute or chronic, clinically significant<BR/>pulmonary, cardiovascular, hepatic or renal disease.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-12-14 09:37:51 +0000" MODIFIED_BY="[Empty name]">
<P>1. IPT with Sulphadoxine Pyrimethamine (SP) and Amodiaquine (AQ)</P>
<P>Dosage of SP (500 mg sulphadoxine/25 mg pyrimethamine)<BR/>Children aged from three to 11 months: half a tablet<BR/>Children aged from one to 5 years: a whole tablet<BR/>Dosage of AQ (200 mg base tablets)</P>
<P>Children aged from three to 11 months: One quarter tablet</P>
<P>Children aged from one to 2 years: half tablet</P>
<P>Children aged from three to five years: whole tablet</P>
<P>2. Placebo (same tablet dose given)</P>
<P>All children had HMM.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-13 15:31:33 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome:</P>
<UL>
<LI>Incidence of clinical malaria (axillary temp &#8805; 37.5°C or a history of fever within the previous 48 hours accompanied by asexual malaria parasitaemia at a density of &#8805;5000 parasites/&#956;L)</LI>
</UL>
<P>Secondary outcomes:</P>
<UL>
<LI>Incidence of a febrile illness with parasitaemia at any density among children seen by a village health worker (VHW) or at a health centre or hospital,</LI>
<LI>Incidence of anaemia among children seen at a health centre or hospital,</LI>
<LI>Prevalence of parasitaemia at the end of malaria transmission season</LI>
<LI>Prevalence of anaemia at the end of malaria transmission season</LI>
<LI>Proportion of children who received three IPTc treatment courses</LI>
<LI>Proportion of children who received no IPTc treatment course.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-16 15:31:03 +0000" MODIFIED_BY="[Empty name]">
<P>Location: The Gambia</P>
<P>Transmission: Seasonal (rainy season and immediately afterwards: July to November); peak<BR/>during October and November.</P>
<P>Entomological inoculation rate: varies across the country with reported estimates in the range of one to 177 infective bites per person per year</P>
<P>Adverse events measurement: Passive surveillance for malaria was carried out during the 2008 transmission season. VHWs referred children who failed to improve on malaria treatment and those with danger signs (breathing difficulty, severe weakness, convulsions, severe diarrhoea or vomiting) to the nearest health facility for further evaluation and management.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-12-14 09:38:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tagbor-2011">
<CHAR_METHODS MODIFIED="2011-12-14 09:38:09 +0000" MODIFIED_BY="[Empty name]">
<P>Design: Randomized controlled trial (units of randomization = communities).</P>
<P>Unit of randomization: Community</P>
<P>Cluster adjusted: Yes, by analysing at the cluster-level.</P>
<P>Intra-cluster correlation coefficients: Haemoglobin (ICC 0.05) and Parasitaemia (ICC 0.04).</P>
<P>Length of follow up: 17 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-14 09:38:12 +0000" MODIFIED_BY="[Empty name]">
<P>Number enrolled: 1490 children aged between three and 59 months</P>
<P>Number of clusters: 13</P>
<P>Average cluster size: 114.55</P>
<P>Inclusion criteria: All children were eligible for enrolment unless they were known to suffer from chronic diseases</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-12-14 09:38:15 +0000" MODIFIED_BY="[Empty name]">
<P>1. Intermittent treatment with AS+AQ every two months and HMM (six communities)</P>
<P>2. HMM (Seven communities)</P>
<P>Duration of study: April 2007 to November 2008.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-20 02:49:59 +0100" MODIFIED_BY="[Empty name]">
<P>1. Parasitaemia</P>
<P>2.Severe anaemia</P>
<P>3.Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-08-26 12:59:28 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Kwaso subdistrict, Ashanti Region of Ghana</P>
<P>First dose of treatment observed by study team while 2nd and 3rd doses were given by the caregiver at home</P>
<P>Adverse events measurement: &#8220;It was not possible to maintain comprehensive surveillance of adverse events and compliance.&#8221;&#8220;A subset of children, approximately 100 in each intervention group, were assessed for adverse events after treatment for febrile episodes.&#8221;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-01-13 14:45:31 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-01-13 14:02:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-A_x002d_Schellenberg-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-13 14:02:39 +0000" MODIFIED_BY="[Empty name]">
<P>Participants &lt; 6 years (young infants).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Akenzua-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Includes participants aged more than 6 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:38:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Allen-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:38:19 +0000" MODIFIED_BY="[Empty name]">
<P>Cross-sectional survey to determine sensitivity of <I>P. falciparum</I> after chemoprophylaxis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:38:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alonso-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:38:20 +0000" MODIFIED_BY="[Empty name]">
<P>Chemoprophylaxis (not IPT)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Archibald-1956">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized intervention trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:38:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barger-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:38:22 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized control trial with participants aged from six to13 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-03 19:46:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bell-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-03 19:46:46 +0100" MODIFIED_BY="[Empty name]">
<P>Control arm was not given placebo or no preventive intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:38:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bjorkman-1985a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:38:23 +0000" MODIFIED_BY="[Empty name]">
<P>Non-randomized prospective study to investigate susceptibility of <I>P. falciparum</I> following a period of chemosuppression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bjorkman-1985b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Surveys</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bjorkman-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-06 13:29:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bojang-2010a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-06 13:29:01 +0100" MODIFIED_BY="[Empty name]">
<P>Control arm not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-13 14:02:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bojang-2010b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-13 14:02:55 +0000" MODIFIED_BY="[Empty name]">
<P>Only anaemic participants included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bradley_x002d_Moore-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Quasi-randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-13 14:02:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chandramohan-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-13 14:02:54 +0000" MODIFIED_BY="[Empty name]">
<P>Participants &lt; 6 years (young infants)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:38:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Charles-1961">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:38:24 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial with participants aged from five to 14 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-04-22 00:15:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cisse-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-04-22 00:15:10 +0100" MODIFIED_BY="[Empty name]">
<P>No control arm (placebo or no preventive treatment)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:38:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clarke-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:38:26 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial with participants aged from five to 18 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Colbourne-1955">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized intervention study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:38:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coosemans-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:38:27 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial with participants aged from six to 14 years and no group given placebo only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Coulibaly-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomized controlled trial; adults and older children included as participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:38:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-David-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:38:29 +0000" MODIFIED_BY="[Empty name]">
<P>Chemoprophylaxis (not IPT)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-13 14:45:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Delmont-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-13 14:45:31 +0000" MODIFIED_BY="[Empty name]">
<P>Mass drug administration with participants &gt; 6 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-13 14:03:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Desai-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-13 14:03:04 +0000" MODIFIED_BY="[Empty name]">
<P>Only anaemic participants included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-03 21:30:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dicko-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-03 21:30:09 +0100" MODIFIED_BY="[Empty name]">
<P>No desired outcomes measured</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Escudie-1961">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:38:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fasan-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:38:30 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial with participants aged from six to 12 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:38:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fasan-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:38:31 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial with participants aged from five to 12 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:38:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fernando-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:38:32 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial of school children aged from six to 12 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-13 14:03:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gosling-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-13 14:03:09 +0000" MODIFIED_BY="[Empty name]">
<P>Participants &lt; 6 years (young infants).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:38:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greenwood-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:38:34 +0000" MODIFIED_BY="[Empty name]">
<P>Chemoprophylaxis (not IPT)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:38:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greenwood-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:38:36 +0000" MODIFIED_BY="[Empty name]">
<P>Chemoprophylaxis (not IPT)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:38:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greenwood-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:38:37 +0000" MODIFIED_BY="[Empty name]">
<P>Chemoprophylaxis (not IPT)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-13 14:03:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grobusch-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-13 14:03:13 +0000" MODIFIED_BY="[Empty name]">
<P>Participants &lt; 6 years (young infants).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Harland-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Longitudinal observational study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:38:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hogh-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:38:39 +0000" MODIFIED_BY="[Empty name]">
<P>Chemoprophylaxis (not IPT)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:38:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hogh-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:38:40 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial with participants aged from seven to 12 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-13 14:03:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karunakaran-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-13 14:03:16 +0000" MODIFIED_BY="[Empty name]">
<P>Included patients aged over 6 years (0-20+ years)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:38:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karwacki-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:38:48 +0000" MODIFIED_BY="[Empty name]">
<P>Two randomized controlled trials with participants aged from six to 15 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-13 14:03:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kobbe-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-13 14:03:20 +0000" MODIFIED_BY="[Empty name]">
<P>Participants &lt; 6 years (young infants).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-13 14:03:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kollaritsch-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-13 14:03:23 +0000" MODIFIED_BY="[Empty name]">
<P>Included patients aged 9-60 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-04-22 00:22:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kweku-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-04-22 00:22:14 +0100" MODIFIED_BY="[Empty name]">
<P>No control arm (placebo or no preventive antimalarial treatment). Both study arms received same antimalarial regimen for IPTc.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Laing-ABG-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:38:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lell-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:38:49 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial with participants aged from four to 16 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:38:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lell-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:38:50 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial with participants aged from 12 to 20 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:38:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lemnge-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:38:52 +0000" MODIFIED_BY="[Empty name]">
<P>Chemoprophylaxis (not IPT)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lewis-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:38:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Limsomwong-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:38:53 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial with participants aged from five to 16 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:38:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lucas-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:38:55 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial with participants aged from eight to 17 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:04:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lwin-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:04:42 +0000" MODIFIED_BY="[Empty name]">
<P>Participants of all ages</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-MacCormack-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Malaria suppression project with chloroquine (not a randomized controlled trial)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-13 14:03:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Macete-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-13 14:03:29 +0000" MODIFIED_BY="[Empty name]">
<P>Participants &lt; 6 years (young infants).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-13 14:03:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Massaga-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-13 14:03:31 +0000" MODIFIED_BY="[Empty name]">
<P>Participants &lt; 6 years (young infants).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McGregor-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomized controlled trial with both children and adult participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:38:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Menendez-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:38:56 +0000" MODIFIED_BY="[Empty name]">
<P>Chemoprophylaxis (not IPT)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:38:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Menon-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:38:58 +0000" MODIFIED_BY="[Empty name]">
<P>Chemoprophylaxis (not IPT)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Miller-1954">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-13 14:03:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mockenhaupt-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-13 14:03:35 +0000" MODIFIED_BY="[Empty name]">
<P>Participants &lt; 6 years (young infants).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:38:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Murphy-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:38:59 +0000" MODIFIED_BY="[Empty name]">
<P>Chemoprophylaxis for <I>P. vivax</I> malaria (not a randomized controlled trial)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-03 19:48:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nahum-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-03 19:48:50 +0100" MODIFIED_BY="[Empty name]">
<P>Control arm was not given placebo or no preventive intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:39:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nakibuuka-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:39:02 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial with participants aged from six months to 12 years</P>
<P>Control arm was not given placebo or no preventive intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:39:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nevill-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:39:04 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial with participants aged from six to 18 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:39:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nevill-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:39:06 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial with participants aged from eight to nine years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-03 19:51:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nsimba-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-03 19:51:56 +0100" MODIFIED_BY="[Empty name]">
<P>Control arm was not given placebo or no preventive intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nwokolo-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomized controlled trial with both children and adult participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-13 14:03:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Odhiambo-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-13 14:03:38 +0000" MODIFIED_BY="[Empty name]">
<P>Participants &lt; 6 years (young infants).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Onori-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Seroepidemiological survey to determine whether chloroquinized salt affected immunity to malaria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:39:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Otoo-1988a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:39:09 +0000" MODIFIED_BY="[Empty name]">
<P>Chemoprophylaxis (not IPT)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oyediran-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Quasi-randomized (alternate allocation) of preschool children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:39:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pang-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:39:10 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial with participants aged from six to 15 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Panton-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Drug sensitivity survey</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:39:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pividal-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:39:12 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial with participants aged from seven to 12 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pribadi-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Chemoprophylaxis given to all villagers (including adults)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:39:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pringle-1966">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:39:13 +0000" MODIFIED_BY="[Empty name]">
<P>Observational study following chemoprophylaxis to document early course of untreated <I>P. falciparum</I> malaria in semi-immune children</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ringwald-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomized controlled trial with adult participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Robert-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Prospective non-randomized study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:39:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rohner-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:39:15 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial with participants aged from six to 14 years</P>
<P>Control arm was not given placebo or no preventive intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:39:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rooth-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:39:16 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial with participants aged from six to 14 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rosen-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Saarinen-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:39:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schapira-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:39:17 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial with participants aged from seven to 14 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-04-24 21:08:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schellenberg-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-04-24 21:08:07 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial of mostly infants (IPTi)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:39:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schellenberg-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:39:23 +0000" MODIFIED_BY="[Empty name]">
<P>Open-label randomized controlled trial of participants aged from two months to four years in which sulfadoxine-pyrimethamine was given to both the control group (one dose) and intervention group (three doses at monthly intervals)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-13 14:03:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schellenberg-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-13 14:03:43 +0000" MODIFIED_BY="[Empty name]">
<P>Participants &lt; 6 years (young infants).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schneider-1962">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomized trial in which the control group received a different antimalarial and not placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-03 19:53:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sokhna-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-03 19:53:59 +0100" MODIFIED_BY="[Empty name]">
<P>Control arm was not given placebo or no preventive intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stace-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sukwa-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomized controlled trial with adult participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:39:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thera--2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:39:24 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial with participants aged from five to 15 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-13 14:03:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Verhoef-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-13 14:03:47 +0000" MODIFIED_BY="[Empty name]">
<P>Only anaemic participants included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-von-Seidlein-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Adults and children &gt; 6 years included as participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:39:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vrbova-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:39:25 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial with participants aged from seven to 14 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:39:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Watkins-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:39:30 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial with participants aged from six to 10 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:39:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weiss-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:39:35 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial with participants aged from nine to 14 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Win-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomized controlled trial with adult participants aged 18 to 40 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-14 09:39:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wolde-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-14 09:39:37 +0000" MODIFIED_BY="[Empty name]">
<P>Chemoprophylaxis (not IPT)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2012-01-17 07:52:59 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-01-13 14:47:15 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-12-14 09:37:09 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-14 09:35:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ciss_x00e9_-2006">
<DESCRIPTION>
<P>Computer-generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-22 12:27:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dicko-2008">
<DESCRIPTION>
<P>Computer generated list of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-14 09:36:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dicko-2011">
<DESCRIPTION>
<P>Children were individually randomized using a computer-generated random<BR/>number sequence and blocks of varying length.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-14 09:37:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Konate-2011">
<DESCRIPTION>
<P>Randomization list was prepared by a statistician in three strata; treatment group was assigned in each stratum in a 1:1 ratio in permuted blocks of 10.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-06 12:13:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kweku-2008">
<DESCRIPTION>
<P>Simple balloting with tokens representing treatment groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-21 15:23:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sesay-2011">
<DESCRIPTION>
<P>Computer generated list of random numbers in blocks of 12</P>
<P>Unit of randomization: individual</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-22 18:05:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tagbor-2011">
<DESCRIPTION>
<P>Cluster randomized.</P>
<P>Procedure used to generate allocation sequence not described. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-12-14 09:37:10 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-14 09:35:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ciss_x00e9_-2006">
<DESCRIPTION>
<P>Identical and centrally-coded drugs and placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-14 09:35:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dicko-2008">
<DESCRIPTION>
<P>Sealed opaque envelopes used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-21 12:15:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dicko-2011">
<DESCRIPTION>
<P>Treatment allocations were provided within sealed, opaque envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-14 09:37:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Konate-2011">
<DESCRIPTION>
<P>Number sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-05 11:07:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kweku-2008">
<DESCRIPTION>
<P>Centrally packed and labelled drug containers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-21 09:47:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sesay-2011">
<DESCRIPTION>
<P>Sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-22 17:49:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tagbor-2011">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-01-05 13:43:22 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-05 19:04:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ciss_x00e9_-2006">
<DESCRIPTION>
<P>Participants, care providers, and assessor were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-22 12:27:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dicko-2008">
<DESCRIPTION>
<P>Described as open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-21 12:17:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dicko-2011">
<DESCRIPTION>
<P>Identical placebo tablets used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-21 11:37:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Konate-2011">
<DESCRIPTION>
<P>Placebo tablets used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-06 12:11:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kweku-2008">
<DESCRIPTION>
<P>Participants, care providers, and assessor were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-21 15:24:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sesay-2011">
<DESCRIPTION>
<P>Placebo tablets identical with treatments used </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-01-05 13:43:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tagbor-2011">
<DESCRIPTION>
<P>No blinding procedure described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="GROUP" NO="9">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-01-13 14:45:29 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-13 14:45:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ciss_x00e9_-2006">
<DESCRIPTION>
<P>Used intention-to-treat analysis for main outcomes; accounted for 90% of trial participants in per protocol analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-22 12:53:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dicko-2008">
<DESCRIPTION>
<P>Atttrition rate 16.8% in the treatment arm and 15.3% in the control arm.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-21 12:17:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dicko-2011">
<DESCRIPTION>
<P>Attrition rate was 2.5% and 2.9% in control and treatment arms respectively </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-21 11:56:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Konate-2011">
<DESCRIPTION>
<P>Attrition rate 0.7% and 0.1% in control and intervention groups respectively </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-07-08 01:11:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kweku-2008">
<DESCRIPTION>
<P>Attrition rate 5.7% to 8.3% (average 6%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-21 15:27:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sesay-2011">
<DESCRIPTION>
<P>Attrition rate 16.5% in treatment group and 19.5% in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-22 17:48:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tagbor-2011">
<DESCRIPTION>
<P>Attrition rate quite high (19.8% in treatment arm and 28.6% in control arm)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-01-13 14:02:34 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-13 13:49:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ciss_x00e9_-2006">
<DESCRIPTION>
<P>No apparent risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-13 13:49:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dicko-2008">
<DESCRIPTION>
<P>No apparent risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-21 12:18:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dicko-2011">
<DESCRIPTION>
<P>Trial was registered; no selective reporting observed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-21 11:58:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Konate-2011">
<DESCRIPTION>
<P>Trial registered, and outcomes in protocol were essentially accounted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-10 13:06:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kweku-2008">
<DESCRIPTION>
<P>Study protocol available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-13 14:02:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sesay-2011">
<DESCRIPTION>
<P>No apparent risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-13 14:02:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tagbor-2011">
<DESCRIPTION>
<P>No apparent risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-01-13 14:47:15 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-13 13:49:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ciss_x00e9_-2006">
<DESCRIPTION>
<P>No apparent risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-08 01:05:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dicko-2008">
<DESCRIPTION>
<P>No other potential risk of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-21 12:18:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dicko-2011">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-21 11:59:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Konate-2011">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-08 01:12:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kweku-2008">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-08 01:13:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sesay-2011">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-13 14:47:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tagbor-2011">
<DESCRIPTION>
<P>Adjusted for clustering in the analysis (analysed at the cluster level); had reasonably comparable treatment groups at baseline; no apparent loss of clusters; no obvious recruitment bias; and no obvious differences with the trials that randomized individuals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2012-01-17 13:45:14 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2012-01-17 13:45:14 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-11-08 10:29:15 +0000" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>IPTc compared with placebo for reducing malaria morbidity and all cause mortality</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>Children aged less than 5 years</P>
<P>
<B>Settings: </B>Areas with seasonal transmission</P>
<P>
<B>Intervention: </B>Intermittent Preventive Treatment of malaria</P>
<P>
<B>Comparison: </B>Placebo</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Placebo</P>
</TH>
<TH VALIGN="TOP">
<P>IPTc</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Clinical malaria</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>2.5 episodes per child per year</B>
<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0.7 episodes per child per year</B> (0.4 to 1.0)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Rate Ratio 0.26</B> (0.17 to 0.38)</P>
</TD>
<TD VALIGN="TOP">
<P>9321<BR/>(6 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Severe malaria</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>35 episodes per 1000 children per year</B>
<SUP>4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>9 episodes per 1000 children per year</B>
<BR/>(4 to 27)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Rate Ratio 0.27</B> (0.1 to 0.76)</P>
</TD>
<TD VALIGN="TOP">
<P>5964<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Death from any cause</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>3 per 1000 per year</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>2 per 1,000 per year</B>
</P>
<P>(1 to 5)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Risk Ratio 0.66</B> (0.31 to 1.39)</P>
</TD>
<TD VALIGN="TOP">
<P>9533<BR/>(6 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>5</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Moderately severe anaemia</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>67 per 1000 per year</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>47 per 1000 per year</B>
<BR/>(35 to 65)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Risk Ratio 0.71</B> (0.52 to 0.98)</P>
</TD>
<TD VALIGN="TOP">
<P>8805<BR/>(5 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>6</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Serious drug related adverse events</B>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>9533<BR/>(6 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>7</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Non-serious adverse events</B>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>9533<BR/>(6 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>8</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The <B>assumed risk</B> is taken from the sum of events and participants in the control groups in the trials unless stated otherwise in the footnotes.</P>
<P>The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> The included trials were conducted in children aged &lt; 5 years in Ghana, Mali (2), The Gambia, Senegal and Burkina Faso. Three studies administered monthly AQ+SP, two studies used SP every two months, and one study used monthly SP + AS. Two studies which also distributed ITNs showed that these benefits remain even where usage of bednets is over 90%.<BR/>
<SUP>2</SUP> There was no reason to downgrade for study limitations, inconsistency, indirectness or imprecision.<BR/>
<SUP>3 </SUP>The incidence of malaria in the control groups was 2.25 episodes per child per year in Senegal, 2.4 in Mali, and 2.88 in Burkina Faso.<BR/>
<SUP>4</SUP> The incidence of severe malaria in the control groups was 37 per 1,000 children per year in Mali, and 32 per 1,000 children per year in Burkina Faso<BR/>
<SUP>5</SUP> Downgraded by one for imprecision: There were very few deaths in these trials, and none of the trials were adequately powered to detect an effect on mortality. Larger trials are necessary to have full confidence in this effect. However, a reduction in death would be consistent with the high quality evidence of a reduction in severe malaria.<BR/>
<SUP>6 </SUP>There was substantial heterogeneity between these five trials and the trials from Ghana and the Gambia did not show an effect. Downgraded by one for inconsistency. There was no reason to downgrade for study limitations, directness or precision.<BR/>
<SUP>7</SUP> No drug-related serious adverse events are reported. Downgraded by one under precision as trials of this size are underpowered to fully detect or exclude rare serious adverse events.<BR/>
<SUP>8</SUP> Downgraded by one under study limitations. All seven trials commented on observed adverse events. However, the thoroughness of the methods used to collect these data are incomplete in some of these trials. The only adverse event found to be statistically more common with IPTc was vomiting after AQ+SP</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2012-01-06 12:35:39 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2012-01-06 12:35:39 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-01-06 12:34:48 +0000" MODIFIED_BY="[Empty name]">IPTc (AS+AQ) versus placebo or no IPTc: Non-serious adverse events (during intervention)</TITLE>
<TABLE COLS="4" ROWS="18">
<TR>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>Prevention</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Treatment</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>IPTc</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>HMM</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>IPTc</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adverse event</P>
</TD>
<TD VALIGN="TOP">
<P>(<I>N</I> = 429)</P>
</TD>
<TD VALIGN="TOP">
<P>(<I>N</I> = 86)</P>
</TD>
<TD VALIGN="TOP">
<P>(<I>N</I> = 64)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Dark urine</P>
</TD>
<TD VALIGN="TOP">
<P>5.4 (23)</P>
</TD>
<TD VALIGN="TOP">
<P>4.7 (4)</P>
</TD>
<TD VALIGN="TOP">
<P>0 (0)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Dizziness</P>
</TD>
<TD VALIGN="TOP">
<P>0.9 (4)</P>
</TD>
<TD VALIGN="TOP">
<P>1.2 (1)</P>
</TD>
<TD VALIGN="TOP">
<P>3.1 (2)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Dysphagia</P>
</TD>
<TD VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD VALIGN="TOP">
<P>0 (0)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Headache</P>
</TD>
<TD VALIGN="TOP">
<P>2.6 (11)</P>
</TD>
<TD VALIGN="TOP">
<P>1.2 (1)</P>
</TD>
<TD VALIGN="TOP">
<P>6.3 (4)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Itching</P>
</TD>
<TD VALIGN="TOP">
<P>2.6 (11)</P>
</TD>
<TD VALIGN="TOP">
<P>1.2 (1)</P>
</TD>
<TD VALIGN="TOP">
<P>1.6 (1)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Jaundice</P>
</TD>
<TD VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD VALIGN="TOP">
<P>2.3 (2)</P>
</TD>
<TD VALIGN="TOP">
<P>0 (0)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Nausea</P>
</TD>
<TD VALIGN="TOP">
<P>0.5 (2)</P>
</TD>
<TD VALIGN="TOP">
<P>1.2 (1)</P>
</TD>
<TD VALIGN="TOP">
<P>0 (0)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Palpitation</P>
</TD>
<TD VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD VALIGN="TOP">
<P>0 (0)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Skin rash</P>
</TD>
<TD VALIGN="TOP">
<P>1.4 (6)</P>
</TD>
<TD VALIGN="TOP">
<P>7.0 (6)</P>
</TD>
<TD VALIGN="TOP">
<P>0 (0)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Sought medical attention</P>
</TD>
<TD VALIGN="TOP">
<P>1.2 (5)</P>
</TD>
<TD VALIGN="TOP">
<P>4.7 (4)</P>
</TD>
<TD VALIGN="TOP">
<P>3.1 (2)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Sleeplessness</P>
</TD>
<TD VALIGN="TOP">
<P>2.6 (11)</P>
</TD>
<TD VALIGN="TOP">
<P>15.1 (13)</P>
</TD>
<TD VALIGN="TOP">
<P>3.1 (2)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Sore mouth</P>
</TD>
<TD VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD VALIGN="TOP">
<P>0 (0)</P>
</TD>
<TD VALIGN="TOP">
<P>4.7 (3)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Vomiting</P>
</TD>
<TD VALIGN="TOP">
<P>0.7 (3)</P>
</TD>
<TD VALIGN="TOP">
<P>2.3 (2)</P>
</TD>
<TD VALIGN="TOP">
<P>0 (0)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Weakness</P>
</TD>
<TD VALIGN="TOP">
<P>3.0 (13)</P>
</TD>
<TD VALIGN="TOP">
<P>7.0 (6)</P>
</TD>
<TD VALIGN="TOP">
<P>3.1 (2)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Other</P>
</TD>
<TD VALIGN="TOP">
<P>2.1 (9)</P>
</TD>
<TD VALIGN="TOP">
<P>1.2 (1)</P>
</TD>
<TD VALIGN="TOP">
<P>1.6 (1)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Data reported by <LINK REF="STD-Tagbor-2011" TYPE="STUDY">Tagbor 2011</LINK> but does not adjust for clustering.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-01-17 13:42:45 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2012-01-17 13:42:45 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>IPTc versus placebo or no IPTc</NAME>
<IV_OUTCOME CHI2="253.9918212785345" CI_END="0.9265141709899053" CI_START="0.6708633025994777" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_SIZE="0.7883935290548147" ESTIMABLE="YES" I2="96.85029228117273" I2_Q="97.22978244911454" ID="CMP-001.01" LOG_CI_END="-0.033147933780967885" LOG_CI_START="-0.17336596414506245" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.10325694896301517" MODIFIED="2012-01-16 15:25:59 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.220446049250313E-16" P_Q="1.8761905362651987E-9" P_Z="0.0038937217366646908" Q="36.09824794014343" RANDOM="YES" SCALE="1000.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.45118171850307653" TOTALS="SUB" TOTAL_1="5781" TOTAL_2="5839" WEIGHT="200.0" Z="2.8866458984696077">
<NAME>Clinical malaria</NAME>
<GROUP_LABEL_1>IPTc</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPTc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favour control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Rate Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="84.2830290389123" CI_END="0.3823895301182659" CI_START="0.17157477051589112" DF="5" EFFECT_SIZE="0.25614135917051917" ESTIMABLE="YES" I2="94.06760761090875" ID="CMP-001.01.01" LOG_CI_END="-0.41749400728012076" LOG_CI_START="-0.7655465733129945" LOG_EFFECT_SIZE="-0.5915202902965576" MODIFIED="2012-01-05 12:50:28 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="-4.440892098500626E-16" P_Z="2.701749703881237E-11" STUDIES="6" TAU2="0.19901687281814023" TOTAL_1="4643" TOTAL_2="4678" WEIGHT="100.00000000000001" Z="6.661973381322111">
<NAME>During intervention</NAME>
<IV_DATA CI_END="0.19845230540114145" CI_START="0.09799943974484829" EFFECT_SIZE="0.13945685621505094" ESTIMABLE="YES" ESTIMATE="-1.97" LOG_CI_END="-0.702343851570732" LOG_CI_START="-1.0087764071280803" LOG_EFFECT_SIZE="-0.8555601293494061" MODIFIED="2011-10-14 12:46:45 +0100" MODIFIED_BY="[Empty name]" ORDER="205" SE="0.18" STUDY_ID="STD-Ciss_x00e9_-2006" TOTAL_1="435" TOTAL_2="437" WEIGHT="18.062167415739854"/>
<IV_DATA CI_END="0.687699051631925" CI_START="0.4468215244327472" EFFECT_SIZE="0.5543272847345071" ESTIMABLE="YES" ESTIMATE="-0.59" LOG_CI_END="-0.1626015745692844" LOG_CI_START="-0.3498659140765527" LOG_EFFECT_SIZE="-0.2562337443229185" MODIFIED="2011-10-14 12:46:45 +0100" MODIFIED_BY="[Empty name]" ORDER="202" SE="0.11" STUDY_ID="STD-Dicko-2008" TOTAL_1="116" TOTAL_2="116" WEIGHT="19.798940008309312"/>
<IV_DATA CI_END="0.2031921407593108" CI_START="0.14278764411741937" EFFECT_SIZE="0.17033298882540943" ESTIMABLE="YES" ESTIMATE="-1.77" LOG_CI_END="-0.6920930940794188" LOG_CI_START="-0.8453093718580927" LOG_EFFECT_SIZE="-0.7687012329687557" MODIFIED="2011-10-14 12:46:45 +0100" MODIFIED_BY="[Empty name]" ORDER="206" SE="0.09" STUDY_ID="STD-Dicko-2011" TOTAL_1="1481" TOTAL_2="1485" WEIGHT="20.18131233247421"/>
<IV_DATA CI_END="0.31917944821425354" CI_START="0.26237035642715373" EFFECT_SIZE="0.28938421793905067" ESTIMABLE="YES" ESTIMATE="-1.24" LOG_CI_END="-0.49596508039928944" LOG_CI_START="-0.5810852347207751" LOG_EFFECT_SIZE="-0.5385251575600323" MODIFIED="2011-10-14 12:46:45 +0100" MODIFIED_BY="[Empty name]" ORDER="200" SE="0.05" STUDY_ID="STD-Konate-2011" TOTAL_1="1504" TOTAL_2="1494" WEIGHT="20.742135590007816"/>
<IV_DATA CI_END="0.36905628133534085" CI_START="0.189532668273697" EFFECT_SIZE="0.26447726129982396" ESTIMABLE="YES" ESTIMATE="-1.33" LOG_CI_END="-0.43290739858479943" LOG_CI_START="-0.7223159232778504" LOG_EFFECT_SIZE="-0.577611660931325" MODIFIED="2012-01-05 12:50:28 +0000" MODIFIED_BY="[Empty name]" ORDER="203" SE="0.17" STUDY_ID="STD-Kweku-2008" TOTAL_1="594" TOTAL_2="613" WEIGHT="18.33953865716405">
<FOOTNOTE>Data based on AQ+AS monthly versus placebo (SP and AQ+AS bi-monthly trial arms not used).</FOOTNOTE>
</IV_DATA>
<IV_DATA CI_END="3.0500551202979667" CI_START="0.03781083176844232" EFFECT_SIZE="0.3395955256449391" ESTIMABLE="YES" ESTIMATE="-1.08" LOG_CI_END="0.4843076879451268" LOG_CI_START="-1.4223837688561507" LOG_EFFECT_SIZE="-0.469038040455512" MODIFIED="2011-10-14 12:46:45 +0100" MODIFIED_BY="[Empty name]" ORDER="207" SE="1.12" STUDY_ID="STD-Sesay-2011" TOTAL_1="513" TOTAL_2="533" WEIGHT="2.8759059963047755"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0025469365180327847" CI_END="1.169341975694143" CI_START="0.821752927509516" DF="2" EFFECT_SIZE="0.9802602673710811" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.06794153976545238" LOG_CI_START="-0.08525874006171517" LOG_EFFECT_SIZE="-0.00865860014813139" MODIFIED="2012-01-05 12:50:40 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9987273426014679" P_Z="0.824666410452289" STUDIES="3" TAU2="0.0" TOTAL_1="1138" TOTAL_2="1161" WEIGHT="100.0" Z="0.22154717296882254">
<NAME>Post-intervention</NAME>
<IV_DATA CI_END="1.169290036956863" CI_START="0.8216861589386553" EFFECT_SIZE="0.9801986733067553" ESTIMABLE="YES" ESTIMATE="-0.02" LOG_CI_END="0.06792224925127197" LOG_CI_START="-0.0852940285274021" LOG_EFFECT_SIZE="-0.008685889638065058" MODIFIED="2011-10-14 12:46:56 +0100" MODIFIED_BY="[Empty name]" ORDER="208" SE="0.09" STUDY_ID="STD-Ciss_x00e9_-2006" TOTAL_1="435" TOTAL_2="437" WEIGHT="99.97911825488517"/>
<IV_DATA CI_END="2.7341662576305832E13" CI_START="4.2070367727164126E-14" EFFECT_SIZE="1.0725081812542165" ESTIMABLE="YES" ESTIMATE="0.07" LOG_CI_END="13.43682491936721" LOG_CI_START="-13.376023691900754" LOG_EFFECT_SIZE="0.030400613733227652" MODIFIED="2011-10-14 12:46:56 +0100" MODIFIED_BY="[Empty name]" ORDER="210" SE="15.75" STUDY_ID="STD-Dicko-2008" TOTAL_1="109" TOTAL_2="111" WEIGHT="0.0032646242695472706"/>
<IV_DATA CI_END="813056.4458271682" CI_START="2.332532862925102E-6" EFFECT_SIZE="1.377127764335957" ESTIMABLE="YES" ESTIMATE="0.32" LOG_CI_END="5.910120697205764" LOG_CI_START="-5.632172228787683" LOG_EFFECT_SIZE="0.13897423420904054" MODIFIED="2012-01-05 12:50:40 +0000" MODIFIED_BY="[Empty name]" ORDER="209" SE="6.78" STUDY_ID="STD-Kweku-2008" TOTAL_1="594" TOTAL_2="613" WEIGHT="0.017617120845288714">
<FOOTNOTE>Data based on AQ+AS monthly versus placebo (SP and AQ+AS bi-monthly trial arms not used)</FOOTNOTE>
</IV_DATA>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.3687697929354447" CI_END="0.7609894869595721" CI_START="0.09517421380984017" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.26912186113159015" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.11862134294951071" LOG_CI_START="-1.0214807020046208" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.5700510224770657" MODIFIED="2012-01-17 13:42:45 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5436758731886959" P_Q="1.0" P_Z="0.013324359987042232" Q="0.0" RANDOM="NO" SCALE="155.08262659002983" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="2985" TOTAL_2="2979" WEIGHT="100.0" Z="2.474980100055835">
<NAME>Severe malaria</NAME>
<GROUP_LABEL_1>IPTc</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPTc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Rate Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.3687697929354447" CI_END="0.7609894869595721" CI_START="0.09517421380984017" DF="1" EFFECT_SIZE="0.26912186113159015" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-0.11862134294951071" LOG_CI_START="-1.0214807020046208" LOG_EFFECT_SIZE="-0.5700510224770657" MODIFIED="2012-01-17 13:40:03 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5436758731886959" P_Z="0.013324359987042232" STUDIES="2" TAU2="0.0" TOTAL_1="2985" TOTAL_2="2979" WEIGHT="100.0" Z="2.474980100055835">
<NAME>During intervention</NAME>
<IV_DATA CI_END="1.6947797980657695" CI_START="0.009976202024594313" EFFECT_SIZE="0.1300287108784259" ESTIMABLE="YES" ESTIMATE="-2.04" LOG_CI_END="0.2291132785288276" LOG_CI_START="-2.0010347646940954" LOG_EFFECT_SIZE="-0.8859607430826337" MODIFIED="2012-01-06 10:50:51 +0000" MODIFIED_BY="[Empty name]" ORDER="215" SE="1.31" STUDY_ID="STD-Dicko-2011" TOTAL_1="1481" TOTAL_2="1485" WEIGHT="16.389768574908647"/>
<IV_DATA CI_END="0.9673248645985975" CI_START="0.09958147645720376" EFFECT_SIZE="0.31036694126548503" ESTIMABLE="YES" ESTIMATE="-1.17" LOG_CI_END="-0.01442764876218816" LOG_CI_START="-1.001821438891421" LOG_EFFECT_SIZE="-0.5081245438268046" MODIFIED="2012-01-06 10:50:51 +0000" MODIFIED_BY="[Empty name]" ORDER="216" SE="0.58" STUDY_ID="STD-Konate-2011" TOTAL_1="1504" TOTAL_2="1494" WEIGHT="83.61023142509136"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-01-17 13:40:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Post-intervention</NAME>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="189.7700933485244" CI_END="1.0039908142219773" CI_START="0.7844084413046257" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8874338677715784" ESTIMABLE="YES" EVENTS_1="634" EVENTS_2="1351" I2="96.83827947063259" I2_Q="96.7316368388957" ID="CMP-001.03" LOG_CI_END="0.0017297393518721361" LOG_CI_START="-0.10545774137817848" LOG_EFFECT_SIZE="-0.05186400101315317" METHOD="MH" MODIFIED="2012-01-17 12:01:02 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.1102230246251565E-16" P_Q="3.1769991748475945E-8" P_Z="0.057866738655354445" Q="30.59635513888627" RANDOM="YES" SCALE="7.14" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.4380961228613188" TOTALS="SUB" TOTAL_1="5170" TOTAL_2="5238" WEIGHT="200.0" Z="1.8967060964131905">
<NAME>Parasitaemia</NAME>
<GROUP_LABEL_1>IPTc</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPTc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="27.037306650802353" CI_END="0.5010086916570291" CI_START="0.2494416104068315" DF="4" EFFECT_SIZE="0.35351437718252565" ESTIMABLE="YES" EVENTS_1="355" EVENTS_2="1066" I2="85.2056269817789" ID="CMP-001.03.01" LOG_CI_END="-0.30015473978955376" LOG_CI_START="-0.6030310983204722" LOG_EFFECT_SIZE="-0.451592919055013" MODIFIED="2012-01-17 12:01:02 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.9536773000261576E-5" P_Z="5.075800259751717E-9" STUDIES="5" TAU2="0.11422338696276094" TOTAL_1="4368" TOTAL_2="4413" WEIGHT="100.00000000000001" Z="5.8446678460760975">
<NAME>During intervention</NAME>
<DICH_DATA CI_END="0.4801997670164689" CI_START="0.28292871804483594" EFFECT_SIZE="0.3685950413223141" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="165" LOG_CI_END="-0.31857805499012537" LOG_CI_START="-0.548322968218491" LOG_EFFECT_SIZE="-0.4334505116043082" MODIFIED="2012-01-05 12:13:03 +0000" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="0.1349532992860039" STUDY_ID="STD-Ciss_x00e9_-2006" TOTAL_1="440" TOTAL_2="446" VAR="0.018212392988177742" WEIGHT="23.90014967675124"/>
<DICH_DATA CI_END="0.6850245324609353" CI_START="0.43219334552211824" EFFECT_SIZE="0.5441167562656167" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="188" LOG_CI_END="-0.16429387504534013" LOG_CI_START="-0.3643219242303632" LOG_EFFECT_SIZE="-0.2643078996378516" MODIFIED="2011-07-01 15:47:12 +0100" MODIFIED_BY="[Empty name]" ORDER="221" O_E="0.0" SE="0.11749746624609504" STUDY_ID="STD-Dicko-2011" TOTAL_1="1405" TOTAL_2="1423" VAR="0.013805654574252245" WEIGHT="24.722788871848707"/>
<DICH_DATA CI_END="0.3215565183829354" CI_START="0.23508270726827143" EFFECT_SIZE="0.2749406788404003" ESTIMABLE="YES" EVENTS_1="164" EVENTS_2="594" LOG_CI_END="-0.492742682258957" LOG_CI_START="-0.6287793164904737" LOG_EFFECT_SIZE="-0.5607609993747154" MODIFIED="2011-07-01 15:47:12 +0100" MODIFIED_BY="[Empty name]" ORDER="216" O_E="0.0" SE="0.0799085923397927" STUDY_ID="STD-Konate-2011" TOTAL_1="1436" TOTAL_2="1430" VAR="0.006385383129727175" WEIGHT="26.243820917479585"/>
<DICH_DATA CI_END="0.3588259782262723" CI_START="0.16016308599818402" EFFECT_SIZE="0.23973042362002567" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="114" LOG_CI_END="-0.4451161225066903" LOG_CI_START="-0.7954375718635659" LOG_EFFECT_SIZE="-0.6202768471851281" MODIFIED="2012-01-05 12:50:49 +0000" MODIFIED_BY="[Empty name]" ORDER="220" O_E="0.0" SE="0.20578055347137056" STUDY_ID="STD-Kweku-2008" TOTAL_1="574" TOTAL_2="581" VAR="0.0423456361869836" WEIGHT="20.216227320760993">
<FOOTNOTE>Data based on AQ+AS monthly versus placebo (SP and AQ+AS bi-monthly trial arms not used)</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.5951196491452833" CI_START="0.14974930056721053" EFFECT_SIZE="0.623391812865497" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.4141573859862704" LOG_CI_START="-0.8246351973894711" LOG_EFFECT_SIZE="-0.2052389057016004" MODIFIED="2011-10-14 10:47:25 +0100" MODIFIED_BY="[Empty name]" ORDER="217" O_E="0.0" SE="0.7276728955970959" STUDY_ID="STD-Sesay-2011" TOTAL_1="513" TOTAL_2="533" VAR="0.529507842986662" WEIGHT="4.917013213159495"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5510306701370866" CI_END="1.155233400856597" CI_START="0.8872898458343529" DF="1" EFFECT_SIZE="1.0124361047240191" ESTIMABLE="YES" EVENTS_1="279" EVENTS_2="285" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.06266973701054332" LOG_CI_START="-0.05193448852877922" LOG_EFFECT_SIZE="0.005367624240882029" MODIFIED="2012-01-05 12:50:53 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4578969651360455" P_Z="0.8543316131213377" STUDIES="2" TAU2="0.0" TOTAL_1="802" TOTAL_2="825" WEIGHT="100.0" Z="0.18359445553014586">
<NAME>Post-intervention</NAME>
<DICH_DATA CI_END="1.1734004256609374" CI_START="0.773461050082314" EFFECT_SIZE="0.9526696832579186" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="130" LOG_CI_END="0.0694462414243411" LOG_CI_START="-0.11156155159646287" LOG_EFFECT_SIZE="-0.02105765508606089" MODIFIED="2011-07-01 15:47:12 +0100" MODIFIED_BY="[Empty name]" ORDER="223" O_E="0.0" SE="0.10632487362344625" STUDY_ID="STD-Ciss_x00e9_-2006" TOTAL_1="425" TOTAL_2="435" VAR="0.011304978751041816" WEIGHT="40.08729158191233"/>
<DICH_DATA CI_END="1.2504871311846344" CI_START="0.8892381049146291" EFFECT_SIZE="1.0545050055617353" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="155" LOG_CI_END="0.09707922674684169" LOG_CI_START="-0.050981935537166664" LOG_EFFECT_SIZE="0.023048645604837513" MODIFIED="2012-01-05 12:50:53 +0000" MODIFIED_BY="[Empty name]" ORDER="222" O_E="0.0" SE="0.08697185964020013" STUDY_ID="STD-Kweku-2008" TOTAL_1="377" TOTAL_2="390" VAR="0.007564104369274672" WEIGHT="59.912708418087675">
<FOOTNOTE>Data based on AQ+AS monthly versus placebo (SP and AQ+AS bi-monthly trial arms not used)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.534894185201136" CI_END="1.3968451506578368" CI_START="0.4317642192332096" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7766001261031806" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.1451482644232361" LOG_CI_START="-0.364753350962975" LOG_EFFECT_SIZE="-0.10980254326986941" METHOD="MH" MODIFIED="2012-01-06 09:36:24 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8645422031651426" P_Q="0.47625636058221343" P_Z="0.39860246097254204" Q="0.5074235745788457" RANDOM="NO" SCALE="95.23" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="5345" TOTAL_2="5395" WEIGHT="199.99999999999997" Z="0.8441198212594042">
<NAME>Death from any cause</NAME>
<GROUP_LABEL_1>IPTc</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPTc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.0960306178487054" CI_END="1.3895211622285935" CI_START="0.31477682666453183" DF="5" EFFECT_SIZE="0.6613539612261568" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="16" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.14286516541286276" LOG_CI_START="-0.5019972471584662" LOG_EFFECT_SIZE="-0.17956604087280165" MODIFIED="2012-01-05 12:51:03 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8357042372850265" P_Z="0.275040248877493" STUDIES="6" TAU2="0.0" TOTAL_1="4751" TOTAL_2="4782" WEIGHT="99.99999999999997" Z="1.091528878396862">
<NAME>During intervention</NAME>
<DICH_DATA CI_END="8.27310994423829" CI_START="0.01379231146884014" EFFECT_SIZE="0.33779477374123645" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9176687958562924" LOG_CI_START="-1.8603629438285874" LOG_EFFECT_SIZE="-0.4713470739861476" MODIFIED="2011-10-13 12:08:02 +0100" MODIFIED_BY="[Empty name]" ORDER="242" O_E="0.0" SE="1.6318295953697908" STUDY_ID="STD-Ciss_x00e9_-2006" TOTAL_1="522" TOTAL_2="529" VAR="2.662867828324735" WEIGHT="8.539336362200787"/>
<DICH_DATA CI_END="8.108313613203613" CI_START="0.013703356383524339" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9089305379797485" LOG_CI_START="-1.8631730474190737" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-08-04 21:48:20 +0100" MODIFIED_BY="[Empty name]" ORDER="239" O_E="0.0" SE="1.6283473681973237" STUDY_ID="STD-Dicko-2008" TOTAL_1="131" TOTAL_2="131" VAR="2.651515151515151" WEIGHT="8.596482972655284"/>
<DICH_DATA CI_END="8.988159828901802" CI_START="0.2516833708192953" EFFECT_SIZE="1.5040513166779204" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.953670786509991" LOG_CI_START="-0.5991454781345831" LOG_EFFECT_SIZE="0.17726265418770393" MODIFIED="2011-10-13 12:08:06 +0100" MODIFIED_BY="[Empty name]" ORDER="243" O_E="0.0" SE="0.9121319604167001" STUDY_ID="STD-Dicko-2011" TOTAL_1="1481" TOTAL_2="1485" VAR="0.8319847132136124" WEIGHT="11.44651947179364"/>
<DICH_DATA CI_END="1.6431884408032502" CI_START="0.11029722364182475" EFFECT_SIZE="0.42572188449848025" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.2156873711698164" LOG_CI_START="-0.957435419311492" LOG_EFFECT_SIZE="-0.37087402407083786" MODIFIED="2011-10-13 12:08:24 +0100" MODIFIED_BY="[Empty name]" ORDER="240" O_E="0.0" SE="0.6890981341801884" STUDY_ID="STD-Konate-2011" TOTAL_1="1504" TOTAL_2="1494" VAR="0.47485623853061687" WEIGHT="40.25073281570595"/>
<DICH_DATA CI_END="4.046465217456598" CI_START="0.25543556056087546" EFFECT_SIZE="1.0166666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6070758116427958" LOG_CI_START="-0.5927186423885491" LOG_EFFECT_SIZE="0.007178584627123376" MODIFIED="2012-01-05 12:51:03 +0000" MODIFIED_BY="[Empty name]" ORDER="245" O_E="0.0" SE="0.7047652013763437" STUDY_ID="STD-Kweku-2008" TOTAL_1="600" TOTAL_2="610" VAR="0.4966939890710383" WEIGHT="22.734500423551165">
<FOOTNOTE>Data based on AQ+AS monthly versus placebo (SP and AQ+AS bi-monthly trial arms not used)</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="8.481403154841578" CI_START="0.014139890920204052" EFFECT_SIZE="0.3463035019455253" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9284677074447286" LOG_CI_START="-1.8495539408174921" LOG_EFFECT_SIZE="-0.46054311668638176" MODIFIED="2011-10-14 10:47:48 +0100" MODIFIED_BY="[Empty name]" ORDER="241" O_E="0.0" SE="1.6318236676181677" STUDY_ID="STD-Sesay-2011" TOTAL_1="513" TOTAL_2="533" VAR="2.662848482198808" WEIGHT="8.43242795409316"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7317679351360917" CI_START="0.3898560300469056" DF="0" EFFECT_SIZE="1.031986531986532" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.4364438030729793" LOG_CI_START="-0.4090957439985363" LOG_EFFECT_SIZE="0.013674029537221499" MODIFIED="2012-01-05 12:51:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9494536343808923" STUDIES="1" TAU2="0.0" TOTAL_1="594" TOTAL_2="613" WEIGHT="100.0" Z="0.06339290813614482">
<NAME>Post-intervention</NAME>
<DICH_DATA CI_END="2.7317679351360926" CI_START="0.3898560300469055" EFFECT_SIZE="1.031986531986532" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.4364438030729795" LOG_CI_START="-0.40909574399853643" LOG_EFFECT_SIZE="0.013674029537221499" MODIFIED="2012-01-05 12:51:07 +0000" MODIFIED_BY="[Empty name]" ORDER="248" O_E="0.0" SE="0.4966741154380691" STUDY_ID="STD-Kweku-2008" TOTAL_1="594" TOTAL_2="613" VAR="0.24668517694618838" WEIGHT="100.0">
<FOOTNOTE>Data based on AQ+AS monthly versus placebo (SP and AQ+AS bi-monthly trial arms not used)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="1.8710124421382832" CI_END="1.0493054451113402" CI_START="0.4123200963817851" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="0.6577611437765534" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.02090192653229008" LOG_CI_START="-0.38476549727475634" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.1819317853712331" MODIFIED="2012-01-06 09:37:01 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5996052658700846" P_Q="0.8711075814464553" P_Z="0.07874911874442078" Q="0.026325650925008107" RANDOM="NO" SCALE="1000.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="4173" TOTAL_2="4205" WEIGHT="200.0" Z="1.7579905412384969">
<NAME>Hospital admission for any reason</NAME>
<GROUP_LABEL_1>IPTc</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPTc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Rate Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="1.844686791213275" CI_END="1.04765575924972" CI_START="0.4106847060003824" DF="2" EFFECT_SIZE="0.6559391720861613" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.02021860476850213" LOG_CI_START="-0.38649147007869555" LOG_EFFECT_SIZE="-0.18313643265509671" MODIFIED="2012-01-05 12:51:14 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3975862999461658" P_Z="0.07754792276654095" STUDIES="3" TAU2="0.0" TOTAL_1="3579" TOTAL_2="3592" WEIGHT="100.0" Z="1.7650942745688798">
<NAME>During intervention</NAME>
<IV_DATA CI_END="2.74995193374742" CI_START="0.4531267311604696" EFFECT_SIZE="1.1162780704588713" ESTIMABLE="YES" ESTIMATE="0.11" LOG_CI_END="0.43932510288819143" LOG_CI_START="-0.3437803168694761" LOG_EFFECT_SIZE="0.0477723930093577" MODIFIED="2011-10-14 12:47:36 +0100" MODIFIED_BY="[Empty name]" ORDER="322" SE="0.46" STUDY_ID="STD-Dicko-2011" TOTAL_1="1481" TOTAL_2="1485" WEIGHT="26.973009295699956"/>
<IV_DATA CI_END="0.9312662271349899" CI_START="0.3107427387647588" EFFECT_SIZE="0.5379444375946745" ESTIMABLE="YES" ESTIMATE="-0.62" LOG_CI_END="-0.030926146679856454" LOG_CI_START="-0.5075990108801758" LOG_EFFECT_SIZE="-0.26926257878001614" MODIFIED="2011-10-14 12:47:36 +0100" MODIFIED_BY="[Empty name]" ORDER="323" SE="0.28" STUDY_ID="STD-Konate-2011" TOTAL_1="1504" TOTAL_2="1494" WEIGHT="72.79960161951672"/>
<IV_DATA CI_END="18387.37492195698" CI_START="5.4385142210042524E-5" EFFECT_SIZE="1.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="4.264519731506429" LOG_CI_START="-4.264519731506429" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-05 12:51:14 +0000" MODIFIED_BY="[Empty name]" ORDER="324" SE="5.01" STUDY_ID="STD-Kweku-2008" TOTAL_1="594" TOTAL_2="613" WEIGHT="0.22738908478333203">
<FOOTNOTE>Data based on AQ+AS monthly versus placebo (SP and AQ+AS bi-monthly trial arms not used)</FOOTNOTE>
</IV_DATA>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.736808830801284E-35" CI_END="770.2229886084288" CI_START="0.001650494946428678" DF="0" EFFECT_SIZE="1.1274968515793757" ESTIMABLE="YES" I2="100.0" ID="CMP-001.05.02" LOG_CI_END="2.8866164767338605" LOG_CI_START="-2.7823858010770803" LOG_EFFECT_SIZE="0.05211533782839024" MODIFIED="2012-01-05 12:51:17 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.9712536250007415" STUDIES="1" TAU2="0.0" TOTAL_1="594" TOTAL_2="613" WEIGHT="100.0" Z="0.036036036036036036">
<NAME>Post-intervention</NAME>
<IV_DATA CI_END="770.2229886084288" CI_START="0.001650494946428678" EFFECT_SIZE="1.1274968515793757" ESTIMABLE="YES" ESTIMATE="0.12" LOG_CI_END="2.8866164767338605" LOG_CI_START="-2.7823858010770803" LOG_EFFECT_SIZE="0.05211533782839024" MODIFIED="2012-01-05 12:51:17 +0000" MODIFIED_BY="[Empty name]" ORDER="325" SE="3.33" STUDY_ID="STD-Kweku-2008" TOTAL_1="594" TOTAL_2="613" WEIGHT="100.0">
<FOOTNOTE>Data based on AQ+AS monthly versus placebo (SP and AQ+AS bi-monthly trial arms not used)</FOOTNOTE>
</IV_DATA>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.4391225453167905" CI_END="0.9438382690166337" CI_START="0.060033067374819116" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2380367752991294" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.025102417662906048" LOG_CI_START="-1.2216094659074195" LOG_EFFECT_SIZE="-0.6233559417851627" METHOD="MH" MODIFIED="2012-01-06 09:37:20 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.5075462928601568" P_Q="1.0" P_Z="0.04113139012989404" Q="0.0" RANDOM="NO" SCALE="186.82" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2985" TOTAL_2="2979" WEIGHT="100.0" Z="2.0422030898029324">
<NAME>Severe anaemia</NAME>
<GROUP_LABEL_1>IPTc</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPTc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.4391225453167905" CI_END="0.9438382690166337" CI_START="0.060033067374819116" DF="1" EFFECT_SIZE="0.2380367752991294" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="-0.025102417662906048" LOG_CI_START="-1.2216094659074195" LOG_EFFECT_SIZE="-0.6233559417851627" MODIFIED="2011-10-13 10:36:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5075462928601568" P_Z="0.04113139012989404" STUDIES="2" TAU2="0.0" TOTAL_1="2985" TOTAL_2="2979" WEIGHT="100.0" Z="2.0422030898029324">
<NAME>During intervention</NAME>
<DICH_DATA CI_END="1.6532935172422762" CI_START="0.0675694397493322" EFFECT_SIZE="0.33423362592842676" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.21834996282888888" LOG_CI_START="-1.1702496820041683" LOG_EFFECT_SIZE="-0.47594985958763975" MODIFIED="2011-10-13 10:36:02 +0100" MODIFIED_BY="[Empty name]" ORDER="225" O_E="0.0" SE="0.815670305054037" STUDY_ID="STD-Dicko-2011" TOTAL_1="1481" TOTAL_2="1485" VAR="0.6653180465469458" WEIGHT="57.02827250734754"/>
<DICH_DATA CI_END="2.0482256247147843" CI_START="0.00594766599092371" EFFECT_SIZE="0.11037283130306386" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3113777951609442" LOG_CI_START="-2.2256534285784215" LOG_EFFECT_SIZE="-0.9571378167087387" MODIFIED="2011-10-13 10:36:09 +0100" MODIFIED_BY="[Empty name]" ORDER="224" O_E="0.0" SE="1.4902646993316018" STUDY_ID="STD-Konate-2011" TOTAL_1="1504" TOTAL_2="1494" VAR="2.2208888740739092" WEIGHT="42.971727492652455"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.533319310684037" CI_END="0.9536537099146092" CI_START="0.5762455507849584" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.741308780015361" ESTIMABLE="YES" EVENTS_1="239" EVENTS_2="343" I2="63.05414891043994" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-0.020609297387116525" LOG_CI_START="-0.2393924147944879" LOG_EFFECT_SIZE="-0.1300008560908022" METHOD="MH" MODIFIED="2012-01-06 09:37:43 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.01886204467819641" P_Q="0.6527456109468239" P_Z="0.019847418981423354" Q="0.20245611761374332" RANDOM="YES" SCALE="3.61" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.06874571362439319" TOTALS="SUB" TOTAL_1="4749" TOTAL_2="4824" WEIGHT="200.0" Z="2.32921990432121">
<NAME>Moderately severe anaemia</NAME>
<GROUP_LABEL_1>IPTc</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPTc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="13.295836984450943" CI_END="0.975068406191654" CI_START="0.515130081745368" DF="4" EFFECT_SIZE="0.7087221372222209" ESTIMABLE="YES" EVENTS_1="203" EVENTS_2="296" I2="69.91539528742814" ID="CMP-001.07.01" LOG_CI_END="-0.010964915184091487" LOG_CI_START="-0.2880830881420249" LOG_EFFECT_SIZE="-0.14952400166305815" MODIFIED="2012-01-05 12:51:27 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.00991720727183798" P_Z="0.03442429469061137" STUDIES="5" TAU2="0.09220698457632112" TOTAL_1="4373" TOTAL_2="4432" WEIGHT="100.00000000000001" Z="2.115066326800502">
<NAME>During intervention</NAME>
<DICH_DATA CI_END="1.166660320349703" CI_START="0.537775433477822" EFFECT_SIZE="0.7920866489832007" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="52" LOG_CI_END="0.06694442719238396" LOG_CI_START="-0.26939904099094225" LOG_EFFECT_SIZE="-0.10122730689927917" MODIFIED="2011-10-14 10:40:27 +0100" MODIFIED_BY="[Empty name]" ORDER="228" O_E="0.0" SE="0.1975698181379049" STUDY_ID="STD-Ciss_x00e9_-2006" TOTAL_1="435" TOTAL_2="437" VAR="0.03903383303904481" WEIGHT="20.18999869084649"/>
<DICH_DATA CI_END="0.8640037410646617" CI_START="0.34274023069263954" EFFECT_SIZE="0.5441772151898734" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="50" LOG_CI_END="-0.06348437705788731" LOG_CI_START="-0.4650349152889818" LOG_EFFECT_SIZE="-0.26425964617343456" MODIFIED="2011-07-01 15:47:12 +0100" MODIFIED_BY="[Empty name]" ORDER="229" O_E="0.0" SE="0.23587277386416647" STUDY_ID="STD-Dicko-2011" TOTAL_1="1422" TOTAL_2="1433" VAR="0.05563596545037622" WEIGHT="17.922747992794864"/>
<DICH_DATA CI_END="0.6325991163104847" CI_START="0.3022833280444663" EFFECT_SIZE="0.4372918547106975" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="89" LOG_CI_END="-0.19887141909394165" LOG_CI_START="-0.5195858049821477" LOG_EFFECT_SIZE="-0.3592286120380446" MODIFIED="2011-10-13 10:47:46 +0100" MODIFIED_BY="[Empty name]" ORDER="226" O_E="0.0" SE="0.18838921783254622" STUDY_ID="STD-Konate-2011" TOTAL_1="1444" TOTAL_2="1441" VAR="0.035490497395558554" WEIGHT="20.750228547367634"/>
<DICH_DATA CI_END="1.2973359164363858" CI_START="0.6405938741460491" EFFECT_SIZE="0.9116279069767442" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="60" LOG_CI_END="0.11305244159372667" LOG_CI_START="-0.19341721871198522" LOG_EFFECT_SIZE="-0.040182388559129256" MODIFIED="2012-01-05 12:51:27 +0000" MODIFIED_BY="[Empty name]" ORDER="227" O_E="0.0" SE="0.18002179551286032" STUDY_ID="STD-Kweku-2008" TOTAL_1="559" TOTAL_2="588" VAR="0.0324078468596741" WEIGHT="21.263535851274888">
<FOOTNOTE>Data based on AQ+AS monthly versus placebo (SP and AQ+AS bi-monthly trial arms not used)</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.5117000601249861" CI_START="0.6827070425635653" EFFECT_SIZE="1.0158977691141433" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="45" LOG_CI_END="0.17946563034866603" LOG_CI_START="-0.16576561709746665" LOG_EFFECT_SIZE="0.006850006625599711" MODIFIED="2011-10-13 10:50:47 +0100" MODIFIED_BY="[Empty name]" ORDER="230" O_E="0.0" SE="0.20279054367209434" STUDY_ID="STD-Sesay-2011" TOTAL_1="513" TOTAL_2="533" VAR="0.0411240046028236" WEIGHT="19.873488917716127"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.203746829690522" CI_START="0.5297495220038811" DF="0" EFFECT_SIZE="0.7985513807152558" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="47" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="0.08053515633219607" LOG_CI_START="-0.2759294264834641" LOG_EFFECT_SIZE="-0.097697135075634" MODIFIED="2012-01-05 12:51:29 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.28266836344423707" STUDIES="1" TAU2="0.0" TOTAL_1="376" TOTAL_2="392" WEIGHT="100.0" Z="1.0743444110407443">
<NAME>Post-intervention</NAME>
<DICH_DATA CI_END="1.203746829690522" CI_START="0.5297495220038811" EFFECT_SIZE="0.7985513807152558" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="47" LOG_CI_END="0.08053515633219607" LOG_CI_START="-0.2759294264834641" LOG_EFFECT_SIZE="-0.097697135075634" MODIFIED="2012-01-05 12:51:29 +0000" MODIFIED_BY="[Empty name]" ORDER="231" O_E="0.0" SE="0.20938906047406167" STUDY_ID="STD-Kweku-2008" TOTAL_1="376" TOTAL_2="392" VAR="0.04384377864621026" WEIGHT="100.0">
<FOOTNOTE>Data based on AQ+AS monthly versus placebo (SP and AQ+AS bi-monthly trial arms not used)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="34.48397608545515" CI_END="1.0373937332240126" CI_START="0.6547376926187392" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8241485177006811" ESTIMABLE="YES" EVENTS_1="1474" EVENTS_2="1890" I2="94.20020477034383" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.0159436201425757" LOG_CI_START="-0.18393265644301937" LOG_EFFECT_SIZE="-0.08399451815022184" METHOD="MH" MODIFIED="2012-01-06 09:37:59 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="3.25016050739535E-8" P_Q="1.0" P_Z="0.09950023129426935" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03477243085630312" TOTALS="SUB" TOTAL_1="3379" TOTAL_2="3407" WEIGHT="100.0" Z="1.6472813410923342">
<NAME>Any anaemia</NAME>
<GROUP_LABEL_1>IPTc</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPTc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="34.48397608545515" CI_END="1.0373937332240126" CI_START="0.6547376926187392" DF="2" EFFECT_SIZE="0.8241485177006811" ESTIMABLE="YES" EVENTS_1="1474" EVENTS_2="1890" I2="94.20020477034383" ID="CMP-001.08.01" LOG_CI_END="0.0159436201425757" LOG_CI_START="-0.18393265644301937" LOG_EFFECT_SIZE="-0.08399451815022184" MODIFIED="2011-10-14 10:40:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.25016050739535E-8" P_Z="0.09950023129426935" STUDIES="3" TAU2="0.03477243085630312" TOTAL_1="3379" TOTAL_2="3407" WEIGHT="100.0" Z="1.6472813410923342">
<NAME>During intervention</NAME>
<DICH_DATA CI_END="0.9399689209825822" CI_START="0.827982441073329" EFFECT_SIZE="0.882200522403054" ESTIMABLE="YES" EVENTS_1="766" EVENTS_2="875" LOG_CI_END="-0.026886505622539643" LOG_CI_START="-0.08197887314968501" LOG_EFFECT_SIZE="-0.05443268938611234" MODIFIED="2011-07-01 15:47:12 +0100" MODIFIED_BY="[Empty name]" ORDER="233" O_E="0.0" SE="0.03236152939706269" STUDY_ID="STD-Dicko-2011" TOTAL_1="1422" TOTAL_2="1433" VAR="0.0010472685849169526" WEIGHT="38.483606715688126"/>
<DICH_DATA CI_END="0.7226403937794472" CI_START="0.6294608300855623" EFFECT_SIZE="0.6744433424104418" ESTIMABLE="YES" EVENTS_1="638" EVENTS_2="944" LOG_CI_END="-0.14107776612087652" LOG_CI_START="-0.2010312898721988" LOG_EFFECT_SIZE="-0.17105452799653767" MODIFIED="2011-07-01 15:47:12 +0100" MODIFIED_BY="[Empty name]" ORDER="234" O_E="0.0" SE="0.03521699662625561" STUDY_ID="STD-Konate-2011" TOTAL_1="1444" TOTAL_2="1441" VAR="0.001240236851373699" WEIGHT="38.27739830771321"/>
<DICH_DATA CI_END="1.3925321222398221" CI_START="0.7535183768328586" EFFECT_SIZE="1.024352744145183" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="71" LOG_CI_END="0.14380522205086393" LOG_CI_START="-0.1229061516309889" LOG_EFFECT_SIZE="0.010449535209937522" MODIFIED="2011-10-14 10:40:55 +0100" MODIFIED_BY="[Empty name]" ORDER="232" O_E="0.0" SE="0.15666758114331267" STUDY_ID="STD-Sesay-2011" TOTAL_1="513" TOTAL_2="533" VAR="0.024544730981296458" WEIGHT="23.23899497659867">
<FOOTNOTE>Assumes patients did not have anaemia more than once</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.84025070580602" CI_END="0.1329265713916802" CI_START="-0.07153412863174938" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.03069622137996541" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2012-01-06 09:38:16 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.41691683710274063" P_Q="0.9955926345796735" P_Z="0.5561906497009634" Q="3.0512824708977865E-5" RANDOM="NO" SCALE="0.57" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="1708" TOTAL_2="1765" UNITS="" WEIGHT="200.0" Z="0.5885090715164952">
<NAME>Haemoglobin</NAME>
<GROUP_LABEL_1>IPTc</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IPTc</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.8402201929813105" CI_END="0.14145392417529523" CI_START="-0.07982301426201968" DF="2" EFFECT_SIZE="0.03081545495663777" ESTIMABLE="YES" I2="29.58292441753791" ID="CMP-001.09.01" MODIFIED="2011-10-13 10:21:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.24168773140621425" P_Z="0.5851369080234147" STUDIES="3" TAU2="0.0" TOTAL_1="1114" TOTAL_2="1152" WEIGHT="100.0" Z="0.5458967600397826">
<NAME>During intervention</NAME>
<CONT_DATA CI_END="0.24391219276297368" CI_START="-0.043912192762974395" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="9.4" MEAN_2="9.3" MODIFIED="2011-07-01 15:47:12 +0100" MODIFIED_BY="[Empty name]" ORDER="235" SD_1="1.22" SD_2="1.33" SE="0.07342593736320414" STUDY_ID="STD-Kweku-2008" TOTAL_1="594" TOTAL_2="613" WEIGHT="59.104035632770106"/>
<CONT_DATA CI_END="0.08811204790005175" CI_START="-0.2881120479000546" EFFECT_SIZE="-0.10000000000000142" ESTIMABLE="YES" MEAN_1="10.2" MEAN_2="10.3" MODIFIED="2011-07-01 15:47:12 +0100" MODIFIED_BY="[Empty name]" ORDER="236" SD_1="1.6" SD_2="1.5" SE="0.0959772982482622" STUDY_ID="STD-Sesay-2011" TOTAL_1="513" TOTAL_2="533" WEIGHT="34.59227252168075"/>
<CONT_DATA CI_END="0.5406651147822887" CI_START="-0.3406651147822895" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="11.02" MEAN_2="10.92" MODIFIED="2011-10-13 10:21:08 +0100" MODIFIED_BY="[Empty name]" ORDER="237" SD_1="0.42" SD_2="0.39" SE="0.22483327155917116" STUDY_ID="STD-Tagbor-2011" TOTAL_1="7" TOTAL_2="6" WEIGHT="6.303691845549141"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.29735022274315714" CI_START="-0.23735022274315487" DF="0" EFFECT_SIZE="0.030000000000001137" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.02" MODIFIED="2012-01-05 12:51:40 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8259239674999754" STUDIES="1" TAU2="0.0" TOTAL_1="594" TOTAL_2="613" WEIGHT="100.0" Z="0.21993218832172853">
<NAME>Post-intervention</NAME>
<CONT_DATA CI_END="0.29735022274315714" CI_START="-0.23735022274315487" EFFECT_SIZE="0.030000000000001137" ESTIMABLE="YES" MEAN_1="9.32" MEAN_2="9.29" MODIFIED="2012-01-05 12:51:40 +0000" MODIFIED_BY="[Empty name]" ORDER="238" SD_1="3.1" SD_2="1.22" SE="0.13640568135536185" STUDY_ID="STD-Kweku-2008" TOTAL_1="594" TOTAL_2="613" WEIGHT="100.0">
<FOOTNOTE>Data based on AQ+AS monthly versus placebo (SP and AQ+AS bi-monthly trial arms not used)</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2012-01-06 09:39:24 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>IPTc versus placebo or no IPTc (subgroup analysis: additional interventions)</NAME>
<IV_OUTCOME CHI2="84.28302903891229" CI_END="0.3698034304256589" CI_START="0.15621661978477325" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="0.24035274470226048" ESTIMABLE="YES" I2="94.06760761090875" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.43202906449100426" LOG_CI_START="-0.806272763692707" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.6191509140918556" MODIFIED="2012-01-06 09:38:41 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="-1.3322676295501878E-15" P_Q="0.8689342253156095" P_Z="8.86428278816027E-11" Q="0.2809757151267499" RANDOM="YES" SCALE="75.79" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.19901687281814026" TOTALS="SUB" TOTAL_1="4643" TOTAL_2="4678" WEIGHT="300.0" Z="6.485151227414807">
<NAME>Clinical malaria</NAME>
<GROUP_LABEL_1>IPTc</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPTc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favour control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Rate Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="46.32383245237145" CI_END="0.6293398187131969" CI_START="0.12096743895188511" DF="2" EFFECT_SIZE="0.2759159765221635" ESTIMABLE="YES" I2="95.68256792644189" ID="CMP-002.01.01" LOG_CI_END="-0.20111478930712184" LOG_CI_START="-0.9173315138698511" LOG_EFFECT_SIZE="-0.5592231515884866" MODIFIED="2012-01-05 12:51:51 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="8.728007205860422E-11" P_Z="0.0022083058073673716" STUDIES="3" TAU2="0.5066715258855587" TOTAL_1="1145" TOTAL_2="1166" WEIGHT="100.0" Z="3.060685959556699">
<NAME>During intervention (no additional)</NAME>
<IV_DATA CI_END="0.19845230540114145" CI_START="0.09799943974484829" EFFECT_SIZE="0.13945685621505094" ESTIMABLE="YES" ESTIMATE="-1.97" LOG_CI_END="-0.702343851570732" LOG_CI_START="-1.0087764071280803" LOG_EFFECT_SIZE="-0.8555601293494061" MODIFIED="2012-01-05 12:01:06 +0000" MODIFIED_BY="[Empty name]" ORDER="417" SE="0.18" STUDY_ID="STD-Ciss_x00e9_-2006" TOTAL_1="435" TOTAL_2="437" WEIGHT="32.833541372432464"/>
<IV_DATA CI_END="0.687699051631925" CI_START="0.4468215244327472" EFFECT_SIZE="0.5543272847345071" ESTIMABLE="YES" ESTIMATE="-0.59" LOG_CI_END="-0.1626015745692844" LOG_CI_START="-0.3498659140765527" LOG_EFFECT_SIZE="-0.2562337443229185" MODIFIED="2012-01-05 12:01:06 +0000" MODIFIED_BY="[Empty name]" ORDER="418" SE="0.11" STUDY_ID="STD-Dicko-2008" TOTAL_1="116" TOTAL_2="116" WEIGHT="34.11834760523911"/>
<IV_DATA CI_END="0.36905628133534085" CI_START="0.189532668273697" EFFECT_SIZE="0.26447726129982396" ESTIMABLE="YES" ESTIMATE="-1.33" LOG_CI_END="-0.43290739858479943" LOG_CI_START="-0.7223159232778504" LOG_EFFECT_SIZE="-0.577611660931325" MODIFIED="2012-01-05 12:51:51 +0000" MODIFIED_BY="[Empty name]" ORDER="419" SE="0.17" STUDY_ID="STD-Kweku-2008" TOTAL_1="594" TOTAL_2="613" WEIGHT="33.04811102232843">
<FOOTNOTE>Data based on AQ+AS monthly versus placebo (SP and AQ+AS bi-monthly trial arms not used)</FOOTNOTE>
</IV_DATA>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="26.500000000000004" CI_END="0.37514984393563766" CI_START="0.13278762742395142" DF="1" EFFECT_SIZE="0.2231933191309251" ESTIMABLE="YES" I2="96.22641509433963" ID="CMP-002.01.02" LOG_CI_END="-0.42579522988262997" LOG_CI_START="-0.8768423887618974" LOG_EFFECT_SIZE="-0.6513188093222637" MODIFIED="2011-10-14 12:49:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="2.635416015417391E-7" P_Z="1.5099037061666722E-8" STUDIES="2" TAU2="0.13515000000000005" TOTAL_1="2985" TOTAL_2="2979" WEIGHT="100.0" Z="5.6604343186511334">
<NAME>During intervention (ITN)</NAME>
<IV_DATA CI_END="0.2031921407593108" CI_START="0.14278764411741937" EFFECT_SIZE="0.17033298882540943" ESTIMABLE="YES" ESTIMATE="-1.77" LOG_CI_END="-0.6920930940794188" LOG_CI_START="-0.8453093718580927" LOG_EFFECT_SIZE="-0.7687012329687557" MODIFIED="2011-10-14 12:49:22 +0100" MODIFIED_BY="[Empty name]" ORDER="420" SE="0.09" STUDY_ID="STD-Dicko-2011" TOTAL_1="1481" TOTAL_2="1485" WEIGHT="49.00320398718405"/>
<IV_DATA CI_END="0.31917944821425354" CI_START="0.26237035642715373" EFFECT_SIZE="0.28938421793905067" ESTIMABLE="YES" ESTIMATE="-1.24" LOG_CI_END="-0.49596508039928944" LOG_CI_START="-0.5810852347207751" LOG_EFFECT_SIZE="-0.5385251575600323" MODIFIED="2011-10-14 12:49:22 +0100" MODIFIED_BY="[Empty name]" ORDER="421" SE="0.05" STUDY_ID="STD-Konate-2011" TOTAL_1="1504" TOTAL_2="1494" WEIGHT="50.99679601281594"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="3.0500551202979667" CI_START="0.03781083176844232" DF="0" EFFECT_SIZE="0.3395955256449391" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="0.4843076879451268" LOG_CI_START="-1.4223837688561507" LOG_EFFECT_SIZE="-0.469038040455512" MODIFIED="2011-10-14 12:49:30 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.3349027132309512" STUDIES="1" TAU2="0.0" TOTAL_1="513" TOTAL_2="533" WEIGHT="100.0" Z="0.9642857142857143">
<NAME>During intervention (HMM)</NAME>
<IV_DATA CI_END="3.0500551202979667" CI_START="0.03781083176844232" EFFECT_SIZE="0.3395955256449391" ESTIMABLE="YES" ESTIMATE="-1.08" LOG_CI_END="0.4843076879451268" LOG_CI_START="-1.4223837688561507" LOG_EFFECT_SIZE="-0.469038040455512" MODIFIED="2011-10-14 12:49:30 +0100" MODIFIED_BY="[Empty name]" ORDER="422" SE="1.12" STUDY_ID="STD-Sesay-2011" TOTAL_1="513" TOTAL_2="533" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="28.36750105034714" CI_END="0.4968966240158204" CI_START="0.2537308015429464" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3550746100406479" ESTIMABLE="YES" EVENTS_1="357" EVENTS_2="1069" I2="82.37419647530493" I2_Q="11.821360012927755" ID="CMP-002.02" LOG_CI_END="-0.3037339539010377" LOG_CI_START="-0.5956268085837132" LOG_EFFECT_SIZE="-0.44968038124237547" METHOD="MH" MODIFIED="2012-01-06 09:38:53 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="3.084615782755762E-5" P_Q="0.3217242677004315" P_Z="1.5515867013070932E-9" Q="2.268122983404164" RANDOM="YES" SCALE="16.3" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.11440940941052588" TOTALS="SUB" TOTAL_1="4374" TOTAL_2="4420" WEIGHT="300.0" Z="6.038910083958334">
<NAME>Parasitaemia</NAME>
<GROUP_LABEL_1>IPTc</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPTc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.1043276716026" CI_END="0.465729161291634" CI_START="0.2005038961800783" DF="1" EFFECT_SIZE="0.305582249817709" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="279" I2="67.78690570754881" ID="CMP-002.02.01" LOG_CI_END="-0.3318665681837781" LOG_CI_START="-0.6978771837766263" LOG_EFFECT_SIZE="-0.5148718759802022" MODIFIED="2012-01-05 12:52:00 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07808474225459083" P_Z="3.503431591514554E-8" STUDIES="2" TAU2="0.06371696826550481" TOTAL_1="1014" TOTAL_2="1027" WEIGHT="100.00000000000001" Z="5.514213471318168">
<NAME>During intervention (no additional)</NAME>
<DICH_DATA CI_END="0.4801997670164689" CI_START="0.28292871804483594" EFFECT_SIZE="0.3685950413223141" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="165" LOG_CI_END="-0.31857805499012537" LOG_CI_START="-0.548322968218491" LOG_EFFECT_SIZE="-0.4334505116043082" MODIFIED="2012-01-05 12:13:22 +0000" MODIFIED_BY="[Empty name]" ORDER="236" O_E="0.0" SE="0.1349532992860039" STUDY_ID="STD-Ciss_x00e9_-2006" TOTAL_1="440" TOTAL_2="446" VAR="0.018212392988177742" WEIGHT="56.41869005096894"/>
<DICH_DATA CI_END="0.3588259782262723" CI_START="0.16016308599818402" EFFECT_SIZE="0.23973042362002567" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="114" LOG_CI_END="-0.4451161225066903" LOG_CI_START="-0.7954375718635659" LOG_EFFECT_SIZE="-0.6202768471851281" MODIFIED="2012-01-05 12:52:00 +0000" MODIFIED_BY="[Empty name]" ORDER="240" O_E="0.0" SE="0.20578055347137056" STUDY_ID="STD-Kweku-2008" TOTAL_1="574" TOTAL_2="581" VAR="0.0423456361869836" WEIGHT="43.58130994903107">
<FOOTNOTE>Data based on AQ+AS monthly versus placebo (SP and AQ+AS bi-monthly trial arms not used)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="23.08480389005173" CI_END="0.7509915027448669" CI_START="0.19705008772623137" DF="1" EFFECT_SIZE="0.38468550986166655" ESTIMABLE="YES" EVENTS_1="265" EVENTS_2="782" I2="95.66814600304686" ID="CMP-002.02.02" LOG_CI_END="-0.12436497688650132" LOG_CI_START="-0.7054233674514625" LOG_EFFECT_SIZE="-0.41489417216898195" MODIFIED="2011-08-26 13:25:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.5501368825221462E-6" P_Z="0.005126855991095952" STUDIES="2" TAU2="0.2229575540145129" TOTAL_1="2841" TOTAL_2="2853" WEIGHT="100.0" Z="2.7989532482479604">
<NAME>During intervention (ITN)</NAME>
<DICH_DATA CI_END="0.6850245324609353" CI_START="0.43219334552211824" EFFECT_SIZE="0.5441167562656167" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="188" LOG_CI_END="-0.16429387504534013" LOG_CI_START="-0.3643219242303632" LOG_EFFECT_SIZE="-0.2643078996378516" MODIFIED="2011-08-16 14:11:23 +0100" MODIFIED_BY="[Empty name]" ORDER="284" O_E="0.0" SE="0.11749746624609504" STUDY_ID="STD-Dicko-2011" TOTAL_1="1405" TOTAL_2="1423" VAR="0.013805654574252245" WEIGHT="49.20401484592572"/>
<DICH_DATA CI_END="0.3215565183829354" CI_START="0.23508270726827143" EFFECT_SIZE="0.2749406788404003" ESTIMABLE="YES" EVENTS_1="164" EVENTS_2="594" LOG_CI_END="-0.492742682258957" LOG_CI_START="-0.6287793164904737" LOG_EFFECT_SIZE="-0.5607609993747154" MODIFIED="2011-08-16 14:11:23 +0100" MODIFIED_BY="[Empty name]" ORDER="283" O_E="0.0" SE="0.0799085923397927" STUDY_ID="STD-Konate-2011" TOTAL_1="1436" TOTAL_2="1430" VAR="0.006385383129727175" WEIGHT="50.79598515407428"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.04897477759963274" CI_END="1.9048520341921187" CI_START="0.25484448410310656" DF="1" EFFECT_SIZE="0.6967359858270875" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="0.27986124603282275" LOG_CI_START="-0.5937247619163873" LOG_EFFECT_SIZE="-0.1569317579417823" MODIFIED="2011-10-14 10:42:15 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8248569378345303" P_Z="0.4813211228119323" STUDIES="2" TAU2="0.0" TOTAL_1="519" TOTAL_2="540" WEIGHT="100.0" Z="0.704179304150058">
<NAME>During intervention (HMM)</NAME>
<DICH_DATA CI_END="2.5951196491452833" CI_START="0.14974930056721053" EFFECT_SIZE="0.623391812865497" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.4141573859862704" LOG_CI_START="-0.8246351973894711" LOG_EFFECT_SIZE="-0.2052389057016004" MODIFIED="2011-10-14 10:42:15 +0100" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="0.7276728955970959" STUDY_ID="STD-Sesay-2011" TOTAL_1="513" TOTAL_2="533" VAR="0.529507842986662" WEIGHT="49.72950606546674"/>
<DICH_DATA CI_END="3.2129944731384708" CI_START="0.18827865303298552" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.506909978496576" LOG_CI_START="-0.7251989173467122" LOG_EFFECT_SIZE="-0.10914446942506803" MODIFIED="2011-10-13 11:35:21 +0100" MODIFIED_BY="[Empty name]" ORDER="288" O_E="0.0" SE="0.7237468644557459" STUDY_ID="STD-Tagbor-2011" TOTAL_1="6" TOTAL_2="7" VAR="0.5238095238095237" WEIGHT="50.270493934533256"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.295836984450943" CI_END="0.8311022227974932" CI_START="0.5891841004058227" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.699765829034414" ESTIMABLE="YES" EVENTS_1="203" EVENTS_2="296" I2="69.91539528742814" I2_Q="84.01108141595279" ID="CMP-002.03" LOG_CI_END="-0.08034555615986227" LOG_CI_START="-0.22974898144784647" LOG_EFFECT_SIZE="-0.15504726880385436" METHOD="MH" MODIFIED="2012-01-06 09:39:10 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.00991720727183798" P_Q="0.0019221231654152904" P_Z="4.741703132275853E-5" Q="12.508663356354077" RANDOM="NO" SCALE="3.37" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="4373" TOTAL_2="4432" WEIGHT="300.0" Z="4.0680066360071">
<NAME>Moderately severe anaemia</NAME>
<GROUP_LABEL_1>IPTc</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPTc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.27655431777531575" CI_END="1.110155010979334" CI_START="0.6591561346605768" DF="1" EFFECT_SIZE="0.8554329230928676" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="112" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.04538362357293191" LOG_CI_START="-0.18101170165791744" LOG_EFFECT_SIZE="-0.06781403904249278" MODIFIED="2012-01-05 12:52:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5989686422967425" P_Z="0.24032775760773384" STUDIES="2" TAU2="0.0" TOTAL_1="994" TOTAL_2="1025" WEIGHT="100.0" Z="1.1741680092903946">
<NAME>During intervention (no additional)</NAME>
<DICH_DATA CI_END="1.166660320349703" CI_START="0.537775433477822" EFFECT_SIZE="0.7920866489832007" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="52" LOG_CI_END="0.06694442719238396" LOG_CI_START="-0.26939904099094225" LOG_EFFECT_SIZE="-0.10122730689927917" MODIFIED="2011-10-14 10:43:01 +0100" MODIFIED_BY="[Empty name]" ORDER="257" O_E="0.0" SE="0.1975698181379049" STUDY_ID="STD-Ciss_x00e9_-2006" TOTAL_1="435" TOTAL_2="437" VAR="0.03903383303904481" WEIGHT="47.00886106361028"/>
<DICH_DATA CI_END="1.2973359164363858" CI_START="0.6405938741460491" EFFECT_SIZE="0.9116279069767442" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="60" LOG_CI_END="0.11305244159372667" LOG_CI_START="-0.19341721871198522" LOG_EFFECT_SIZE="-0.040182388559129256" MODIFIED="2012-01-05 12:52:07 +0000" MODIFIED_BY="[Empty name]" ORDER="259" O_E="0.0" SE="0.18002179551286032" STUDY_ID="STD-Kweku-2008" TOTAL_1="559" TOTAL_2="588" VAR="0.0324078468596741" WEIGHT="52.99113893638972">
<FOOTNOTE>Data based on AQ+AS monthly versus placebo (SP and AQ+AS bi-monthly trial arms not used)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5248082966907368" CI_END="0.634436282787699" CI_START="0.3565585951337352" DF="1" EFFECT_SIZE="0.47561929070702247" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="139" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="-0.19761198810548786" LOG_CI_START="-0.4478690900697053" LOG_EFFECT_SIZE="-0.32274053908759653" MODIFIED="2011-08-26 13:26:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4687978465938277" P_Z="4.2976028786663455E-7" STUDIES="2" TAU2="0.0" TOTAL_1="2866" TOTAL_2="2874" WEIGHT="100.0" Z="5.05527977426332">
<NAME>During intervention (ITN)</NAME>
<DICH_DATA CI_END="0.8640037410646617" CI_START="0.34274023069263954" EFFECT_SIZE="0.5441772151898734" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="50" LOG_CI_END="-0.06348437705788731" LOG_CI_START="-0.4650349152889818" LOG_EFFECT_SIZE="-0.26425964617343456" MODIFIED="2011-08-16 14:13:34 +0100" MODIFIED_BY="[Empty name]" ORDER="294" O_E="0.0" SE="0.23587277386416647" STUDY_ID="STD-Dicko-2011" TOTAL_1="1422" TOTAL_2="1433" VAR="0.05563596545037622" WEIGHT="35.85845229365362"/>
<DICH_DATA CI_END="0.6325991163104847" CI_START="0.3022833280444663" EFFECT_SIZE="0.4372918547106975" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="89" LOG_CI_END="-0.19887141909394165" LOG_CI_START="-0.5195858049821477" LOG_EFFECT_SIZE="-0.3592286120380446" MODIFIED="2011-08-16 14:13:34 +0100" MODIFIED_BY="[Empty name]" ORDER="295" O_E="0.0" SE="0.18838921783254622" STUDY_ID="STD-Konate-2011" TOTAL_1="1444" TOTAL_2="1441" VAR="0.035490497395558554" WEIGHT="64.14154770634639"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5117000601249861" CI_START="0.6827070425635653" DF="0" EFFECT_SIZE="1.0158977691141433" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="45" I2="0.0" ID="CMP-002.03.03" LOG_CI_END="0.17946563034866603" LOG_CI_START="-0.16576561709746665" LOG_EFFECT_SIZE="0.006850006625599711" MODIFIED="2011-08-26 13:26:31 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.9380043321412831" STUDIES="1" TAU2="0.0" TOTAL_1="513" TOTAL_2="533" WEIGHT="99.99999999999999" Z="0.07777839566582709">
<NAME>During intervention (HMM)</NAME>
<DICH_DATA CI_END="1.5117000601249861" CI_START="0.6827070425635653" EFFECT_SIZE="1.0158977691141433" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="45" LOG_CI_END="0.17946563034866603" LOG_CI_START="-0.16576561709746665" LOG_EFFECT_SIZE="0.006850006625599711" MODIFIED="2011-08-19 11:03:42 +0100" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="0.20279054367209434" STUDY_ID="STD-Sesay-2011" TOTAL_1="513" TOTAL_2="533" VAR="0.0411240046028236" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="34.48397608545515" CI_END="1.0628586228263872" CI_START="0.7124436089435064" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8701878148096286" ESTIMABLE="YES" EVENTS_1="1474" EVENTS_2="1890" I2="94.20020477034383" I2_Q="46.88323148750343" ID="CMP-002.04" LOG_CI_END="0.026475500262025237" LOG_CI_START="-0.1472495050652242" LOG_EFFECT_SIZE="-0.060387002401599464" METHOD="MH" MODIFIED="2012-01-06 09:39:24 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="3.25016050739535E-8" P_Q="0.1700340830849637" P_Z="0.17301767115369654" Q="1.8826446487698778" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03477243085630312" TOTALS="SUB" TOTAL_1="3379" TOTAL_2="3407" WEIGHT="200.0" Z="1.3625712616156602">
<NAME>Any anaemia</NAME>
<GROUP_LABEL_1>IPTc</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPTc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="31.628705667890785" CI_END="1.0043615382014979" CI_START="0.592834888056877" DF="1" EFFECT_SIZE="0.771634991474802" ESTIMABLE="YES" EVENTS_1="1404" EVENTS_2="1819" I2="96.838315135307" ID="CMP-002.04.01" LOG_CI_END="0.0018900731501216026" LOG_CI_START="-0.2270662462487986" LOG_EFFECT_SIZE="-0.11258808654933852" MODIFIED="2011-08-26 13:26:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.866529841798581E-8" P_Z="0.05390436163219879" STUDIES="2" TAU2="0.035031665360923225" TOTAL_1="2866" TOTAL_2="2874" WEIGHT="100.0" Z="1.9276043160049396">
<NAME>During intervention (ITN)</NAME>
<DICH_DATA CI_END="0.9399689209825822" CI_START="0.827982441073329" EFFECT_SIZE="0.882200522403054" ESTIMABLE="YES" EVENTS_1="766" EVENTS_2="875" LOG_CI_END="-0.026886505622539643" LOG_CI_START="-0.08197887314968501" LOG_EFFECT_SIZE="-0.05443268938611234" MODIFIED="2011-08-16 14:14:38 +0100" MODIFIED_BY="[Empty name]" ORDER="299" O_E="0.0" SE="0.03236152939706269" STUDY_ID="STD-Dicko-2011" TOTAL_1="1422" TOTAL_2="1433" VAR="0.0010472685849169526" WEIGHT="50.13335593387959"/>
<DICH_DATA CI_END="0.7226403937794472" CI_START="0.6294608300855623" EFFECT_SIZE="0.6744433424104418" ESTIMABLE="YES" EVENTS_1="638" EVENTS_2="944" LOG_CI_END="-0.14107776612087652" LOG_CI_START="-0.2010312898721988" LOG_EFFECT_SIZE="-0.17105452799653767" MODIFIED="2011-08-16 14:14:38 +0100" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.0" SE="0.03521699662625561" STUDY_ID="STD-Konate-2011" TOTAL_1="1444" TOTAL_2="1441" VAR="0.001240236851373699" WEIGHT="49.866644066120415"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3925321222398221" CI_START="0.7535183768328586" DF="0" EFFECT_SIZE="1.024352744145183" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="71" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="0.14380522205086393" LOG_CI_START="-0.1229061516309889" LOG_EFFECT_SIZE="0.010449535209937522" MODIFIED="2011-10-14 10:43:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8779412251998737" STUDIES="1" TAU2="0.0" TOTAL_1="513" TOTAL_2="533" WEIGHT="100.0" Z="0.1535795971797678">
<NAME>During intervention (HMM)</NAME>
<DICH_DATA CI_END="1.3925321222398221" CI_START="0.7535183768328586" EFFECT_SIZE="1.024352744145183" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="71" LOG_CI_END="0.14380522205086393" LOG_CI_START="-0.1229061516309889" LOG_EFFECT_SIZE="0.010449535209937522" MODIFIED="2011-10-14 10:43:19 +0100" MODIFIED_BY="[Empty name]" ORDER="264" O_E="0.0" SE="0.15666758114331267" STUDY_ID="STD-Sesay-2011" TOTAL_1="513" TOTAL_2="533" VAR="0.024544730981296458" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2012-01-06 09:40:03 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>IPTc versus placebo or no IPTc (subgroup analysis: type of antimalarial drug)</NAME>
<IV_OUTCOME CHI2="135.8777101808558" CI_END="0.42963851980044027" CI_START="0.3211436602594314" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_SIZE="0.37145078656150077" ESTIMABLE="YES" I2="95.58426470977919" I2_Q="95.15305104115825" ID="CMP-003.01" LOG_CI_END="-0.3668967883261323" LOG_CI_START="-0.493300647031547" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.43009871767883967" MODIFIED="2012-01-06 09:39:40 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="-2.220446049250313E-16" P_Q="2.3026025530725747E-13" P_Z="1.394185734668547E-40" Q="61.89460680264502" RANDOM="YES" SCALE="29.94" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.26670768465031164" TOTALS="SUB" TOTAL_1="5205" TOTAL_2="5291" WEIGHT="400.0" Z="13.337852263069818">
<NAME>Clinical malaria</NAME>
<GROUP_LABEL_1>IPTc</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPTc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favour control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Rate Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="1.5094339622641502" CI_END="0.7407605307109063" CI_START="0.5008632728370256" DF="1" EFFECT_SIZE="0.6091139005148023" ESTIMABLE="YES" I2="33.749999999999964" ID="CMP-003.01.01" LOG_CI_END="-0.13032216583896247" LOG_CI_START="-0.30028081296811165" LOG_EFFECT_SIZE="-0.2153014894035371" MODIFIED="2011-11-01 22:20:44 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.21922587025650397" P_Z="6.844815089004066E-7" STUDIES="2" TAU2="0.006749999999999992" TOTAL_1="678" TOTAL_2="729" WEIGHT="100.0" Z="4.965715745290742">
<NAME>During intervention (SP)</NAME>
<IV_DATA CI_END="0.687699051631925" CI_START="0.4468215244327472" EFFECT_SIZE="0.5543272847345071" ESTIMABLE="YES" ESTIMATE="-0.59" LOG_CI_END="-0.1626015745692844" LOG_CI_START="-0.3498659140765527" LOG_EFFECT_SIZE="-0.2562337443229185" MODIFIED="2011-10-14 12:49:56 +0100" MODIFIED_BY="[Empty name]" ORDER="423" SE="0.11" STUDY_ID="STD-Dicko-2008" TOTAL_1="116" TOTAL_2="116" WEIGHT="52.87500000000001"/>
<IV_DATA CI_END="0.8565827756138384" CI_START="0.5351566998025659" EFFECT_SIZE="0.6770568744981647" ESTIMABLE="YES" ESTIMATE="-0.39" LOG_CI_END="-0.06723066275648552" LOG_CI_START="-0.27151903312805087" LOG_EFFECT_SIZE="-0.16937484794226823" MODIFIED="2011-10-14 12:50:14 +0100" MODIFIED_BY="[Empty name]" ORDER="424" SE="0.12" STUDY_ID="STD-Kweku-2008" TOTAL_1="562" TOTAL_2="613" WEIGHT="47.125"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="26.564653609063377" CI_END="0.37395592171210207" CI_START="0.1385587889240869" DF="2" EFFECT_SIZE="0.2276288198436646" ESTIMABLE="YES" I2="92.47119864827584" ID="CMP-003.01.02" LOG_CI_END="-0.42717958519351534" LOG_CI_START="-0.8583659212698926" LOG_EFFECT_SIZE="-0.642772753231704" MODIFIED="2011-11-01 22:21:11 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.7043739725108864E-6" P_Z="5.112559566516246E-9" STUDIES="3" TAU2="0.1292983359683794" TOTAL_1="3498" TOTAL_2="3512" WEIGHT="99.99999999999999" Z="5.843466460656292">
<NAME>During intervention (SP+AQ)</NAME>
<IV_DATA CI_END="0.2031921407593108" CI_START="0.14278764411741937" EFFECT_SIZE="0.17033298882540943" ESTIMABLE="YES" ESTIMATE="-1.77" LOG_CI_END="-0.6920930940794188" LOG_CI_START="-0.8453093718580927" LOG_EFFECT_SIZE="-0.7687012329687557" MODIFIED="2011-10-14 12:50:28 +0100" MODIFIED_BY="[Empty name]" ORDER="425" SE="0.09" STUDY_ID="STD-Dicko-2011" TOTAL_1="1481" TOTAL_2="1485" WEIGHT="46.689982480920364"/>
<IV_DATA CI_END="0.31917944821425354" CI_START="0.26237035642715373" EFFECT_SIZE="0.28938421793905067" ESTIMABLE="YES" ESTIMATE="-1.24" LOG_CI_END="-0.49596508039928944" LOG_CI_START="-0.5810852347207751" LOG_EFFECT_SIZE="-0.5385251575600323" MODIFIED="2011-10-14 12:50:28 +0100" MODIFIED_BY="[Empty name]" ORDER="426" SE="0.05" STUDY_ID="STD-Konate-2011" TOTAL_1="1504" TOTAL_2="1494" WEIGHT="48.673800409819584"/>
<IV_DATA CI_END="3.0500551202979667" CI_START="0.03781083176844232" EFFECT_SIZE="0.3395955256449391" ESTIMABLE="YES" ESTIMATE="-1.08" LOG_CI_END="0.4843076879451268" LOG_CI_START="-1.4223837688561507" LOG_EFFECT_SIZE="-0.469038040455512" MODIFIED="2011-10-14 12:50:35 +0100" MODIFIED_BY="[Empty name]" ORDER="427" SE="1.12" STUDY_ID="STD-Sesay-2011" TOTAL_1="513" TOTAL_2="533" WEIGHT="4.636217109260036"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.19845230540114145" CI_START="0.09799943974484829" DF="0" EFFECT_SIZE="0.13945685621505094" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="-0.702343851570732" LOG_CI_START="-1.0087764071280803" LOG_EFFECT_SIZE="-0.8555601293494061" MODIFIED="2011-11-01 22:21:26 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="7.064950935326666E-28" STUDIES="1" TAU2="0.0" TOTAL_1="435" TOTAL_2="437" WEIGHT="100.0" Z="10.944444444444445">
<NAME>During intervention (SP+AS)</NAME>
<IV_DATA CI_END="0.19845230540114145" CI_START="0.09799943974484829" EFFECT_SIZE="0.13945685621505094" ESTIMABLE="YES" ESTIMATE="-1.97" LOG_CI_END="-0.702343851570732" LOG_CI_START="-1.0087764071280803" LOG_EFFECT_SIZE="-0.8555601293494061" MODIFIED="2011-10-14 12:50:43 +0100" MODIFIED_BY="[Empty name]" ORDER="428" SE="0.18" STUDY_ID="STD-Ciss_x00e9_-2006" TOTAL_1="435" TOTAL_2="437" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.36905628133534085" CI_START="0.189532668273697" DF="0" EFFECT_SIZE="0.26447726129982396" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.04" LOG_CI_END="-0.43290739858479943" LOG_CI_START="-0.7223159232778504" LOG_EFFECT_SIZE="-0.577611660931325" MODIFIED="2011-11-01 22:21:53 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="5.136254933338895E-15" STUDIES="1" TAU2="0.0" TOTAL_1="594" TOTAL_2="613" WEIGHT="100.0" Z="7.823529411764706">
<NAME>During intervention (AQ+AS)</NAME>
<IV_DATA CI_END="0.36905628133534085" CI_START="0.189532668273697" EFFECT_SIZE="0.26447726129982396" ESTIMABLE="YES" ESTIMATE="-1.33" LOG_CI_END="-0.43290739858479943" LOG_CI_START="-0.7223159232778504" LOG_EFFECT_SIZE="-0.577611660931325" MODIFIED="2011-10-14 12:50:54 +0100" MODIFIED_BY="[Empty name]" ORDER="429" SE="0.17" STUDY_ID="STD-Kweku-2008" TOTAL_1="594" TOTAL_2="613" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="69.04487851105537" CI_END="0.6458217297362048" CI_START="0.45720904590654393" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5433926176149286" ESTIMABLE="YES" EVENTS_1="445" EVENTS_2="1183" I2="91.30999991688118" I2_Q="85.41008822473664" ID="CMP-003.02" LOG_CI_END="-0.1898873465195978" LOG_CI_START="-0.33988518565113923" LOG_EFFECT_SIZE="-0.2648862660853685" METHOD="MH" MODIFIED="2012-01-06 09:39:51 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="6.421529974431905E-13" P_Q="1.297840729697075E-4" P_Z="4.442634788784953E-12" Q="20.56215312478027" RANDOM="YES" SCALE="7.7" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.23160104802762374" TOTALS="SUB" TOTAL_1="4914" TOTAL_2="5001" WEIGHT="400.0" Z="6.9223336087039105">
<NAME>Parasitaemia</NAME>
<GROUP_LABEL_1>IPTc</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPTc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0688236181792417" CI_START="0.6453782792448595" DF="0" EFFECT_SIZE="0.8305393112410656" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="114" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.028906041998599384" LOG_CI_START="-0.19018565523648287" LOG_EFFECT_SIZE="-0.08063980661894175" MODIFIED="2011-11-01 22:19:04 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.14908102150286942" STUDIES="1" TAU2="0.0" TOTAL_1="540" TOTAL_2="581" WEIGHT="100.0" Z="1.442785086682805">
<NAME>During intervention (SP)</NAME>
<DICH_DATA CI_END="1.0688236181792417" CI_START="0.6453782792448595" EFFECT_SIZE="0.8305393112410656" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="114" LOG_CI_END="0.028906041998599384" LOG_CI_START="-0.19018565523648287" LOG_EFFECT_SIZE="-0.08063980661894175" MODIFIED="2011-10-13 12:37:23 +0100" MODIFIED_BY="[Empty name]" ORDER="317" O_E="0.0" SE="0.12869554747727957" STUDY_ID="STD-Kweku-2008" TOTAL_1="540" TOTAL_2="581" VAR="0.016562543940476723" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="23.76465269788809" CI_END="0.754543408113573" CI_START="0.22241518855321427" DF="2" EFFECT_SIZE="0.4096607308336561" ESTIMABLE="YES" EVENTS_1="268" EVENTS_2="787" I2="91.5841395814813" ID="CMP-003.02.02" LOG_CI_END="-0.12231577065059313" LOG_CI_START="-0.6528355584586143" LOG_EFFECT_SIZE="-0.3875756645546037" MODIFIED="2011-11-01 22:19:30 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="6.911516654994898E-6" P_Z="0.004186766166035219" STUDIES="3" TAU2="0.21339988898297763" TOTAL_1="3354" TOTAL_2="3386" WEIGHT="100.0" Z="2.8637361367794596">
<NAME>During intervention (SP+AQ)</NAME>
<DICH_DATA CI_END="0.6850245324609353" CI_START="0.43219334552211824" EFFECT_SIZE="0.5441167562656167" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="188" LOG_CI_END="-0.16429387504534013" LOG_CI_START="-0.3643219242303632" LOG_EFFECT_SIZE="-0.2643078996378516" MODIFIED="2011-08-16 14:32:28 +0100" MODIFIED_BY="[Empty name]" ORDER="373" O_E="0.0" SE="0.11749746624609504" STUDY_ID="STD-Dicko-2011" TOTAL_1="1405" TOTAL_2="1423" VAR="0.013805654574252245" WEIGHT="42.74245420624652"/>
<DICH_DATA CI_END="0.3215565183829354" CI_START="0.23508270726827143" EFFECT_SIZE="0.2749406788404003" ESTIMABLE="YES" EVENTS_1="164" EVENTS_2="594" LOG_CI_END="-0.492742682258957" LOG_CI_START="-0.6287793164904737" LOG_EFFECT_SIZE="-0.5607609993747154" MODIFIED="2011-08-16 14:32:28 +0100" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="0.0799085923397927" STUDY_ID="STD-Konate-2011" TOTAL_1="1436" TOTAL_2="1430" VAR="0.006385383129727175" WEIGHT="44.18550181979587"/>
<DICH_DATA CI_END="2.5951196491452833" CI_START="0.14974930056721053" EFFECT_SIZE="0.623391812865497" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.4141573859862704" LOG_CI_START="-0.8246351973894711" LOG_EFFECT_SIZE="-0.2052389057016004" MODIFIED="2011-10-14 10:45:31 +0100" MODIFIED_BY="[Empty name]" ORDER="375" O_E="0.0" SE="0.7276728955970959" STUDY_ID="STD-Sesay-2011" TOTAL_1="513" TOTAL_2="533" VAR="0.529507842986662" WEIGHT="13.07204397395762"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.4801997670164689" CI_START="0.28292871804483594" DF="0" EFFECT_SIZE="0.3685950413223141" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="165" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="-0.31857805499012537" LOG_CI_START="-0.548322968218491" LOG_EFFECT_SIZE="-0.4334505116043082" MODIFIED="2012-01-05 12:19:42 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.408020573787342E-13" STUDIES="1" TAU2="0.0" TOTAL_1="440" TOTAL_2="446" WEIGHT="100.0" Z="7.395570851925306">
<NAME>During intervention (SP+AS)</NAME>
<DICH_DATA CI_END="0.4801997670164689" CI_START="0.28292871804483594" EFFECT_SIZE="0.3685950413223141" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="165" LOG_CI_END="-0.31857805499012537" LOG_CI_START="-0.548322968218491" LOG_EFFECT_SIZE="-0.4334505116043082" MODIFIED="2012-01-05 12:19:42 +0000" MODIFIED_BY="[Empty name]" ORDER="376" O_E="0.0" SE="0.1349532992860039" STUDY_ID="STD-Ciss_x00e9_-2006" TOTAL_1="440" TOTAL_2="446" VAR="0.018212392988177742" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.479437962415289" CI_END="1.050261850377616" CI_START="0.11856879462023444" DF="1" EFFECT_SIZE="0.352885649516796" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="117" I2="59.66827905523103" ID="CMP-003.02.04" LOG_CI_END="0.021297590495268377" LOG_CI_START="-0.926029595183031" LOG_EFFECT_SIZE="-0.4523660023438812" MODIFIED="2011-11-01 22:20:11 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.11534372355149103" P_Z="0.061229147797168086" STUDIES="2" TAU2="0.41879571815806726" TOTAL_1="580" TOTAL_2="588" WEIGHT="99.99999999999999" Z="1.8718370713483454">
<NAME>During intervention (AQ+AS)</NAME>
<DICH_DATA CI_END="0.3588259782262723" CI_START="0.16016308599818402" EFFECT_SIZE="0.23973042362002567" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="114" LOG_CI_END="-0.4451161225066903" LOG_CI_START="-0.7954375718635659" LOG_EFFECT_SIZE="-0.6202768471851281" MODIFIED="2011-10-13 12:34:48 +0100" MODIFIED_BY="[Empty name]" ORDER="384" O_E="0.0" SE="0.20578055347137056" STUDY_ID="STD-Kweku-2008" TOTAL_1="574" TOTAL_2="581" VAR="0.0423456361869836" WEIGHT="67.14924505915982"/>
<DICH_DATA CI_END="3.2129944731384708" CI_START="0.18827865303298552" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.506909978496576" LOG_CI_START="-0.7251989173467122" LOG_EFFECT_SIZE="-0.10914446942506803" MODIFIED="2011-10-13 12:34:57 +0100" MODIFIED_BY="[Empty name]" ORDER="383" O_E="0.0" SE="0.7237468644557459" STUDY_ID="STD-Tagbor-2011" TOTAL_1="6" TOTAL_2="7" VAR="0.5238095238095237" WEIGHT="32.85075494084016"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="19.97051555110793" CI_END="0.887735002003121" CI_START="0.6398319004241738" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7536585257294677" ESTIMABLE="YES" EVENTS_1="228" EVENTS_2="311" I2="79.9704720202975" I2_Q="84.56561035010564" ID="CMP-003.03" LOG_CI_END="-0.051716656229732955" LOG_CI_START="-0.19393411087145548" LOG_EFFECT_SIZE="-0.12282538355059422" METHOD="MH" MODIFIED="2012-01-06 09:40:03 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="5.061388506197861E-4" P_Q="2.2200918311510165E-4" P_Z="7.106789076803952E-4" Q="19.437114573691833" RANDOM="NO" SCALE="3.5" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="4412" TOTAL_2="4487" WEIGHT="400.0" Z="3.385425913477977">
<NAME>Moderately severe anaemia</NAME>
<GROUP_LABEL_1>IPTc</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPTc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.696949964403116" CI_START="0.8843071578293877" DF="0" EFFECT_SIZE="1.225" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="60" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.22966903707077768" LOG_CI_START="-0.05339685966967507" LOG_EFFECT_SIZE="0.0881360887005513" MODIFIED="2011-11-01 22:22:32 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.22226846318566884" STUDIES="1" TAU2="0.0" TOTAL_1="552" TOTAL_2="588" WEIGHT="100.0" Z="1.2205183427638353">
<NAME>During intervention (SP)</NAME>
<DICH_DATA CI_END="1.696949964403116" CI_START="0.8843071578293877" EFFECT_SIZE="1.225" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="60" LOG_CI_END="0.22966903707077768" LOG_CI_START="-0.05339685966967507" LOG_EFFECT_SIZE="0.0881360887005513" MODIFIED="2011-10-13 12:42:50 +0100" MODIFIED_BY="[Empty name]" ORDER="336" O_E="0.0" SE="0.16627430894412906" STUDY_ID="STD-Kweku-2008" TOTAL_1="552" TOTAL_2="588" VAR="0.027647145814847677" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5248082966907368" CI_END="0.634436282787699" CI_START="0.3565585951337352" DF="1" EFFECT_SIZE="0.47561929070702247" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="139" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="-0.19761198810548786" LOG_CI_START="-0.4478690900697053" LOG_EFFECT_SIZE="-0.32274053908759653" MODIFIED="2011-11-01 22:22:53 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4687978465938277" P_Z="4.2976028786663455E-7" STUDIES="2" TAU2="0.0" TOTAL_1="2866" TOTAL_2="2874" WEIGHT="100.0" Z="5.05527977426332">
<NAME>During intervention (SP+AQ)</NAME>
<DICH_DATA CI_END="0.8640037410646617" CI_START="0.34274023069263954" EFFECT_SIZE="0.5441772151898734" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="50" LOG_CI_END="-0.06348437705788731" LOG_CI_START="-0.4650349152889818" LOG_EFFECT_SIZE="-0.26425964617343456" MODIFIED="2011-08-16 14:35:02 +0100" MODIFIED_BY="[Empty name]" ORDER="391" O_E="0.0" SE="0.23587277386416647" STUDY_ID="STD-Dicko-2011" TOTAL_1="1422" TOTAL_2="1433" VAR="0.05563596545037622" WEIGHT="35.85845229365362"/>
<DICH_DATA CI_END="0.6325991163104847" CI_START="0.3022833280444663" EFFECT_SIZE="0.4372918547106975" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="89" LOG_CI_END="-0.19887141909394165" LOG_CI_START="-0.5195858049821477" LOG_EFFECT_SIZE="-0.3592286120380446" MODIFIED="2011-08-16 14:35:02 +0100" MODIFIED_BY="[Empty name]" ORDER="389" O_E="0.0" SE="0.18838921783254622" STUDY_ID="STD-Konate-2011" TOTAL_1="1444" TOTAL_2="1441" VAR="0.035490497395558554" WEIGHT="64.14154770634639"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1666603203497028" CI_START="0.5377754334778221" DF="0" EFFECT_SIZE="0.7920866489832007" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="52" I2="0.0" ID="CMP-003.03.03" LOG_CI_END="0.06694442719238387" LOG_CI_START="-0.2693990409909422" LOG_EFFECT_SIZE="-0.10122730689927917" MODIFIED="2011-11-01 22:23:23 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.2380966717191958" STUDIES="1" TAU2="0.0" TOTAL_1="435" TOTAL_2="437" WEIGHT="100.0" Z="1.179757566550571">
<NAME>During intervention (SP+AS)</NAME>
<DICH_DATA CI_END="1.166660320349703" CI_START="0.537775433477822" EFFECT_SIZE="0.7920866489832007" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="52" LOG_CI_END="0.06694442719238396" LOG_CI_START="-0.26939904099094225" LOG_EFFECT_SIZE="-0.10122730689927917" MODIFIED="2011-10-14 12:52:40 +0100" MODIFIED_BY="[Empty name]" ORDER="397" O_E="0.0" SE="0.1975698181379049" STUDY_ID="STD-Ciss_x00e9_-2006" TOTAL_1="435" TOTAL_2="437" VAR="0.03903383303904481" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2973359164363858" CI_START="0.6405938741460491" DF="0" EFFECT_SIZE="0.9116279069767442" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="60" I2="0.0" ID="CMP-003.03.04" LOG_CI_END="0.11305244159372667" LOG_CI_START="-0.19341721871198522" LOG_EFFECT_SIZE="-0.040182388559129256" MODIFIED="2011-11-01 22:23:50 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.6072824179097769" STUDIES="1" TAU2="0.0" TOTAL_1="559" TOTAL_2="588" WEIGHT="100.0" Z="0.5139564830667177">
<NAME>During intervention (AQ+AS)</NAME>
<DICH_DATA CI_END="1.2973359164363858" CI_START="0.6405938741460491" EFFECT_SIZE="0.9116279069767442" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="60" LOG_CI_END="0.11305244159372667" LOG_CI_START="-0.19341721871198522" LOG_EFFECT_SIZE="-0.040182388559129256" MODIFIED="2011-10-13 12:42:35 +0100" MODIFIED_BY="[Empty name]" ORDER="398" O_E="0.0" SE="0.18002179551286032" STUDY_ID="STD-Kweku-2008" TOTAL_1="559" TOTAL_2="588" VAR="0.0324078468596741" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2012-01-13 14:05:50 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>IPTc (SP +AQ) versus placebo or no IPTc</NAME>
<DICH_OUTCOME CHI2="101.31557216201892" CI_END="1.4802781206786668" CI_START="1.2307214927436723" CI_STUDY="95" CI_TOTAL="95" DF="17" EFFECT_MEASURE="RR" EFFECT_SIZE="1.34974445668706" ESTIMABLE="YES" EVENTS_1="983" EVENTS_2="686" I2="83.22074323104603" I2_Q="91.28891359249859" ID="CMP-004.01" LOG_CI_END="0.17034332007632827" LOG_CI_START="0.09015978497901891" LOG_EFFECT_SIZE="0.1302515525276736" METHOD="MH" MODIFIED="2012-01-13 14:05:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="5.029310301551959E-14" P_Q="5.551115123125783E-16" P_Z="1.92008463123747E-10" Q="91.83699513198405" RANDOM="NO" SCALE="121.56" SORT_BY="WEIGHT" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="17313" TOTAL_2="15476" WEIGHT="900.0" Z="6.367600320311493">
<NAME>Non-serious adverse events (during intervention)</NAME>
<GROUP_LABEL_1>IPTc</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPTc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5254228933230396" CI_END="3.346086273006396" CI_START="2.3144910981588067" DF="1" EFFECT_SIZE="2.7828918219263716" ESTIMABLE="YES" EVENTS_1="387" EVENTS_2="131" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.524537134297502" LOG_CI_START="0.3644555147675901" LOG_EFFECT_SIZE="0.444496324532546" MODIFIED="2011-08-26 13:02:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4685376242812521" P_Z="1.367852721691382E-27" STUDIES="2" TAU2="0.0" TOTAL_1="1814" TOTAL_2="1730" WEIGHT="100.00000000000001" Z="10.88440746542337">
<NAME>Vomiting</NAME>
<DICH_DATA CI_END="4.598875063249485" CI_START="0.9609607155716708" EFFECT_SIZE="2.102222222222222" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="9" LOG_CI_END="0.6626516113399964" LOG_CI_START="-0.017294366087098265" LOG_EFFECT_SIZE="0.3226786226264491" MODIFIED="2011-08-16 15:06:24 +0100" MODIFIED_BY="[Empty name]" ORDER="450" O_E="0.0" SE="0.3994036329275464" STUDY_ID="STD-Dicko-2011" TOTAL_1="475" TOTAL_2="473" VAR="0.1595232619957222" WEIGHT="6.687041539158011"/>
<DICH_DATA CI_END="3.423305045816245" CI_START="2.342285215366211" EFFECT_SIZE="2.8316703191762875" ESTIMABLE="YES" EVENTS_1="368" EVENTS_2="122" LOG_CI_END="0.5344456002223085" LOG_CI_START="0.369639777123128" LOG_EFFECT_SIZE="0.4520426886727182" MODIFIED="2011-08-16 15:06:24 +0100" MODIFIED_BY="[Empty name]" ORDER="451" O_E="0.0" SE="0.09680775629043999" STUDY_ID="STD-Konate-2011" TOTAL_1="1339" TOTAL_2="1257" VAR="0.009371741677989223" WEIGHT="93.312958460842"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6774780810347643" CI_END="1.4332289451589364" CI_START="0.8953193837718546" DF="1" EFFECT_SIZE="1.1327831460538615" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="119" I2="40.38670243708086" ID="CMP-004.01.02" LOG_CI_END="0.15631557049314174" LOG_CI_START="-0.048022012877773884" LOG_EFFECT_SIZE="0.05414677880768394" MODIFIED="2012-01-06 11:41:04 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.19525997144717244" P_Z="0.29893057929198874" STUDIES="2" TAU2="0.0" TOTAL_1="2025" TOTAL_2="1926" WEIGHT="100.0" Z="1.0387294847201622">
<NAME>Diarrhoea</NAME>
<DICH_DATA CI_END="2.2532570425265357" CI_START="0.9293633518756133" EFFECT_SIZE="1.447098655130255" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="31" LOG_CI_END="0.35281073712257593" LOG_CI_START="-0.03181445730583028" LOG_EFFECT_SIZE="0.16049813990837283" MODIFIED="2012-01-06 11:41:04 +0000" MODIFIED_BY="[Empty name]" ORDER="453" O_E="0.0" SE="0.22593074313266437" STUDY_ID="STD-Dicko-2011" TOTAL_1="686" TOTAL_2="669" VAR="0.05104470069247796" WEIGHT="25.693125914324987"/>
<DICH_DATA CI_END="1.3534283408092036" CI_START="0.7749099846041906" EFFECT_SIZE="1.0241021114807523" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="88" LOG_CI_END="0.13143526637545475" LOG_CI_START="-0.11074874324875761" LOG_EFFECT_SIZE="0.010343261563348558" MODIFIED="2011-08-16 15:06:24 +0100" MODIFIED_BY="[Empty name]" ORDER="452" O_E="0.0" SE="0.14226008608344443" STUDY_ID="STD-Konate-2011" TOTAL_1="1339" TOTAL_2="1257" VAR="0.02023793209246902" WEIGHT="74.30687408567502"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2877652895348557" CI_END="4.958183872044535" CI_START="0.9453702931221177" DF="1" EFFECT_SIZE="2.165021879905166" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="0.6953226283482232" LOG_CI_START="-0.02439804888718003" LOG_EFFECT_SIZE="0.33546228973052156" MODIFIED="2011-08-26 13:02:53 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5916562289179059" P_Z="0.06768758372685466" STUDIES="2" TAU2="0.0" TOTAL_1="2025" TOTAL_2="1925" WEIGHT="100.0" Z="1.8270810519679228">
<NAME>Loss of appetite</NAME>
<DICH_DATA CI_END="6.533315855058504" CI_START="0.3746909863979034" EFFECT_SIZE="1.5646004480955937" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8151336547906199" LOG_CI_START="-0.42632675421000976" LOG_EFFECT_SIZE="0.19440345029030515" MODIFIED="2011-08-16 15:06:24 +0100" MODIFIED_BY="[Empty name]" ORDER="455" O_E="0.0" SE="0.729239989575105" STUDY_ID="STD-Konate-2011" TOTAL_1="1339" TOTAL_2="1257" VAR="0.5317909623954993" WEIGHT="37.920274681596936"/>
<DICH_DATA CI_END="7.062549152833251" CI_START="0.9075904263329093" EFFECT_SIZE="2.5317784256559768" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.848961483373331" LOG_CI_START="-0.042110093894107026" LOG_EFFECT_SIZE="0.403425694739612" MODIFIED="2011-08-16 15:06:24 +0100" MODIFIED_BY="[Empty name]" ORDER="454" O_E="0.0" SE="0.5234198553623383" STUDY_ID="STD-Dicko-2011" TOTAL_1="686" TOTAL_2="668" VAR="0.27396834498753114" WEIGHT="62.07972531840307"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.9420941204896" CI_START="0.013227017004787" DF="0" EFFECT_SIZE="0.32411450752062104" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-004.01.04" LOG_CI_END="0.8999350295129382" LOG_CI_START="-1.8785380881202725" LOG_EFFECT_SIZE="-0.4893015293036672" MODIFIED="2011-08-26 13:03:06 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.48999497218466426" STUDIES="1" TAU2="0.0" TOTAL_1="686" TOTAL_2="667" WEIGHT="100.0" Z="0.6903168282819124">
<NAME>Jaundice</NAME>
<DICH_DATA CI_END="7.9420941204896" CI_START="0.013227017004787" EFFECT_SIZE="0.32411450752062104" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8999350295129382" LOG_CI_START="-1.8785380881202725" LOG_EFFECT_SIZE="-0.4893015293036672" MODIFIED="2011-08-16 15:06:24 +0100" MODIFIED_BY="[Empty name]" ORDER="456" O_E="0.0" SE="1.6320888629614967" STUDY_ID="STD-Dicko-2011" TOTAL_1="686" TOTAL_2="667" VAR="2.6637140566029514" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5616882958433163" CI_END="1.5217209524761064" CI_START="0.499614475567079" DF="2" EFFECT_SIZE="0.8719368186002847" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="25" I2="0.0" ID="CMP-004.01.05" LOG_CI_END="0.18233502043014396" LOG_CI_START="-0.30136498709567877" LOG_EFFECT_SIZE="-0.05951498333276742" MODIFIED="2012-01-06 11:07:04 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.45801935975438024" P_Z="0.6295841351617573" STUDIES="3" TAU2="0.0" TOTAL_1="2663" TOTAL_2="2564" WEIGHT="100.0" Z="0.4823122681737747">
<NAME>Skin rash</NAME>
<DICH_DATA CI_END="73.61924118697047" CI_START="0.12263357934697693" EFFECT_SIZE="3.004694835680751" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8669913367453954" LOG_CI_START="-0.9113905956550966" LOG_EFFECT_SIZE="0.4778003705451494" MODIFIED="2012-01-06 11:07:04 +0000" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="1.6320353003044235" STUDY_ID="STD-Sesay-2011" TOTAL_1="638" TOTAL_2="639" VAR="2.6635392214397497" WEIGHT="1.9070635302354986">
<FOOTNOTE>&#8220;One child in the SP/AQ group developed a drug eruption which presented as multiple areas of macular hyperpigmentation of different sizes mainly on the trunk with sharply demarcated outlines.&#8221;</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.000663325730854" CI_START="0.07583167781077918" EFFECT_SIZE="0.3895043731778426" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3011740111353164" LOG_CI_START="-1.1201493349418035" LOG_EFFECT_SIZE="-0.4094876619032436" MODIFIED="2011-08-16 15:06:24 +0100" MODIFIED_BY="[Empty name]" ORDER="458" O_E="0.0" SE="0.8348923691497331" STUDY_ID="STD-Dicko-2011" TOTAL_1="686" TOTAL_2="668" VAR="0.6970452680644541" WEIGHT="19.339279883027224"/>
<DICH_DATA CI_END="1.7363783777408583" CI_START="0.5075338726180907" EFFECT_SIZE="0.9387602688573562" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.23964436914644896" LOG_CI_START="-0.29453496779855143" LOG_EFFECT_SIZE="-0.027445299326051248" MODIFIED="2011-08-16 15:06:24 +0100" MODIFIED_BY="[Empty name]" ORDER="457" O_E="0.0" SE="0.31377958675185674" STUDY_ID="STD-Konate-2011" TOTAL_1="1339" TOTAL_2="1257" VAR="0.09845762906216599" WEIGHT="78.75365658673728"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7777355963066979" CI_END="1.6278596801542211" CI_START="0.6481113435006527" DF="1" EFFECT_SIZE="1.0271486378977948" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="34" I2="0.0" ID="CMP-004.01.06" LOG_CI_END="0.21161696642472017" LOG_CI_START="-0.1883503772868172" LOG_EFFECT_SIZE="0.011633294568951494" MODIFIED="2011-08-26 13:03:28 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.3778346132123498" P_Z="0.9092270917705566" STUDIES="2" TAU2="0.0" TOTAL_1="2025" TOTAL_2="1924" WEIGHT="99.99999999999999" Z="0.11401350002781557">
<NAME>Itching</NAME>
<DICH_DATA CI_END="5.785580207408572" CI_START="0.5004176453554506" EFFECT_SIZE="1.7015306122448979" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7623469187312459" LOG_CI_START="-0.30066738493906253" LOG_EFFECT_SIZE="0.2308397668960917" MODIFIED="2011-08-16 15:06:24 +0100" MODIFIED_BY="[Empty name]" ORDER="460" O_E="0.0" SE="0.6244198639816069" STUDY_ID="STD-Dicko-2011" TOTAL_1="686" TOTAL_2="667" VAR="0.3899001665348084" WEIGHT="11.587808808598524"/>
<DICH_DATA CI_END="1.5480206788227395" CI_START="0.5692888050147604" EFFECT_SIZE="0.9387602688573562" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="30" LOG_CI_END="0.18977675779301373" LOG_CI_START="-0.24466735644511625" LOG_EFFECT_SIZE="-0.027445299326051248" MODIFIED="2011-08-16 15:06:24 +0100" MODIFIED_BY="[Empty name]" ORDER="459" O_E="0.0" SE="0.25519462323652636" STUDY_ID="STD-Konate-2011" TOTAL_1="1339" TOTAL_2="1257" VAR="0.06512429572883265" WEIGHT="88.41219119140146"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4421085430542571" CI_END="1.0946808295073462" CI_START="0.7896148381114669" DF="1" EFFECT_SIZE="0.9297183584156922" ESTIMABLE="YES" EVENTS_1="248" EVENTS_2="253" I2="0.0" ID="CMP-004.01.07" LOG_CI_END="0.03928751261059605" LOG_CI_START="-0.10258469918165161" LOG_EFFECT_SIZE="-0.031648593285527805" MODIFIED="2012-01-13 14:05:36 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.5061065274875601" P_Z="0.38187305408042016" STUDIES="2" TAU2="0.0" TOTAL_1="2025" TOTAL_2="1926" WEIGHT="100.0" Z="0.8744503552510374">
<NAME>Fever</NAME>
<DICH_DATA CI_END="1.4043430504102226" CI_START="0.7401864065882693" EFFECT_SIZE="1.0195467797508613" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="66" LOG_CI_END="0.14747320943325218" LOG_CI_START="-0.1306588949203361" LOG_EFFECT_SIZE="0.00840715725645802" MODIFIED="2012-01-06 11:40:19 +0000" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="0.16337617487341868" STUDY_ID="STD-Dicko-2011" TOTAL_1="686" TOTAL_2="669" VAR="0.026691774516269886" WEIGHT="25.729335507011115"/>
<DICH_DATA CI_END="1.0865688190056109" CI_START="0.7431474847099862" EFFECT_SIZE="0.898599401740464" ESTIMABLE="YES" EVENTS_1="179" EVENTS_2="187" LOG_CI_END="0.036057238036093835" LOG_CI_START="-0.12892498780140782" LOG_EFFECT_SIZE="-0.046433874882657" MODIFIED="2012-01-06 11:43:57 +0000" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.09691137613213753" STUDY_ID="STD-Konate-2011" TOTAL_1="1339" TOTAL_2="1257" VAR="0.009391814823824635" WEIGHT="74.27066449298889"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6676857196138262" CI_END="4.666180762486517" CI_START="0.1460725658970582" DF="1" EFFECT_SIZE="0.8255913013809539" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="40.03666348887591" ID="CMP-004.01.08" LOG_CI_END="0.6689615588533252" LOG_CI_START="-0.835431341891107" LOG_EFFECT_SIZE="-0.08323489151889088" MODIFIED="2012-01-13 14:05:42 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.19656887421251346" P_Z="0.8283008040826431" STUDIES="2" TAU2="0.0" TOTAL_1="2025" TOTAL_2="926" WEIGHT="100.0" Z="0.21688136065172575">
<NAME>Drowsiness</NAME>
<DICH_DATA CI_END="71.69304797504964" CI_START="0.1193992492966145" EFFECT_SIZE="2.925764192139738" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8554770444759536" LOG_CI_START="-0.9229984037540767" LOG_EFFECT_SIZE="0.46623932036093846" MODIFIED="2012-01-06 11:40:49 +0000" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="1.632090231965605" STUDY_ID="STD-Dicko-2011" TOTAL_1="686" TOTAL_2="669" VAR="2.6637185252775426" WEIGHT="23.17836303915571"/>
<DICH_DATA CI_END="3.0586991069823597" CI_START="0.012043933151605185" EFFECT_SIZE="0.1919342793129201" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.48553675629017423" LOG_CI_START="-1.9192316636516031" LOG_EFFECT_SIZE="-0.7168474536807145" MODIFIED="2012-01-06 11:44:22 +0000" MODIFIED_BY="[Empty name]" ORDER="103" O_E="0.0" SE="1.4125728736694607" STUDY_ID="STD-Konate-2011" TOTAL_1="1339" TOTAL_2="257" VAR="1.995362123426798" WEIGHT="76.82163696084429"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.0906953510834967" CI_END="1.3155778925199044" CI_START="0.8051153556927184" DF="1" EFFECT_SIZE="1.029170521768691" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="114" I2="52.16902359869156" ID="CMP-004.01.09" LOG_CI_END="0.11911656681937002" LOG_CI_START="-0.0941418901270065" LOG_EFFECT_SIZE="0.012487338346181782" MODIFIED="2012-01-13 14:05:50 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.14819865495735685" P_Z="0.8184560837291677" STUDIES="2" TAU2="0.0" TOTAL_1="2025" TOTAL_2="1888" WEIGHT="100.0" Z="0.22953118738392062">
<NAME>Coughing</NAME>
<DICH_DATA CI_END="1.9040513803334576" CI_START="0.870939313907449" EFFECT_SIZE="1.2877551020408162" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="40" LOG_CI_END="0.2796786635307165" LOG_CI_START="-0.060012105099475306" LOG_EFFECT_SIZE="0.10983327921562061" MODIFIED="2012-01-06 11:41:39 +0000" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="0.1995360389897982" STUDY_ID="STD-Dicko-2011" TOTAL_1="686" TOTAL_2="631" VAR="0.03981463085573826" WEIGHT="35.31158614774081"/>
<DICH_DATA CI_END="1.2199708223622268" CI_START="0.6463869770464876" EFFECT_SIZE="0.8880164705407424" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="74" LOG_CI_END="0.08634944392178844" LOG_CI_START="-0.18950740200732955" LOG_EFFECT_SIZE="-0.05157897904277058" MODIFIED="2012-01-06 11:46:02 +0000" MODIFIED_BY="[Empty name]" ORDER="104" O_E="0.0" SE="0.16203967681217396" STUDY_ID="STD-Konate-2011" TOTAL_1="1339" TOTAL_2="1257" VAR="0.026256856861393785" WEIGHT="64.68841385225919"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2012-01-06 13:06:51 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>IPTc (AS+SP) versus placebo or no IPTc</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="279" EVENTS_2="173" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-01-06 13:06:51 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="121.56" SORT_BY="WEIGHT" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="4860" TOTAL_2="4550" WEIGHT="0.0" Z="0.0">
<NAME>Non-serious adverse events (during intervention)</NAME>
<GROUP_LABEL_1>IPTc</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IPTc</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-01-06 12:56:40 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="486" TOTAL_2="455" WEIGHT="0.0" Z="0.0">
<NAME>Severe skin or neurological reaction</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-06 12:56:40 +0000" MODIFIED_BY="[Empty name]" ORDER="138" O_E="0.0" SE="0.0" STUDY_ID="STD-Ciss_x00e9_-2006" TOTAL_1="486" TOTAL_2="455" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-01-06 12:56:40 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="486" TOTAL_2="455" WEIGHT="0.0" Z="0.0">
<NAME>Convulsions</NAME>
<DICH_DATA CI_END="7.642118539430219" CI_START="0.01274722006907407" EFFECT_SIZE="0.31211498973305957" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8832137698900975" LOG_CI_START="-1.894584516429821" LOG_EFFECT_SIZE="-0.5056853732698617" MODIFIED="2012-01-06 12:56:40 +0000" MODIFIED_BY="[Empty name]" ORDER="139" O_E="0.0" SE="1.6316924637075998" STUDY_ID="STD-Ciss_x00e9_-2006" TOTAL_1="486" TOTAL_2="455" VAR="2.662420296120177" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="163" EVENTS_2="110" I2="0.0" ID="CMP-005.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-01-06 12:56:40 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="486" TOTAL_2="455" WEIGHT="0.0" Z="0.0">
<NAME>Nervousness</NAME>
<DICH_DATA CI_END="1.7034322993339022" CI_START="1.129835497733341" EFFECT_SIZE="1.3872989150766928" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="110" LOG_CI_END="0.2313248777865073" LOG_CI_START="0.05301521549459623" LOG_EFFECT_SIZE="0.14217004664055177" MODIFIED="2012-01-06 12:56:40 +0000" MODIFIED_BY="[Empty name]" ORDER="140" O_E="0.0" SE="0.10473997827733203" STUDY_ID="STD-Ciss_x00e9_-2006" TOTAL_1="486" TOTAL_2="455" VAR="0.010970463049535986" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="3" I2="0.0" ID="CMP-005.01.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-01-06 12:56:40 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="486" TOTAL_2="455" WEIGHT="0.0" Z="0.0">
<NAME>Pruritus</NAME>
<DICH_DATA CI_END="13.184704329990183" CI_START="1.0636526889921967" EFFECT_SIZE="3.7448559670781894" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="1.120070395085577" LOG_CI_START="0.026799842359985563" LOG_EFFECT_SIZE="0.5734351187227814" MODIFIED="2012-01-06 12:56:40 +0000" MODIFIED_BY="[Empty name]" ORDER="141" O_E="0.0" SE="0.6421925344475286" STUDY_ID="STD-Ciss_x00e9_-2006" TOTAL_1="486" TOTAL_2="455" VAR="0.41241125130014017" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-005.01.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-01-06 12:56:40 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="486" TOTAL_2="455" WEIGHT="0.0" Z="0.0">
<NAME>Minor skin rash</NAME>
<DICH_DATA CI_END="6.491852793935922" CI_START="0.3750412958650652" EFFECT_SIZE="1.5603566529492456" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8123686634175711" LOG_CI_START="-0.4259209093952203" LOG_EFFECT_SIZE="0.1932238770111754" MODIFIED="2012-01-06 12:56:40 +0000" MODIFIED_BY="[Empty name]" ORDER="142" O_E="0.0" SE="0.7273774247024765" STUDY_ID="STD-Ciss_x00e9_-2006" TOTAL_1="486" TOTAL_2="455" VAR="0.5290779179668068" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="14" I2="0.0" ID="CMP-005.01.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-01-06 12:56:40 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="486" TOTAL_2="455" WEIGHT="0.0" Z="0.0">
<NAME>Dizziness</NAME>
<DICH_DATA CI_END="1.8293913938048862" CI_START="0.4131181315738207" EFFECT_SIZE="0.8693415637860082" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.2623066316573879" LOG_CI_START="-0.3839257436105523" LOG_EFFECT_SIZE="-0.060809555976582226" MODIFIED="2012-01-06 12:56:40 +0000" MODIFIED_BY="[Empty name]" ORDER="143" O_E="0.0" SE="0.3796000961342369" STUDY_ID="STD-Ciss_x00e9_-2006" TOTAL_1="486" TOTAL_2="455" VAR="0.1440962329851219" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="33" EVENTS_2="36" I2="0.0" ID="CMP-005.01.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-01-06 12:59:49 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="486" TOTAL_2="455" WEIGHT="0.0" Z="0.0">
<NAME>Diarrhoea</NAME>
<DICH_DATA CI_END="1.352283906167931" CI_START="0.5446346319531203" EFFECT_SIZE="0.858196159122085" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="36" LOG_CI_END="0.13106787942970802" LOG_CI_START="-0.26389474641886956" LOG_EFFECT_SIZE="-0.06641343349458077" MODIFIED="2012-01-06 12:59:49 +0000" MODIFIED_BY="[Empty name]" ORDER="144" O_E="0.0" SE="0.2320030015199838" STUDY_ID="STD-Ciss_x00e9_-2006" TOTAL_1="486" TOTAL_2="455" VAR="0.053825392714281606" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="1" I2="0.0" ID="CMP-005.01.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-01-06 12:59:56 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="486" TOTAL_2="455" WEIGHT="0.0" Z="0.0">
<NAME>Vomiting after first dose</NAME>
<DICH_DATA CI_END="59.647403413015226" CI_START="0.9404564431450889" EFFECT_SIZE="7.489711934156379" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.7755915425923754" LOG_CI_START="-0.026661313818849737" LOG_EFFECT_SIZE="0.8744651143867627" MODIFIED="2012-01-06 12:59:56 +0000" MODIFIED_BY="[Empty name]" ORDER="146" O_E="0.0" SE="1.0586522491514736" STUDY_ID="STD-Ciss_x00e9_-2006" TOTAL_1="486" TOTAL_2="455" VAR="1.1207445846334736" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="31" EVENTS_2="4" I2="0.0" ID="CMP-005.01.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-01-06 13:01:45 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="486" TOTAL_2="455" WEIGHT="0.0" Z="0.0">
<NAME>Vomiting after second dose</NAME>
<DICH_DATA CI_END="20.39299372106633" CI_START="2.581503238959" EFFECT_SIZE="7.2556584362139915" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="4" LOG_CI_END="1.3094809855183245" LOG_CI_START="0.4118726742839342" LOG_EFFECT_SIZE="0.8606768299011293" MODIFIED="2012-01-06 13:01:45 +0000" MODIFIED_BY="[Empty name]" ORDER="147" O_E="0.0" SE="0.527259565251881" STUDY_ID="STD-Ciss_x00e9_-2006" TOTAL_1="486" TOTAL_2="455" VAR="0.27800264914960254" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="1" I2="0.0" ID="CMP-005.01.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-01-06 13:06:51 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="486" TOTAL_2="455" WEIGHT="0.0" Z="0.0">
<NAME>Vomiting after third dose</NAME>
<DICH_DATA CI_END="99.27251606284707" CI_START="1.730522685802738" EFFECT_SIZE="13.106995884773662" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="1.996829029216708" LOG_CI_START="0.23817729692940584" LOG_EFFECT_SIZE="1.117503163073057" MODIFIED="2012-01-06 13:02:02 +0000" MODIFIED_BY="[Empty name]" ORDER="145" O_E="0.0" SE="1.0330407330120361" STUDY_ID="STD-Ciss_x00e9_-2006" TOTAL_1="486" TOTAL_2="455" VAR="1.067173156062045" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-01-13 14:47:16 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-01-13 14:47:16 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2012-01-13 14:47:16 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2012-01-17 17:23:52 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-10-07 22:14:37 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-10-07 22:14:11 +0100" MODIFIED_BY="[Empty name]">Search methods: detailed search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-07 22:14:37 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="6" ROWS="11">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Search set</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>CIDG SR<SUP>a</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>CENTRAL</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>MEDLINE<SUP>b</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>EMBASE<SUP>b</SUP>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>LILACS<SUP>b</SUP>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>malaria</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>malaria</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MALARIA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MALARIA</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>malaria</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>prophylaxis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>prophylaxis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>malaria</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>malaria</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>prophylaxis</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>intermittent treatment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>intermittent treatment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 or 2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 or 2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>prevention</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>presumptive treatment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>prophylaxis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>prophylaxis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 or 3</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2 or 3 or 4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>chemoprophylaxis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>chemoprophylaxis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 and 4</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 and 5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>prevention</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>prevention</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>intermittent treatment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>intermittent treatment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>presumptive treatment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>presumptive treatment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 or 5 or 6 or 7 or 8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4 or 5 or 6 or 7 or 8</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 and 9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 and 9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8212;</P>
</TD>
</TR>
</TABLE>
<P>
<SUP>a</SUP>Cochrane Infectious Diseases Group Specialized Register.<BR/>
<SUP>b</SUP>Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (<LINK REF="REF-Higgins-2006" TYPE="REFERENCE">Higgins 2006</LINK>); upper case: MeSH or EMTREE heading; lower case: free text term.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-01-17 16:14:30 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-01-17 14:26:01 +0000" MODIFIED_BY="[Empty name]">GRADE profile 1</TITLE>
<APPENDIX_BODY MODIFIED="2012-01-17 16:14:30 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Question: </B>Does IPTc reduce all-cause mortality and malaria morbidity in children aged &lt; 5 years?</P>
<P>
<B>Setting: </B>Areas with marked seasonal malaria transmission</P>
<TABLE COLS="13" ROWS="14">
<TR>
<TH COLSPAN="7">
<P>
<B>Quality assessment</B>
</P>
</TH>
<TH COLSPAN="2">
<P>
<B>No of events/patients</B>
</P>
</TH>
<TH COLSPAN="2">
<P>
<B>Effect</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Quality</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Importance</B>
</P>
</TH>
</TR>
<TR>
<TH>
<P>
<B>No of studies</B>
</P>
</TH>
<TH>
<P>
<B>Design</B>
</P>
</TH>
<TH>
<P>
<B>Risk of bias</B>
</P>
</TH>
<TH>
<P>
<B>Inconsistency</B>
</P>
</TH>
<TH>
<P>
<B>Indirectness</B>
</P>
</TH>
<TH>
<P>
<B>Imprecision</B>
</P>
</TH>
<TH>
<P>
<B>Other considerations</B>
</P>
</TH>
<TH>
<P>IPTc</P>
</TH>
<TH>
<P>
<B>Control</B>
</P>
</TH>
<TH>
<P>
<B>Relative</B>
<BR/>
<B>(95% CI)</B>
</P>
</TH>
<TH>
<P>
<B>Absolute</B>
</P>
</TH>
</TR>
<TR>
<TH COLSPAN="13">
<P>
<B>Clinical malaria </B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>randomized trials</P>
</TD>
<TD VALIGN="TOP">
<P>no serious risk of bias<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious inconsistency<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious indirectness<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious imprecision<SUP>4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>none</P>
</TD>
<TD VALIGN="TOP">
<P>0.7 episodes per child per year</P>
</TD>
<TD VALIGN="TOP">
<P>2.5 episodes per child per year<SUP> 5</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Rate Ratio 0.26 (0.17 to 0.38)</P>
</TD>
<TD VALIGN="TOP">
<P>1.8 fewer episodes per child per year (from 1.6 fewer to 2.1 fewer)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>HIGH</P>
</TD>
<TD VALIGN="TOP">
<P>Critical</P>
</TD>
</TR>
<TR>
<TH COLSPAN="13">
<P>
<B>Severe malaria</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>randomized trials</P>
</TD>
<TD VALIGN="TOP">
<P>no serious risk of bias<SUP>6</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious inconsistency</P>
</TD>
<TD VALIGN="TOP">
<P>no serious indirectness<SUP>7</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious imprecision<SUP>4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>none</P>
</TD>
<TD VALIGN="TOP">
<P>9 episodes per 1000 children per year</P>
</TD>
<TD VALIGN="TOP">
<P>35 episodes per 1000 children per year<SUP>8</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Rate Ratio 0.27 (0.1 to 0.76)</P>
</TD>
<TD VALIGN="TOP">
<P>26 fewer episodes per 1000 children per year (from 8 fewer to 31 fewer)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>HIGH</P>
</TD>
<TD VALIGN="TOP">
<P>Critical</P>
</TD>
</TR>
<TR>
<TH COLSPAN="13">
<P>
<B>Death from any cause </B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>randomized trials</P>
</TD>
<TD VALIGN="TOP">
<P>no serious risk of bias<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious inconsistency</P>
</TD>
<TD VALIGN="TOP">
<P>no serious indirectness<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>serious<SUP>9</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>none</P>
</TD>
<TD VALIGN="TOP">
<P>10/4751<BR/>(0.21%)</P>
</TD>
<TD VALIGN="TOP">
<P>16/4782<BR/>(0.33%)<SUP>10</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.66 (0.31 to 1.39)</P>
</TD>
<TD VALIGN="TOP">
<P>1 fewer per 1000 (from 2 fewer to 1 more)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;<BR/>MODERATE</P>
</TD>
<TD VALIGN="TOP">
<P>Important</P>
</TD>
</TR>
<TR>
<TH COLSPAN="13">
<P>
<B>Moderately severe anaemia</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>randomised trials</P>
</TD>
<TD VALIGN="TOP">
<P>no serious risk of bias</P>
</TD>
<TD VALIGN="TOP">
<P>serious<SUP>11</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious indirectness</P>
</TD>
<TD VALIGN="TOP">
<P>no serious imprecision</P>
</TD>
<TD VALIGN="TOP">
<P>none</P>
</TD>
<TD VALIGN="TOP">
<P>203/4373<BR/>(4.6%)</P>
</TD>
<TD VALIGN="TOP">
<P>296/4432<BR/>(6.7%)<SUP>10</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.71 (0.52 to 0.98)</P>
</TD>
<TD VALIGN="TOP">
<P>19 fewer per 1000 (from 1 fewer to 32 fewer)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;<BR/>MODERATE</P>
</TD>
<TD VALIGN="TOP">
<P>Important</P>
</TD>
</TR>
<TR>
<TH COLSPAN="13">
<P>
<B>Serious drug-related adverse event</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>randomized trials</P>
</TD>
<TD VALIGN="TOP">
<P>no serious risk of bias<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious inconsistency<SUP>12</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious indirectness<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>serious<SUP>13</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>none</P>
</TD>
<TD VALIGN="TOP">
<P>4751</P>
</TD>
<TD VALIGN="TOP">
<P>4782</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;<BR/>MODERATE</P>
</TD>
<TD VALIGN="TOP">
<P>Important</P>
</TD>
</TR>
<TR>
<TH COLSPAN="13">
<P>
<B>Non-serious adverse event</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>randomized trials</P>
</TD>
<TD VALIGN="TOP">
<P>serious<SUP>14</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious inconsistency</P>
</TD>
<TD VALIGN="TOP">
<P>no serious indirectness<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious imprecision</P>
</TD>
<TD VALIGN="TOP">
<P>none</P>
</TD>
<TD VALIGN="TOP">
<P>4751</P>
</TD>
<TD VALIGN="TOP">
<P>4782</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;<BR/>MODERATE</P>
</TD>
<TD VALIGN="TOP">
<P>important</P>
</TD>
</TR>
</TABLE>
<P>
<SUP>1</SUP> The studies were well conducted with allocation concealment at low risk of bias in all studies, and 5 out of 6 studies were blinded and used placebos.<BR/>
<SUP>2</SUP> There was substantial heterogeneity between these 6 trials. All 6 trials showed a statistically significant benefit but the magnitude of this benefit was variable. Not downgraded.<BR/>
<SUP>3 </SUP>The included trials were conducted in Ghana, Mali (2), The Gambia, Senegal and Burkina Faso, in areas described as &#8216;seasonal malaria transmission&#8217;. Most studies were limited to pre-school aged children. Three studies administered monthly AQ+SP, two studies used bimonthly SP, and one study used monthly SP + AS.<BR/>
<SUP>4</SUP> There was no reason to downgrade for study limitations, inconsistency, indirectness or imprecision.<BR/>
<SUP>5 </SUP>The incidence of malaria in the control groups was 2.25 episodes per child per year in Senegal, 2.4 in Mali, and 2.88 in Burkina Faso.<BR/>
<SUP>6 </SUP>These two trials were well conducted and at low risk of bias.<BR/>
<SUP>7 </SUP>These trials were conducted in areas of seasonal transmission in Mali and Burkina Faso. Both trials compared SP+AQ with placebo in pre-school age children. Of note, LLITN use was high in both the intervention and control groups in both studies.<BR/>
<SUP>8</SUP> The incidence of severe malaria in the control groups was 37 per 1,000 children per year in Mali, and 32 per 1,000 children per year in Burkina Faso<BR/>
<SUP>9</SUP> Downgraded by 1 for imprecision: There were very few deaths in these trials, and none of the trials were adequately powered to detect an effect on mortality. Larger trials are necessary to have confidence in this effect. However, a reduction in death would be consistent with the high quality evidence of a reduction in severe malaria.<BR/>
<SUP>10 </SUP>These control group risks are taken from the sum of events and participants in the included trials.<BR/>
<SUP>11</SUP> There was substantial heterogeneity between these 5 trials and the trials from Ghana and The Gambia did not show an effect. Downgraded by 1 for Inconsistency. There was no reason to downgrade for study limitations, directness or precision.<BR/>
<SUP>12</SUP> All six trials reported that there was no case of drug-related serious adverse event. One trial reported that four participants were withdrawn from the treatment arm: two cases for non-severe skin rash, one for itching and another for acute respiratory infection. One trial reported skin eruptions with macular hyper-pigmentation which was neither Stevens Johnson syndrome nor any other form of severe skin lesions.<BR/>
<SUP>13</SUP> Downgraded by 1 under precision. Trials of this size are underpowered to fully detect or exclude rare serious adverse events. Observation should continue once implemented.<BR/>
<SUP>14</SUP> Downgraded by 1 under study limitations. All seven trials commented on observed adverse events. However, the thoroughness of the methods used to collect these data are incomplete in some of these trials. The only adverse event found to be statistically more common with IPTc was vomiting after AQ+SP (see <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>).</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2012-01-17 17:23:29 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2012-01-17 17:23:29 +0000" MODIFIED_BY="[Empty name]">GRADEprofile 2</TITLE>
<APPENDIX_BODY MODIFIED="2012-01-17 15:40:06 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Question:</B> Is IPTc still effective where ITN coverage is high?</P>
<P>
<B>Setting: </B>Areas with marked seasonal transmission</P>
<TABLE COLS="13" ROWS="6">
<TR>
<TH COLSPAN="7">
<P>
<B>Quality assessment</B>
</P>
</TH>
<TH COLSPAN="2">
<P>
<B>No of patients</B>
</P>
</TH>
<TH COLSPAN="2">
<P>
<B>Effect</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Quality</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Importance</B>
</P>
</TH>
</TR>
<TR>
<TH>
<P>
<B>No of studies</B>
</P>
</TH>
<TH>
<P>
<B>Design</B>
</P>
</TH>
<TH>
<P>
<B>Risk of bias</B>
</P>
</TH>
<TH>
<P>
<B>Inconsistency</B>
</P>
</TH>
<TH>
<P>
<B>Indirectness</B>
</P>
</TH>
<TH>
<P>
<B>Imprecision</B>
</P>
</TH>
<TH>
<P>
<B>Other considerations</B>
</P>
</TH>
<TH>
<P>IPTc</P>
</TH>
<TH>
<P>
<B>Control</B>
</P>
</TH>
<TH>
<P>
<B>Relative</B>
<BR/>
<B>(95% CI)</B>
</P>
</TH>
<TH>
<P>
<B>Absolute</B>
</P>
</TH>
</TR>
<TR>
<TH COLSPAN="13">
<P>
<B>Clinical malaria - (where bed-nets are also used)</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>randomized trials</P>
</TD>
<TD VALIGN="TOP">
<P>no serious risk of bias<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious inconsistency</P>
</TD>
<TD VALIGN="TOP">
<P>no serious indirectness<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious imprecision<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>none</P>
</TD>
<TD VALIGN="TOP">
<P>0.6 episodes per child per year</P>
</TD>
<TD VALIGN="TOP">
<P>2.5 episodes per child per year<SUP>4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Rate Ratio 0.22 (0.13 to 0.38)</P>
</TD>
<TD VALIGN="TOP">
<P>1.9 fewer per child per year (from 1.6 fewer to 2.2 fewer)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>HIGH</P>
</TD>
<TD VALIGN="TOP">
<P>Critical</P>
</TD>
</TR>
<TR>
<TH COLSPAN="13">
<P>
<B>Severe malaria</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>randomized trials</P>
</TD>
<TD VALIGN="TOP">
<P>no serious risk of bias<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious inconsistency</P>
</TD>
<TD VALIGN="TOP">
<P>no serious indirectness<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious imprecision<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>none</P>
</TD>
<TD VALIGN="TOP">
<P>9 episodes per 1000 children per year</P>
</TD>
<TD VALIGN="TOP">
<P>35 episodes per 1000 children per year<SUP>5</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Rate Ratio 0.25 (0.1 to 0.68)</P>
</TD>
<TD VALIGN="TOP">
<P>26 fewer episodes per 1000 children per year (from 11 fewer to 32 fewer)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>HIGH</P>
</TD>
<TD VALIGN="TOP">
<P>Critical</P>
</TD>
</TR>
</TABLE>
<P>
<SUP>1</SUP> These trials were well conducted and considered at low risk of bias.<BR/>
<SUP>2</SUP> Two trials compared IPTc with placebo where both groups were also given insecticide treated bednets (ITNs). These trials were conducted in Mali and Burkina Faso. ITN usage was over 99% in both groups in Mali, and 92% in both groups in Burkina Faso.<BR/>
<SUP>3</SUP> There was no reason to downgrade for study limitations, insistency, directness or precision.<BR/>
<SUP>4</SUP> The incidence of malaria in the control groups was 2.4 in Mali, and 2.88 in Burkina Faso.<BR/>
<SUP>5</SUP> The incidence of severe malaria in the control groups was 37 per 1,000 children per year in Mali, and 32 per 1,000 children per year in Burkina Faso</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2012-01-17 17:23:38 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2012-01-17 17:23:38 +0000" MODIFIED_BY="[Empty name]">GRADEprofile 3</TITLE>
<APPENDIX_BODY MODIFIED="2012-01-17 15:40:24 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Question:</B> Is IPTc still effective where home-based management of malaria is practiced?</P>
<P>
<B>Setting: </B>Areas with marked seasonal transmission</P>
<TABLE COLS="13" ROWS="6">
<TR>
<TH COLSPAN="7">
<P>
<B>Quality assessment</B>
</P>
</TH>
<TH COLSPAN="2">
<P>
<B>No of patients</B>
</P>
</TH>
<TH COLSPAN="2">
<P>
<B>Effect</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Quality</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Importance</B>
</P>
</TH>
</TR>
<TR>
<TH>
<P>
<B>No of studies</B>
</P>
</TH>
<TH>
<P>
<B>Design</B>
</P>
</TH>
<TH>
<P>
<B>Risk of bias</B>
</P>
</TH>
<TH>
<P>
<B>Inconsistency</B>
</P>
</TH>
<TH>
<P>
<B>Indirectness</B>
</P>
</TH>
<TH>
<P>
<B>Imprecision</B>
</P>
</TH>
<TH>
<P>
<B>Other considerations</B>
</P>
</TH>
<TH>
<P>IPTc</P>
</TH>
<TH>
<P>
<B>Control</B>
</P>
</TH>
<TH>
<P>
<B>Relative</B>
<BR/>
<B>(95% CI)</B>
</P>
</TH>
<TH>
<P>
<B>Absolute</B>
</P>
</TH>
</TR>
<TR>
<TH COLSPAN="13">
<P>
<B>Clinical malaria - (where home-based management of malaria is used)</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>randomized trials</P>
</TD>
<TD VALIGN="TOP">
<P>serious<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious inconsistency</P>
</TD>
<TD VALIGN="TOP">
<P>no serious indirectness<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>serious<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>none</P>
</TD>
<TD VALIGN="TOP">
<P>0.2 episodes per child per year</P>
</TD>
<TD VALIGN="TOP">
<P>0.5 episodes per child per year<SUP>4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Rate Ratio 0.34 (0.04 to 3.05)</P>
</TD>
<TD VALIGN="TOP">
<P>0.3 fewer episodes per child per year (0.5 fewer to 1.0 more)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;<BR/>LOW</P>
</TD>
<TD VALIGN="TOP">
<P>Critical</P>
</TD>
</TR>
<TR>
<TH COLSPAN="13">
<P>
<B>Severe malaria - Not reported</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-<SUP> </SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>&#8722;</P>
</TD>
<TD VALIGN="TOP">
<P>Critical</P>
</TD>
</TR>
</TABLE>
<P>
<SUP>1 </SUP>Downgraded by 1 for risk of bias: This trial did not adequately describe the methodology to make judgements about the risk of bias.<BR/>
<SUP>2</SUP> One trail conducted in Ghana compared IPTc with no IPTc in the context of an on-going programme of home-based management of malaria.<BR/>
<SUP>3</SUP> Downgraded by 1 for imprecision: The result is not statistically significant.<BR/>
<SUP>4</SUP> The incidence of febrile episodes (treated presumptively as malaria) in the control group was lower in this trial than seen elsewhere.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2012-01-17 17:23:45 +0000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2012-01-17 17:23:45 +0000" MODIFIED_BY="[Empty name]">GRADEprofile 4</TITLE>
<APPENDIX_BODY MODIFIED="2012-01-17 15:41:03 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Question:</B> Is amodiaquine plus sulfadoxine-pyrimethamine an effective and safe option for IPTc?</P>
<P>
<B>Setting: </B>Areas with marked seasonal transmission</P>
<TABLE COLS="13" ROWS="14">
<TR>
<TH COLSPAN="7">
<P>
<B>Quality assessment</B>
</P>
</TH>
<TH COLSPAN="2">
<P>
<B>No of patients</B>
</P>
</TH>
<TH COLSPAN="2">
<P>
<B>Effect</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Quality</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Importance</B>
</P>
</TH>
</TR>
<TR>
<TH>
<P>
<B>No of studies</B>
</P>
</TH>
<TH>
<P>
<B>Design</B>
</P>
</TH>
<TH>
<P>
<B>Risk of bias</B>
</P>
</TH>
<TH>
<P>
<B>Inconsistency</B>
</P>
</TH>
<TH>
<P>
<B>Indirectness</B>
</P>
</TH>
<TH>
<P>
<B>Imprecision</B>
</P>
</TH>
<TH>
<P>
<B>Other considerations</B>
</P>
</TH>
<TH>
<P>
<B>AQ+SP</B>
</P>
</TH>
<TH>
<P>
<B>Control</B>
</P>
</TH>
<TH>
<P>
<B>Relative</B>
<BR/>
<B>(95% CI)</B>
</P>
</TH>
<TH>
<P>
<B>Absolute</B>
</P>
</TH>
</TR>
<TR>
<TH COLSPAN="13">
<P>
<B>Clinical malaria</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>randomized trials</P>
</TD>
<TD VALIGN="TOP">
<P>no serious risk of bias<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious inconsistency<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious indirectness<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious imprecision<SUP>4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>none</P>
</TD>
<TD VALIGN="TOP">
<P>0.6 episodes per child per year</P>
</TD>
<TD VALIGN="TOP">
<P>2.5 episodes per child per year<SUP>5</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Rate Ratio 0.23 (0.14 to 0.37)</P>
</TD>
<TD VALIGN="TOP">
<P>1.9 episodes fewer per child per year (from 1.6 fewer to 2.2 fewer)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>HIGH</P>
</TD>
<TD VALIGN="TOP">
<P>Critical</P>
</TD>
</TR>
<TR>
<TH COLSPAN="13">
<P>
<B>Severe malaria</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>randomized trials</P>
</TD>
<TD VALIGN="TOP">
<P>no serious risk of bias<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious inconsistency</P>
</TD>
<TD VALIGN="TOP">
<P>no serious indirectness<SUP>6</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious imprecision<SUP>7</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>none</P>
</TD>
<TD VALIGN="TOP">
<P>9 episodes per 1000 children per year</P>
</TD>
<TD VALIGN="TOP">
<P>35 episodes per 1000 children per year<SUP>8</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Rate Ratio 0.27 (0.1 to 0.76)</P>
</TD>
<TD VALIGN="TOP">
<P>26 fewer episodes per 1000 children per year (from 8 fewer to 31 fewer)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>HIGH</P>
</TD>
<TD VALIGN="TOP">
<P>Critical</P>
</TD>
</TR>
<TR>
<TH COLSPAN="13">
<P>
<B>Death from any cause</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>randomized trials</P>
</TD>
<TD VALIGN="TOP">
<P>no serious risk of bias<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious inconsistency</P>
</TD>
<TD VALIGN="TOP">
<P>no serious indirectness<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>serious<SUP>9</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>none</P>
</TD>
<TD VALIGN="TOP">
<P>6/3498<BR/>(0.17%)</P>
</TD>
<TD VALIGN="TOP">
<P>10/3512<BR/>(0.28%)<SUP>10</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.62 (0.23 to 1.65)</P>
</TD>
<TD VALIGN="TOP">
<P>1 fewer per 1000 (from 2 fewer to 2 more)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;<BR/>MODERATE</P>
</TD>
<TD VALIGN="TOP">
<P>Important</P>
</TD>
</TR>
<TR>
<TH COLSPAN="13">
<P>
<B>Moderately severe anaemia</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>randomized trials</P>
</TD>
<TD VALIGN="TOP">
<P>no serious risk of bias<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious inconsistency</P>
</TD>
<TD VALIGN="TOP">
<P>no serious indirectness<SUP>6</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious imprecision<SUP>7</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>none</P>
</TD>
<TD VALIGN="TOP">
<P>66/2866<BR/>(2.3%)</P>
</TD>
<TD VALIGN="TOP">
<P>139/2874<BR/>(4.8%)<SUP>10</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.48 (0.36 to 0.63)</P>
</TD>
<TD VALIGN="TOP">
<P>25 fewer per 1000 (from 18 fewer to 31 fewer)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>HIGH</P>
</TD>
<TD VALIGN="TOP">
<P>Important</P>
</TD>
</TR>
<TR>
<TH COLSPAN="13">
<P>
<B>Serious drug-related adverse event</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>randomized trials</P>
</TD>
<TD VALIGN="TOP">
<P>no serious risk of bias<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious inconsistency<SUP>11</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious indirectness<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>serious<SUP>12</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>none</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;<BR/>MODERATE</P>
</TD>
<TD VALIGN="TOP">
<P> Important</P>
</TD>
</TR>
<TR>
<TH COLSPAN="13">
<P>
<B>Non-serious adverse events- vomiting</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>randomized trials</P>
</TD>
<TD VALIGN="TOP">
<P>no serious risk of bias<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious inconsistency</P>
</TD>
<TD VALIGN="TOP">
<P>no serious indirectness<SUP>6</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious imprecision<SUP>7</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>none</P>
</TD>
<TD VALIGN="TOP">
<P>387/1814<BR/>(21.3%)</P>
</TD>
<TD VALIGN="TOP">
<P>131/1730<BR/>(7.6%)<SUP>10</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>RR 2.78 (2.31 to 3.35)</P>
</TD>
<TD VALIGN="TOP">
<P>135 more per 1000 (from 99 more to 178 more)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>HIGH</P>
</TD>
<TD VALIGN="TOP">
<P> Important</P>
</TD>
</TR>
</TABLE>
<P>
<SUP>1</SUP> The studies were well conducted with allocation concealment at low risk of bias in all studies, and all studies were blinded and used placebos.<BR/>
<SUP>2</SUP> There was substantial heterogeneity between these 3 trials. All 3 trials showed a trend to favour IPTc but the magnitude of this benefit was variable. Not downgraded.<BR/>
<SUP>3 </SUP>Two trials compared IPTc with placebo where both groups were also given insecticide treated bednets (ITNs). These trials were conducted in Mali and Burkina Faso. ITN usage was over 99% in both groups in Mali, and 92% in both groups in Burkina Faso. The third trial was conducted in the Gambia. All were in pre-school age children, and administered monthly SP+AQ.<BR/>
<SUP>4 </SUP>There was no reason to downgrade for study limitations, inconsistency, indirectness or imprecision.<BR/>
<SUP>5 </SUP>The incidence of malaria in the control groups was 2.4 in Mali, and 2.88 in Burkina Faso.<BR/>
<SUP>6</SUP> These trials were conducted in areas of seasonal transmission in Mali and Burkina Faso.<BR/>
<SUP>7</SUP> There was no reason to downgrade for study limitations, inconsistency, indirectness or imprecision.<BR/>
<SUP>8</SUP> The incidence of severe malaria in the control groups was 37 per 1,000 children per year in Mali, and 32 per 1,000 children per year in Burkina Faso<SUP> </SUP>
<BR/>
<SUP>9 </SUP>Downgraded by 1 for imprecision: There were very few deaths in these trials, and none of the trials were adequately powered to detect an effect on mortality. Larger trials are necessary to have confidence in this effect. However, a reduction in death would be consistent with the high quality evidence of a reduction in severe malaria.<BR/>
<SUP>10 </SUP>These control group risks are taken from the sum of events and participants in the included trials.<BR/>
<SUP>11</SUP> All three trials reported that there was no case of drug-related serious adverse event. One trial reported that four participants were withdrawn from the treatment arm: two cases for non-severe skin rash, one for itching and another for acute respiratory infection. One trial reported skin eruptions with macular hyper-pigmentation which was neither Stevens Johnson syndrome nor any other form of severe skin lesions.<BR/>
<SUP>12</SUP> Downgraded by 1 under precision. Trials of this size are underpowered to detect or exclude rare serious adverse events.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2012-01-17 17:23:52 +0000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2012-01-17 17:23:52 +0000" MODIFIED_BY="[Empty name]">GRADEprofile 5</TITLE>
<APPENDIX_BODY MODIFIED="2012-01-17 15:39:44 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Question:</B> After stopping IPTc is there a rebound increase in all-cause mortality or malaria morbidity during the following malaria transmission season?</P>
<P>
<B>Setting: </B>Areas with marked seasonal transmission</P>
<TABLE COLS="13" ROWS="10">
<TR>
<TH COLSPAN="7">
<P>
<B>Quality assessment</B>
</P>
</TH>
<TH COLSPAN="2">
<P>
<B>No of patients</B>
</P>
</TH>
<TH COLSPAN="2">
<P>
<B>Effect</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Quality</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Importance</B>
</P>
</TH>
</TR>
<TR>
<TH>
<P>
<B>No of studies</B>
</P>
</TH>
<TH>
<P>
<B>Design</B>
</P>
</TH>
<TH>
<P>
<B>Risk of bias</B>
</P>
</TH>
<TH>
<P>
<B>Inconsistency</B>
</P>
</TH>
<TH>
<P>
<B>Indirectness</B>
</P>
</TH>
<TH>
<P>
<B>Imprecision</B>
</P>
</TH>
<TH>
<P>
<B>Other considerations</B>
</P>
</TH>
<TH>
<P>IPTc</P>
</TH>
<TH>
<P>
<B>Control</B>
</P>
</TH>
<TH>
<P>
<B>Relative</B>
<BR/>
<B>(95% CI)</B>
</P>
</TH>
<TH>
<P>
<B>Absolute</B>
</P>
</TH>
</TR>
<TR>
<TH COLSPAN="13">
<P>
<B>Clinical malaria</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>randomized trials</P>
</TD>
<TD VALIGN="TOP">
<P>no serious risk of bias<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious inconsistency</P>
</TD>
<TD VALIGN="TOP">
<P>no serious indirectness<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious imprecision<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>none</P>
</TD>
<TD VALIGN="TOP">
<P>2.5 episodes per child per year</P>
</TD>
<TD VALIGN="TOP">
<P>2.5 episodes per child per year<SUP>4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Rate Ratio 0.98 (0.82 to 1.17)</P>
</TD>
<TD VALIGN="TOP">
<P>0 fewer episodes per child per year (from 0.5 fewer to 0.4 more)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>HIGH</P>
</TD>
<TD VALIGN="TOP">
<P>Critical</P>
</TD>
</TR>
<TR>
<TH COLSPAN="13">
<P>
<B>Severe malaria - not reported</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Critical</P>
</TD>
</TR>
<TR>
<TH COLSPAN="13">
<P>
<B>Death from any cause</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>randomized trials</P>
</TD>
<TD VALIGN="TOP">
<P>no serious risk of bias<SUP>5</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious inconsistency</P>
</TD>
<TD VALIGN="TOP">
<P>no serious indirectness<SUP>6</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>serious<SUP>7</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>none</P>
</TD>
<TD VALIGN="TOP">
<P>8/594<BR/>(1.3%)</P>
</TD>
<TD VALIGN="TOP">
<P>8/613<BR/>(1.3%)<SUP>8</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>RR 1.03 (0.39 to 2.73)</P>
</TD>
<TD VALIGN="TOP">
<P>0 more per 1000 (from 8 fewer to 23 more)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;<BR/>MODERATE</P>
</TD>
<TD VALIGN="TOP">
<P>Important</P>
</TD>
</TR>
<TR>
<TH COLSPAN="13">
<P>
<B>Moderately severe anaemia</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>randomized trials</P>
</TD>
<TD VALIGN="TOP">
<P>no serious risk of bias<SUP>5</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious inconsistency</P>
</TD>
<TD VALIGN="TOP">
<P>serious indirectness<SUP>9</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>no serious imprecision</P>
</TD>
<TD VALIGN="TOP">
<P>none</P>
</TD>
<TD VALIGN="TOP">
<P>36/376<BR/>(9.6%)</P>
</TD>
<TD VALIGN="TOP">
<P>47/392<BR/>(12%)<SUP>8</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.8 (0.53 to 1.2)</P>
</TD>
<TD VALIGN="TOP">
<P>24 fewer per 1000 (from 56 fewer to 24 more)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;<BR/>MODERATE</P>
</TD>
<TD VALIGN="TOP">
<P>Important</P>
</TD>
</TR>
</TABLE>
<P>
<SUP>1</SUP> These trials were well conducted and considered at low risk of bias.<BR/>
<SUP>2</SUP> Three trials report clinical malaria during the following malaria season when IPTc was not given.  These were conducted in Senegal, Mali, and Ghana.<BR/>
<SUP>3 </SUP>There was no reason to downgrade for study limitations, inconsistency, indirectness or imprecision.<BR/>
<SUP>4</SUP> The incidence of malaria in the control groups was 2.25 episodes per child per year in Senegal, 2.4 in Mali, and 2.88 in Burkina Faso.<BR/>
<SUP>5 </SUP>This trial was well conducted and considered at low risk of bias.<BR/>
<SUP>6</SUP> This trial was conducted in Ghana. A large reduction in clinical malaria was seen during the intervention period, following IPTc with either bimonthly sulfadoxine-pyrimethamine or amodiaquine plus artesunate.<BR/>
<SUP>7</SUP> Downgraded by 1 for imprecision: there were very few deaths in these trials, and none of the trials were adequately powered to detect or exclude an effect on mortality. Larger trials are necessary to have confidence that there is no increase.<BR/>
<SUP>8</SUP> These control group risks are taken from the sum of events and participants in the included trials.<BR/>
<SUP>9 </SUP>Downgraded by 1 for indirectness: only one trial reports the incidence of moderate anaemia during the following transmission season. This trial found no statistically significant benefit on anaemia during the administration of IPTc.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2010-07-09 14:00:47 +0100" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>